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Chapter 1
General introduction
General introduction
Pancreatic cancer, including ampullary, distal bile duct and pancreatic head cancer,
is one of the most lethal human cancers and still is a major unsolved health problem
at the start of the 21st century. It has been estimated that this disease causes 30.000
deaths per year in the USA with an incidence of 9-10 cases per 100.000 and slightly
increased male: female and black: white ratios.1,2 The incidence of pancreatic cancer
in the Netherlands is approximately 8.4 per 100.000 patients.3 This number has
been quite steady over the past ten years. Pancreatic cancer currently ranks as the
fifth most common cause of cancer related deaths in the western countries. Over the
past 20 years the disease continuous to have an appalling prognosis with less than
1% of patients surviving more than 5 years from diagnosis, so that mortality rates
and annual incidence are virtually identical.4-7
In numerous studies, risk factors associated with pancreatic cancer have been ex-
plored (Table 1). Tobacco smoking, diabetes mellitus and age factors are frequently
studied. In diabetic patients K-ras mutation pathway has been described to be related
to a higher risk for pancreatic carcinoma.8
The risk factors consistently referred to, are age and cigarette smoking.9 Age spe-
cific incidence rates show that the disease is uncommon before the age of 45-years
but incidence rates increase steadily thereafter so that more than 80% of cases occur
in the 60-to 80-year-old age group.9 Cigarette smoking has been reported to account
for 20-30% of pancreatic cancer incidence, with reported odds rations ranging from
1.6 to 5.4.10 Another risk factor which has been reported frequently in international
literature is family history.11,12 There are several genetic syndromes associated with
an increased risk of pancreatic cancer, including hereditary pancreatitis. Patients
with hereditary pancreatitis harbour a mutation in trypsinogen gene PRSS1. Auto
activation of trypsin results in repeated attacks of pancreatitis and so mitogenic
stimulant can lead to higher risk of getting carcinoma.13,14 Germline mutation in
DNA mismatch repair genes might provide micro satellite instability and hereditary
non-polyposis colorectal cancer which is also related to increased risks for pancreatic
carcinoma. Further BRCA2 germline mutations (breast cancer) the Peutz-Jeghers
syndrome, familial breast cancer and familial atypical multiple-mole melanoma have
been associated with increased risks for getting pancreatic cancer.11 In the USA, in
the Johns Hopkins Hospital a National Familial Registry for Pancreas Tumours has
been established and encounters the largest collection of familial cases of pancreatic
cancer. Early detection of patients with increased risks might benefit from early
treatment.
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In some epidemiological studies of pancreatic cancer, a protective role has been
noted for diets high in fruits and vegetables.15,16 This effect might be related to
dietary intake.17 Exposure to carcinogens has long been suspected as a causal factor
for pancreatic cancer, but evidence is insufficient.18-20 The primary causal factors for
pancreatic cancer are yet poorly understood. Worldwide research efforts aimed at
exploring and quantifying risk factors are critical to the eventual prevention of the
disease.
Molecular Biology and Genomics
In the past decades, there has been a significant increase in our knowledge of the
biology and pathofysiology of pancreatic cancer although a great deal of mecha-
nisms is yet to be explored. Many malignant diseases, including pancreatic ductal
carcinoma results from the accumulation of acquired mutations. The multigenic
nature of most pancreatic ductal cancers is reflected in the abnormalities of three
broad classifications of genes i.e., oncogenes, tumour-suppressor genes, and genomic
maintenance genes. 21,22
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Table 1 Risk factors for pancreatic cancer
Demographic factors
Old age (most reliable and important factor)
Sex (more common in males than in females)
Ethnic origin (mortality highest in black populations)
Genetic factors and medical conditions
Family history
Herediatry pancreatitis
Heriditary non-polyposis colorectal cancer
Peutz-Jeghers syndrome
Familial breast cancer
Chronic pancreatitis
Diabetes Mellitus
Gastrectomy
Deficiency in carcinogen metabolism and DNA repair
Environmental and lifestyle factors
Cigarette smoking
Occupational exposures
Low dietary intake of fruits and vegetables
Food preparation and cooking methods (grilling or charring confers the highest risk)
The accumulated mutations in such genes are believed to occur in a predictable
time course. Hruban et al. showed that pancreatic cancer follows a stepwise develop-
ment from non-invasive intraepithelial precursor lesions to invasive cancer (figure 1).23
Normal duct epithelium progresses to infiltrating cancer through a series of his-
tological defined precursors (PanINs) e.g. the histological progression from PanIn
1A to papillary duct lesion (PanIN-1B) to atypical papillary duct lesion (Pan IN-2) to
severely atypical duct lesion/carcinoma in situ (PANIN-3) is associated with accumu-
lation of specific genetic alterations.
In 1988, Perucho et al. showed that many human pancreatic carcinomas contain
a mutant K-ras gene.24 Since then there has been an explosion in our understanding
of pancreatic cancer genetics. More than 85% of pancreatic ductal cancers have an
activating point mutation in the K-ras gene at a very early stage of pancreatic-cancer
development.24 K-ras plays a pivotal role in cell proliferation and differentiation.
In the late 90’s K-ras mutations have been detected in the duodenal juice, pan-
creatic juice, and stool of patients with pancreatic cancer. These findings might be
helpful in the near future in order to develop an early detection strategy.25,26
The second most frequently inactivated tumour-suppressor gene is TP53, a well-
characterised tumour-suppressor gene located on chromosome 17p. P53 plays an
important role inducing cell apoptosis when cell damage occurs. Mutations will
lead to loss of inhibitory cell-cycle regulatory mechanisms. Inactivation of this gene
is a late event in tumour genesis. The p16 tumour-suppressor gene is inactivated
in around 95% of pancreatic cancers27,28 and typically occurs later in pancreatic
carcinogenesis. P16 is an inhibitor of CDK4-6 which in his turn phosphorylate the
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Figure 1 Progression model for pancreatic cancer. Normal duct epithelium progresses to infiltrating
cancer (left to right) through a series of histological defined precursors (PanINs). The over-
expression of HER-2/neu and point mutations in the K-ras gene occurs early, inactivation of
the p16 gene at an intermediate stage, and the inactivation of p53, DPC4, and BRCA2 occur rela-
tively late. (With permission from dr. Hruban )
retinoblastoma protein. It also is involved in inhibition of the transforming growth
factor (TGF-B)29 The MADH4 gene (DPC4 or SMAD4) is inactivated in 55% of pancre-
atic adenocarcinomas and plays a role in the TGF-B inhibitory pathway.30 Like TP53,
MADH4 inactivation is a late event in pancreatic tumour genesis.
Depending on the target population and assessment of molecular techniques,
the individual mutational frequencies of tumour-suppressor genes p16, TP53, MADH4,
and BRCA2 were 82%, 76%, 53%, and 10%, respectively. 31
In normal cells, cell growth, cell differentiation, and cell death are controlled and
regulated through various signals that are well coordinated to ensure the mainte-
nance of cell homeostasis. In malignant cells such as pancreatic cancer increased
dysregulation of signalling pathways has been observed and many such neoplastic
cells need neither mitogenic signalling to develop and further proliferate, nor do
they react to inhibitory signals. The biology of pancreatic cancer is thought to be
related to mutation and inactivation of these oncogenes and tumour suppressor
genes, as well as abnormalities in growth factors and their receptors, which affect
the downstream signal transduction pathways involved in the control of growth and
differentiation and longevity genes that control apoptosis.32
These perturbations confer a tremendous survival and growth advantage to pan-
creatic cancer cells, as manifested by development of invasive and metastatic pheno-
types that are resistant to all conventional treatments.
Hanahan and Weinberg have described the typical characteristics of tumour cell
growth. (Table 2) Pancreatic cancer has been known to over express many growth
factors and their receptors. The epidermal growth factor family are transmembrane
proteins that bind to various growth actors resulting in signal transduction, which re-
sults in effects on cell differentiation. EGFR-1 is one of the most frequently described
factors in pancreatic cancer and is known to be significantly over expressed.33,34 Vascu-
lar endothelial growth factors are the main signalling molecules responsible for bind-
ing to endothelial cells of pre-existing blood vessels and activates them in the process
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Table 2 Characteristic of tumours cells and behaviour of growth factors and their receptors.
(After Hanahan and Weinberg, Cell 2000)
Characteristics of malignant growth Pancreatic cancer
Autonomous growth control Increased expression of: EGF, FGE, PDGF, IGF and their receptors
Resistance to growth control inhibition Increased expression of TGF-B and its receptors;
Smad4 mutation Smad 6/7 overexpression
Resistance to apoptosis Increased expression of EGF, IGF and their receptors
Angiogenesis Increased expression of VEGF, FGF-2 and their receptors
Invasiveness and metastasis Increased expression of TGF-B,HGF and their receptors
of angiogenesis35,36 Other molecules are the fibroblast growth factor,37 and many
cytokines, such as transforming growth factor,38 interleukin 1,39 interleukin 6,40
tumour necrosis factor,41 and interleukin 8,42 these factors play a role in cell division,
cell death, migration and tissue repair. The abundance of growth-promoting factors
and the disturbance of growth inhibitory factors lead to evasion of programmed cell
death, self-sufficiency in growth signals, angiogenesis, and metastasis.
An important focus of current pancreatic-cancer research seeks to understand
the upstream molecular mechanisms leading to constitutive activation of these
transcription factors. Aberrant expression of multiple-metastases-related proteins,
such as interleukin 8 and vascular endothelial growth factor, might result from the
alterations of several transcription-factor activities.
In general it is believed that K-ras mutation is the first step in pancreatic cancer
genesis. This is followed by inactivation of tumour suppressor gene p53 and p16 so
that the main mechanisms in cell-cycle regulation are disrupted. Further the trans-
forming growth factor (TGF) inhibitory pathway is disturbed. The acquisition of
aberrations in the aforementioned genes leads to profound and irreversible changes
in cell regulation; this is believed to be the early stage of pancreatic cancer growth.
In the late stage of pancreatic cancer development, however, important stress fac-
tors, such as hypoxia and acidosis, which are frequently encountered in the tumour
microenvironment, further upregulate those metastases related proteins through
activation of many transcription factors. Recent data indicate that tumour hypoxia
plays a crucial role in tumour progression and tumour aggressiveness. Graeber et
al. showed that hypoxia resulted in increased growth of p53 mutated cells, whereas
normal cells under the same condition went into apoptosis.43,44 Therefore, at ad-
vanced stages, uncontrolled tumour growth and the consequent development of a
stress environment might increase tumour angiogenesis, growth, and development
of metastases. Understanding the expression and regulation of these molecules
might unravel the pathophysiology of pancreatic cancer, and suggest new targets
for preventive and treatment approaches to pancreatic cancer.
Tumour types
Almost 80-90% of all pancreas tumours are adenocarcinomas with a ductal pheno-
type. Neuroendocrine tumours and acinar cell carcinomas represent about 2-5%
of all pancreatic tumors.45,46 Pancreatic ductal adenocarcinomas are characterized
histological by atypical glands embedded in a dense fibrotic stroma. Although his-
tological very similar, adenocarcinomas of the distal bile ducts and the ampulla of
Vater should be considered separately because they usually have a better prognosis
owing to a higher rate of resectability due to an earlier detection of symptoms
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(jaundice) and less invasion in large vessels. Trede et al47 showed that even small
periampullary tumours tend to infiltrate in peripancreatic tissue. Pancreatic tumours
(< 2cm) showed 75% infiltration in blood vessels and 60% in perineural tissue,
ampullary cancer (< 2 cm) showed only 33% blood vessel invasion and 25% peri-
neural infiltration, whereas bile duct tumours (< 2 cm) showed similar percentages
ingrowth as pancreatic head cancer.
Pathology reports from large series from high volume centres in Europe (Trede
et al)47 and USA48-50 showed that 80 percent of ductal carcinomas were located in the
head (periampullary region), 16% in the body and 2.5% in the tail of the gland. Of
the tumours in the periampullary region 80% is located in the head, 15 % in the
ampulla and 15% in the distal common bile duct. The diameter of the tumours
depends generally on their location in the pancreas. Carcinomas of the ampulla are
smaller than tumours in the head, bile duct and body. Tumours in the tail are usu-
ally larger than 4 cm.
Nowadays there is evidence that periampullary tumours do differ according to
histological characteristics. Pathological details from the largest series known to date49
showed a median tumour diameter of 3 cm in patients with pancreatic ductal aden-
ocarcinoma. The majority of these cancers were poorly or moderate differentiated.
There was a 29% incidence of margin positivity, and 70% of patients had node posi-
tive resections. In contrast to those with pancreatic head cancer, patients undergoing
resection for ampullary or distal bile duct adenocarcinoma had a significantly lower
incidence of positive resection margins (range 3-9%) and a lower incidence of node
positive resections (range 42%-62%). Tumour diameters are also smaller with a
median diameter of 2 cm for both ampullary and bile duct cancer. After multivariate
analysis four factors were found to adversely effect survival: 1. Tumour diameter
> 3 cm; 2. Positive resection margins; 3. Positive lymph nodes and 4. The presence
of a poorly differentiated tumour.49
These findings suggest ductal adenocarcinoma of the pancreatic head is a biologi-
cal different tumour compared to bile duct and ampullary adenocarcinoma. Most
tumour types other than pancreatic ductal adenocarcinomas tend to be more ame-
nable to therapeutic interventions such as resection, chemotherapy, or irradiation.46
Clinical features
The general features of a periampullary tumour are mainly the consequence of
tumour extension; carcinomas of the head and more particularly those of the distal
common bile duct or ampulla of Vater will cause progressive jaundice in an early
onset.51 In patients with small tumours, painless jaundice might be the only sign.
Many patients however, experience an antecedent period of fatty diarrhoea, weight
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loss, abdominal back pain followed by obstructive jaundice. Back pain is probably
caused by invasion of the tumour into the splanchnic plexus and retroperitoneum.
Nausea and vomiting can be caused by jaundice, or in a progressed stadium by duo-
denal obstruction the latter is a late manifestation of the disease. New onset of dia-
betes is observed in 15% of cases and about 3% of pancreatic cancer patients present
with acute pancreatitis.46
Diagnostics
The overall 5-year survival rate for patients with pancreatic carcinoma is approxi-
mately less than 5%.7 At the time of diagnosis the majority of patients have distant
metastasis or/and locally advanced pancreatic carcinoma. The goal of CT-scanning is
to detect those patients who might undergo a potential curative resection. With
modern scanning techniques it is possible to detect liver lesion smaller than 1cm,
peritoneal metastasis, suspect lymphnodes as well as vascular encasement.
If patients present with painless jaundice, the work-up in the Erasmus MC is first
to perform a CT scan. Thereafter it is mandatory to drain the obstructed biliary tract
using endoscopic retrograde cholangiopancreatography (ERCP).52
In the past high mortality rates of up to 30% made surgeons cautious to perform
a Whipple procedure without a definitive tissue diagnosis. Today however with mor-
tality rates lower than 5% the need for a percutaneous taken tissue sample is not rec-
ommended; moreover there is a risk of peritoneal seeding using this technique.
Therefore in the Erasmus MC biopsy of a suspected pancreatic mass are taken using
endoscopic ultrasound guided biopsy. This technique has the advantage of extra
imaging the tumour in relation with the large vessels, and offers the possibility of a
tissue diagnosis without the risk of seeding out of the resection field. The technique
can also be considered for patients with locally advanced disease in whom neo-
adjuvant therapy is being considered or if palliation with chemoradiotherapy is nec-
essary.53-55 With the use of this technique, pancreatic biopsy samples obtained during
laparotomy are rarely required and should be discouraged. For patients presenting
with liver metastases and an obvious pancreatic mass, liver biopsy is an appropriate
alternative, and if positive for adenocarcinoma, is acceptable as evidence of meta-
static pancreatic cancer.
In sum, thin cut (2mm) dynamic multiphase helical CT scan of the abdomen is
the most important preoperative imaging study.56
Laparoscopy with or without utrasonography is a surgical tool which is fre-
quently recommended to rule out the presence of small superficial livermetatases
or peritoneal metastases for patients who seem to have resectable disease or locally
advanced disease on the basis of preoperative imaging studies.57 For patients with
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locally advanced disease detection of metastases with laparoscopy prevents the non-
effective chemoradiation and for patients with resectable disease an unnecessary
explorative laparotomy.
Resectable disease is defined, based on preoperative work up, as a pancreatic
tumour without evidence of involvement of the superior mesenteric artery or celiac
axis, a patent superior mesenteric portal venous confluence and no evidence of
distant metastases. Around 10-20% of patients admitted to the hospital are suitable
to undergo a resection. Most patients have locally advanced disease or distant meta-
stases at time of diagnosis. Resectable tumours are generally located in the pancreatic
head. Consequently, a standard pancreaticoduodenectomy (Whipple’s operation) or a
modified procedure of this approach (Pylorus preserving technique) is performed.
Pancreaticoduodenectomy
The surgical history of the treatment of periampullary tumours encompasses the
past 100 years. Alessandro Codivilla, an Italian surgeon was the first surgeon to try,
in 1898 to perform an en bloc resection of the head of the pancreas and duodenum
for periampullary carcinoma, but the patient did not survive the postoperative
period.58 In Germany, in 1912 Walter Kausch, described the first successful pan-
creaticoduodenctomy in two stages.59 In 1914, Hirschel reported a successful one-
stage pancreaticoduodenectomy.
In 1935 Allan Oldfather Whipple reported three patient with ampullary cancer
treated by a two stage pancreaticidoudenectomy.60 In 1937 Brunschwig reported ex-
tending the indication for pancreaticoduodenctomy to include cancer of the head of
the pancreas.61 During the 1940s and 1950s pancreaticduodenectomy was accom-
plished routinely as one stage procedure, applied to patients with periampullary
neoplasms and was performed with increased frequency. During the 1960s and
1970s, pancreaticoduodenectomy was a formidable operation, which carried a hos-
pital mortality that approaches 25% in some series and led some authors to suggest
that its use should be abandoned.62,63 There were however exceptions to this high
mortality rate, notably a report by Howard in 1968 describing 41 consecutive patients
treated by pancreaticoduodenctomy without hospital mortality.64 In recent years im-
proved hospital mortality and survival after pancreaticoduodenectomy have been
reported.65-68 Trede et al.69 reviewed 118 consecutive resections without an operative
death in 1990, whereas a report from the Johns Hopkins in 1993 described 145
consecutive pancreaticoduodenectomies without mortality.48 Overall, although pan-
creaticoduodenectomy remains a formidable operation, many centres now have
reported hospital mortality rates of < 4%, with the mortality rate approaching 1% in
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selected series. At present leakage of the pancreaticojejunostomy is the most feared
complication and accounts for the remainder of postoperative mortality. 70
To date the standard resection resection still bares Whipple’s name. Since the
introduction of this technique several modifications have been reported, including
the pylorus-preserving pancreaticoduodenectomy (PPPD) described by Watson in
1944.71 Later on this technique was re-introduced by Traverso and Longmire in the
late 1970s for chronic pancreatitis. 72 The classic Whipple operation consists of an
en bloc removal of the pancreatic head, the duodenum, the common bile duct,
the gall bladder, and the distal portion of the stomach together with the adjacent
lymphnodes. This operation can lead to specific complications such as early and late
dumping, postoperative weight loss and postoperative reflux. Leaving the function-
ing pylorus at the gastric outlet, the PPPD represents a surgical alternative that is
being performed by an increasing number of surgeons. Preservation of the pylorus
in pancreaticoduodenectomy has been shown to lead to a long-term improvement in
gastrointestinal function, improved postoperative weight gain and less dumping.
The pylorus preserving procedure is a less extensive operation, and should lead to
decrease in operative time and less intra-operative blood loss.73 74 On the other hand
prolonged hospital stay due to delayed gastric emptying has been reported.75,76 Another
criticism especially in malignant disease is radicality of the pylorus preserving pan-
creaticoduodenectomy. In some patients, especially the ones with large tumours of
the pancreatic head, the PPPD has been doubted to be curable.50,77 In our centre the
standard Whipple operation is performed for tumours invading the post pyloric
duodenum or tumours with suspected infiltration in the antrum and suspected
lymphnodes around the pylorus. Today the best technique to treat periampullary
cancer is still under debate. In the literature only a few trials had been performed.
Seiler et al.78 randomised 139 patients for either a standard Whipple procedure or a
PPPD. The Whipple group had a significant shorter operation time, and no differ-
ence was found in mortality and morbidity. The incidence of delayed gastric empty-
ing was identical in both groups. For long-term follow-up, a total of 76 patients with
histological proven pancreatic or periampullary carcinoma were analyzed. There
was no difference in tumour recurrence and in long-term survival after a median
follow-up of 1.5 years (0.1-3.5). They concluded both procedures were equal radical.
Lin et al.79 included 36 patient and reported equal intraoperative results for both pro-
cedures. Delayed gastric emptying was observed more frequently after PPPD (six of
16 patients) than after the Whipple procedure (one of 15 patients), with marginal sig-
nificance (P = 0.08, two-sided Fisher’s exact test). Unfortunately no information
about radical resection was given in this paper.
In conclusion literature leaves us inconclusive results. Results from a retrospec-
tive study in the Erasmus MC showed favourable outcome for the PPPD.73 Based on
these results we conducted a multicentre randomised clinical trial to establish
16 chapter 1
P niet cursief?
+ wel/geen
spatie voor&na
<, >,
Zie tevens
elders.
NB, bij = heb ik
consequent alle
spaties
verwijderd
whether the PPPD is a safe and radical procedure in patients with malignant disease
of the periampullary region compared to the standard Whipple’s procedure.
Survival and recurrence
As a result of better surgical technique, mean operating time, morbidity, and mor-
tality as well the need for perioperative transfusions, reinterventions have been
greatly reduced over the past few decades. Decreased hospital mortality, from 25%
(1960-70s) to below 5% in present time, certainly has helped improve survival. The
most stunning example of these better surgical skills is presented in the series of
the John Hopkins. In this series of 1000 consecutive pancreaticoduodenectomies a
mortality rate of 1 % was reached.49 The median operative time decreased from 8.8
hour in the 1970s to 5.5 hours during the 2000s. Postoperative length of stay
dropped from a median of 17 days in the 1980s to 9 days in the 2000s. Overall
survival for patients with pancreatic head adenocarcinomas was 18%; for the
lymphnode negative patient, it was 32%; and for node negative, margin negative
patients, it was 41%. Among the other periampullary tumours, 5-year survival for
distal common bile duct carcinoma was 22%, for ampullary adenocarcinoma 5-year
survival was 39% and for duodenal cancer five-year survival was 52%. Other high
volume institutions report similar survival rates around 20% after resection for
pancreatic head cancer.49,69,80 Compared with survival rates from the past (rates of
less than 5%) todays reported rates truly increased.
Thus, operating time, hospital stay and mortality have been greatly reduced due
to better surgical technique. Important to keep in mind is the facts that at about
80-90% of patients do have nonresectable disease and if resectable, survival is still
disappointing compared with other solid tumours. As is shown in the aforemen-
tioned paragraphs resectable disease is mainly located in the pancreatic head. When
there is no lymph node or vascular invasion, 5-year survival rate is at about 20%.
Prognostic factors include nodal status, negative resection margins and tumour size.
To improve the therapeutic outcomes in patients with pancreatic cancer several strate-
gies haven been pursued: extended pancreaticduodenctomy; total pancreatectomy;
superradical resections procedures and preoperative and intraoperative radiotherapy.
Comparison of these different procedures did not reveal any benefit for extensive
procedures. In a recently published metaanalysis of standard and extended lympa-
denectomy by Michalski et al.81 who found similar survival rates and mortality and
morbidity rate.
Irrespective of the therapy used local recurrence in the retroperitoneal resection
area, followed by liver metastases and peritoneal dissemination are common and
thereby determine survival. Even after a macroscopically radical resection, distant
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micro metastases may already exist and tumour cells are often observed at one or
more edges of the resected specimen (R-1) in 20 to 51% of cases.82,83 51,84-87 An expla-
nation for this early seeding and early local recurrence can be found in tumour
behaviour and tumour characteristics and has been described in several studies.
Relevant prognostic variables reported are tumour size, positive lymph nodes and
histological differentiation.82,83,88,89 These factors strongly limit survival after resec-
tion and together with the metastatic intend of this type of tumour suggest that
pancreatic cancer is a systemic disease. In this manner surgery as sole treatment is
not enough to gain long term survival. Patients treated with surgery alone, develop
local recurrence in up to 50%-80% peritoneal recurrence in 25%, and liver meta-
stases in 50%. 51
Adjuvant treatment
As is shown above comparison of the various surgical approaches does not provide
significant difference in terms of overall survival, moreover reveals higher mortality
and morbidity with the more radical procedures.82
However a comparison of patients with negative and positive resections margins
showed 5-year survival rates of 22% and 0%, respectively.83 Further we know that
positive lymph nodes significantly decrease survival. These results have prompted
several studies of surgery in combination with radiotherapy and/or chemotherapy.
In order to study the benefit of these so called adjuvant treatment much effort has
been put in trials comparing adjuvant chemoradiotherapy and chemotherapy to sur-
gery alone. The results were contradicting among different trails.84,86,90-92
Adjuvant systemic chemotherapy
There are not many studies published on adjuvant chemotherapy alone in pancre-
atic cancer. In 1980 Splinter et al. started a pilot study to investigate the feasibility
of five courses of adjuvant 5-fluorouracil, Adriamycin and mitomycin C (FAM) after
a curative resection of pancreatic or periampullary cancer. The survival of this
group of patients was compared with that of 36 patients who underwent a curative
resection alone between 1977 and 1984. Four patients received less than 20%, 4
patients 50%-60% and 7 patients greater than or equal to 80% of the calculated
dose of adjuvant chemotherapy. The chemotherapy was badly tolerated. Only 1
patient resumed some of his normal activity during chemotherapy. The 3-year actu-
arial survival after curative resection with and without FAM was similar, i.e. 24%
and 28% respectively. These data suggest that adjuvant FAM after a Whipple’s oper-
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ation or total pancreatectomy was not feasible because of additive postoperative and
chemotherapy-induced morbidity.93
In 1994 Baumel et al.82 reported retrospectively a large cohort of 787 patients
who had undergone pancreas resection, 43 of whom received adjuvant chemother-
apy. No difference in survival was demonstrated. The first randomised controlled
trial was performed by Bakkevold et al91 in 1993. In this study 47 patients with
resected pancreatic ductal cancer were randomised to either postoperative combina-
tion chemotherapy of 5-FU, doxorubicin, and mytomycin C every 3 weeks or surgery
only. A significant improvement was seen in median survival from11 months to 23
months with chemotherapy, however no improvement in long-term survival (3 and 5
year) was seen. Unfortunately it is difficult to draw conclusions on this study in relation
to pancreatic head cancer because 14 patients with ampullary cancer were included.
Lately, The European Study Group for Pancreatic Cancer (ESPAC) randomised more
than 500 patients to adjuvant chemotherapy, chemoradiotherapy, and surgery alone.86
The chemotherapy consisted of an intravenous bolus 5-FU (425 mg/m2) and folonic
acid (20 mg/m2) and was given on 5 days out of 28 days for six cycles. The median
survival for patients treated with chemotherapy was 21.6 months for chemotherapy
versus 14.8 months for patients with surgery alone. The same survival benefits for
chemotherapy were observed irrespective of the extent of resection or the develop-
ment of postoperative surgical complications. The ESPAC-1 study showed a reduction
in the hazard ratio (HR) of 36% in favour of adjuvant chemotherapy. (HR 0.64, confi-
dence interval (CI) 0.52-0.78). Despite its size, the ESPAC-1 trial is itself controversial
because of the use of different randomisation options based on doctors preferences.
Further patients in this trial were allowed to receive additional treatment options,
this raises additional questions about the effect of primary treatment and if additionl
treatment has affected the primary outcomes.
One of the latest randomised adjuvant trials is from Japan.94 It consisted of 5-FU
and mitomycin C in resected pancreaticobiliary carcinomas. In total, 508 patients
were randomised, of whom 173 patients had ductal adenocarcinomas. There were
89 patients included to receive chemotherapy and 84 to the control arm, of whom
45 and 47 respectively underwent curative resections. The chemotherapy group re-
ceived rapid infusion mitomycin C on the day of surgery, slow infusion 5-FU for 5
days in week 1 and 3, followed by oral 5-FU. The median survival was approximately
12 months in both the chemotherapy and the control group, with no significant
difference in 5-year survival (11.5% and 18% respectively).
The main chemotherapy regimen in this study was 5-FU which was administered
orally. The surprisingly low survival rates in both groups might be explained by the
unpredictable absorption of 5-FU.
general introduction 19
Recently Oettle et al. finished a large multicentre trial.95 The objective was to test the
hypothesis that adjuvant chemotherapy with gemcitabine administered after com-
plete resection of pancreatic cancer improves disease-free survival by 6 months or
more. Patients received adjuvant chemotherapy with 6 cycles of gemcitabine on
days 1, 8, and 15 every 4 weeks (n=179), or observation ([control] n=175).
Median disease-free survival was 13.4 months in the gemcitabine group (95%
confidence interval, 11.4-15.3) and 6.9 months in the control group (95% confidence
interval, 6.1-7.8; P<. 001, log-rank). Remarkable is the very low survival rate in the
control group in most other series survival after surgery and best supportive care
ranges between 10 and 12 months. Estimated disease-free survival at 3 and 5 years
was 23.5% and 16.5% in the gemcitabine group, and 7.5% and 5.5% in the control
group, respectively. Subgroup analyses showed that the effect of gemcitabine on dis-
ease-free survival was significant in patients with either R0 or R1 resection. There
was no difference in overall survival between the gemcitabine group (median, 22.1
months; 95% confidence interval, 18.4-25.8; estimated survival, 34% at 3 years and
22.5% at 5 years) and the control group (median, 20.2 months; 95% confidence
interval, 17-23.4; estimated survival, 20.5% at 3 years and 11.5% at 5 years; P=.06,
log-rank).
Adjuvant regional chemotherapy
In a surge for high dose chemoradiation without the risks of systemic toxicity a new
treatment module was designed years ago. This technique uses intra-arterial cathe-
ters to deliver high dose local chemotherapy.
The published studies so far have produced encouraging results. Different thera-
peutic regimens have been tried using selective arterial and/or venous delivery. Link
and Beger et al.96,97 reported several studies using adjuvant chemotherapy consisting
of mitoxantrone, folonic acid, cisplatin and, 5-FU. Initially 20 patients (18 with pan-
creatic head adenocarcinoma, 2 cystadenoma) underwent the regimen infused via
the celiac axis. A median survival of 21 months was achieved compared with 9.3
months for historical controls. An update of this study, with 24 patients, showed a
median survival of 23 months and a 4-year survival of 54%.
Ishikawa et al98 delivered postoperative hepatic infusion of 5-FU, via catheters
placed in both the hepatic artery and portal vein, in 27 patients. This perfusion was
undertaken for 28-35 days. There were no treatment related complications in the 20
patients who survived surgery. A 3-year survival rate of 54% was achieved, with
mortality from hepatic metastases at a mere 8%. This was compared to historical
controls and found to be significantly better.
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These results were the reason for starting a prospective randomised controlled
trial in the Erasmus MC to determine the effect of chemotherapy via the celiac trunk
and radiotherapy for the tumour bed in order to gain significant survival benefit.
The trial has been closed now and results are soon going to be published.
Adjuvant chemoradiotherapy
Adjuvant (postoperative) therapy has been studied in a few trials but the role of
adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recom-
mended standard protocol exists.
The Gastrointestinal Tumour study group (GITSG) was the first to report from
adjuvant chemoradiation in a randomised clinical trial.92 The protocol used con-
tained 40 Gy radiotherapy combined with fluorouracil and then weekly fluorouracil
for two years. Median survival was significantly longer in the adjuvant treatment
group compared to the surgery group (20 months versus 11 months), with respec-
tively 18 percent and 8 percent survival at five years.92 Further larger randomised
studies however did not confirm a benefit of adjuvant treatment.84,91,94 Moreover, it
is unclear whether the survival advantage in the GITSG trial was due to the com-
bination of chemoradiation and maintenance chemotherapy or to only one of these
treatments. Therefore ErasmusMC Rotterdam conducted a randomised phase III
multicentre trial in cooperation with the EORTC Gastro-intestinal group. This trial
was initiated in 1987 (EORTC 40891) and used the same amount of radiotherapy
however unlike the GITSG no maintenance 5-FU was given. Based on 218 patients,
this trial results at a median follow-up of 7.3 years did not show a benefit for adjuvant
chemoradiation although they suggested a trend in favour of chemoradiation
(p=0.09) in the patients with ductal pancreatic adenocarcinoma. 84
Later on The European Study Group for Pancreatic Cancer (ESPAC) undertook a
multicentre factorial phase III trial to investigate the possible benefits of adjuvant
chemoradiation and maintenance chemotherapy in patients with pancreatic cancer.
In this study a deleterious effect of adjuvant chemoradiation on survival was shown,
with a median survival of 15.5 months in the 175 patients who received chemo-
radiation compared with 16.7 months in the 180 patients who did not. Also there
was no survival benefit conferred by adjuvant chemoradiation in patients with micro-
scopically positive resection margins (R-1) whereas chemotherapy significantly
improved survival in patients with resected pancreatic cancer.85,86,99
Of interest is the cohort study of Metha et al.100 from Stanford. In this study 52
patients were treated with chemoradiation. The tumour bed and regional lymph
nodes were irradiated with a dose of 45 Gy in 1.8-Gy fractions followed by a boost to
the tumour bed in 355 of patients with a positive resection margin (total dose 54 Gy).
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Concomitant portal venous infusion of 5-FU (200-250 mg/m2 per day, 7 days per
week) was given during the entire radiotherapy course. A remarkable median sur-
vival of 32 months was achieved. Certainly these results are far superior to other
studies that have used concomitant bolus 5-FU or even continuous-infusion 5-FU,
however the results are non-randomised.
Klinkenbijl et al.84 found a trend towards prolonged survival in patients treated
with chemoradiation whereas Neoptolemos et al.86 found a deleterious effect for
chemoradiotherapy and a positive effect of chemotherapy. Long-term follow-up gives
an opportunity to show actual survival curves instead of actuarial survival and thereby
might reveal a define conclusion whether chemoradiotherapy is effective or not.7
Locally advanced disease and therapies
Locally advanced pancreatic cancer is defined as a tumour that encases a vascular
structure, such as the superior mesenteric artery, celiac axis, or superior mesenteric
vein-portal confluence with absence of distant metastases. Tumours associated with
bulky peripancreatic lymph adenopathy are also deemed unresectable.
Since 1982 Erasmus MC has offered treatment to patients with locally advanced
non-resectable adenocarcinoma without presence of distant metastases and with a
Karnofsky performance score of 80 or more. Radiotherapy consisted of 50 Gy exter-
nal upper abdomen radiation in two courses, concomitant with intravenous 5-FU 375
mg/m2 given as a bolus injection 4-6h before radiation on the first 4 days of each
treatment course. The treatment protocol was completed in 18 patients without com-
plications. The median survival time was 10 months, which compares favourably
with a 3-5 months median survival time when treatment is withheld. 101 This inter-
vention provides a survival advantage and offers a palliative benefit.
In the early and mid 1980s the GITSG did a three-treatment group randomised
trial in patients with locally advanced pancreatic cancer.102,103 Patients received radia-
tion alone to a dose of 60 Gy, 5-FU plus intermediate dose radiation to 40 Gy or
fluorouracil plus radiation to 6o Gy. Those receiving chemoradiation had a median
survival of 42-44 weeks; those undergoing radiation alone had a median survival of
23 weeks. Thus the combination therapy doubled survival compared with radiation
alone. Several other trials have shown an improvement in objective response rates,
overall survival and a statistically significant clinical benefit when compared to the
best supportive care.104,105 Despite the fact that the achieved objective response rate is
encouraging there are controversial results concerning overall survival: with 1-year
survival rates from 22% (Gemcitabine-irinotecan) and 34,8% (Gemcitabine-capeci-
tabine).106-108
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In an attempt to increase survival Moore et al.109 added an EGFR targeted agent to
gemcitabine and compared the treatment to gemcitabine alone. In this randomised
phase III clinical trial a total of 569 patients were randomly assigned to gemcitabine
plus erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo. Median survival
was 6.24 versus 5.91 months in the gemcitabine alone group (p=0.038).
The rationale for chemoradiation for locally advanced pancreatic cancer without
metastases has been very recently discussed in a meta-analyses by Sultana et al.110
This analysis included 794 patients in eleven studies up till 2006. Length of sur-
vival with chemoradiation was increased with a 31% reduction in risk of death fol-
lowing chemoradiotherapy, compared to radiation alone (HR 0.69; CI 0.51–0.94)
but chemoradiation followed by chemotherapy did not lead to a survival advantage
over chemotherapy alone ( HR 0.79; CI 0.32–1.95) caution is necessary interpret
ting this conclusion because important clinical differences could not be ruled out
due to the wide C.I. Unfortunately meta-analyses could not be performed for the
comparison therapy versus best supportive care for there where no qualified ran-
domised trials.
Neoadjuvant treatment
Chemoradiation for locally advanced pancreatic cancer has also been studied in neo
adjuvant setting. More over neo-adjuvant treatment has not been studied specifically
for primarily resectable pancreatic cancer but largely in suspected locally advanced
pancreatic cancer. Neo-adjuvant therapy has several theoretical advantages. For even-
tually resectable patients who initially deemed non resectable in pre operative work
up it reduces the time interval between diagnosis and systemic treatment. Many
patients cannot be treated directly after surgery due to wound healing and postoper-
ative complications. Approximately 20%-45% of resected patients never undergo
adjuvant therapy because of postoperative problems.84
Further neoadjuvant therapy may also be given in the hope to downstage locally
advanced cancer and achieve an enhanced resection site. In patients with rapidly
progressive disease a major surgical procedure might be avoided.
There have been only a few (non randomised) studies on the use of neoadjuvant
therapy. Snady et al111 reported median survival of 32 months in 20 patients who had
a resection from an original group of 68 patients treated first with simultaneous
split course EBRT plus 5-FU, streptozin and cisplatin. The median survival of the
whole group was 23.6 months and 32 months in the 20 patients who also had a
resection. During the same period another group of 91 patients with respectable dis-
ease initially underwent resection (5% mortality < 30 days), of which 63 (69%)
received chemotherapy with or without EBRT. The median survival in this latter
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group was 14.0 months (p=0.006) compared with RT-FSP-group). Median survival
in patients who had resection and adjuvant treatment was 16 months compared
with 11 months in those who did not have adjuvant therapy (p=0.025). In contrast
the M.D. Anderson Group in their (non randomised) studies have not shown a sig-
nificant difference in survival between those patients who underwent neoadjuvant
compared with adjuvant treatment.112 Mehta et al have recently reported a median
survival of 30 months with neoadjuvant therapy but only in nine selected patients.113
All aforementioned studies on neoadjuvant therapy suffer more or less from con-
founding factors, however the results and the rationale for introducing neoadjuvant
treatment are sound but yet non –proven due to lack on qualified randomised trials.
There is still place for studies analyzing the effect of chemoradiotherapy for
patients with locally advanced disease. The goal is downstaging the tumour that
might eventually result in making tumours resectable and even curable.
Interferon
Interferon-based adjuvant chemoradiation therapy has been introduced as a novel
treatment option after pancreaticoduodenectomy for pancreatic adenocarcinoma. In
a study by Traverso et al. 43 patients with adenocarcinomas in the pancreatic head
underwent PD and were treated adjuvantly. Pathologic findings were stage I (2%),
II (12%), III (72%), and IVa (14%) while 84% had positive lymph nodes. Tumour
extended through the capsule of the surgical specimen in 70%. These patients then
received our investigational protocol consisting of external-beam irradiation at a
dose of 4,500 to 5,400 Gy (25 fractions over 5 weeks) and three-drug chemotherapy:
continuous infusion 5-FU (200 mg/m(2) daily, days 1 to 35), weekly intravenous
bolus cisplatin (30 mg/m(2) daily, days 1,8,15,22,29), and subcutaneous alpha, inter-
feron (3 x 10(6) units, days 1 to 35). This chemoradiation was followed by continuous
infusion 5-FU (200 mg/m(2) daily, weeks 9 to 14 and 17 to 22). Chemoradiation was
generally initiated between 6 and 8 weeks after surgery.
Actuarial overall survival for the 1-, 2-, and 5-year periods was 95% (confidence
interval [CI] = 91% to 98%), 64% (CI = 56% to 72%), and 55% (CI = 46% to 65%),
respectively.
This follow-up report further suggests overall survival may be improved for
patients with adenocarcinoma in the pancreatic head using an adjuvant interferon-
based chemoradiation protocol. These results are obtained despite a high incidence
of node involvement and advanced tumour stage. From this limited patient series,
the actuarial 2-year and 5-year overall survival rates suggest a potential for improved
long-term survival. Results of a multi-institutional study are underway.
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Summary
Surgery today is the only change of cure for patients with pancreatic cancer.
Adjuvant chemotherapy may positively affect survival although reported survival
benefits are marginal. Chemoradiotherapy, despite the widely acceptance in the USA
should not be given routinely because nowadays there is no evidence that shows
favourable effect compared to surgery alone.
In the future choice of therapy might be based both on molecular and histo-
pathological assessment of the tumour. Knowledge of the molecular basis of pan-
creatic cancer has led to various discoveries concerning its character and type.
Well-known examples of genetic mutations in adenocarcinoma of the pancreas are
k-ras, p53, p16, DPC4. Use of molecular diagnostics and markers in the assessment
of tumour biology, may in future reveal important subtypes of this type of tumour
and may possibly, predict the response to adjuvant therapy. Defining the subtypes
of pancreatic cancer will hopefully lead to target specific, less toxic and finally more
effective therapies eventually resulting in long-term survival or even complete cure.
The main challenge is to improve survival rates over the coming years. Therefore
both evaluation of current surgical and adjuvant therapies, and initiating novel
studies on biological behaviour are of pivotal importance.
AIM of this thesis
The aim of the thesis is to evaluate modern surgical techniques, and to determine
clinical, histological and molecular factors that may predict long-term survival. In
the final part of the thesis the effect and benefit of adjuvant treatment after curative
resection and neoadjuvant therapy for locally advance disease is studied.
Outline of this thesis
A general introduction is given in chapter 1.
In chapter 2 an overview of the results of surgical and adjuvant strategies is dis-
cussed.
A randomised controlled trial comparing the standard Whipple procedure with
the pylorus preserving pancreaticoduodenectomy (PPPD) is described in chapter 3.
The aim of this study was to find out which of the most used surgical resections
to date gives the best chance for cure and the least morbidity. This is emphasized in
a clinical multicentre randomised trial.
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In chapter 4 clinical, pathological and molecular prognostic factors after R-0
resection are described. In this study a search was made for factors, which could
foresee long-term survival and might give a lead for more specific adjuvant treat-
ment
Chapter 5 describes the effect of chemoradiation after curative resection for pan-
creatic cancer. This is studied in a prospective randomised multicentre trial with an
actual follow up exceeding more than ten years.
In chapter 6 we discuss the need for radiotherapy after irradical resections this
is followed by a retrospective analysis of our experience with chemoradiation for
patients with locally advanced adenocarcinoma of the pancreas (chapter 7).
The summary and conclusions are described in chapter 8.
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Chapter 2
Survival after surgical management of
pancreatic adenocarcinoma
Does curative and radical surgery truly exist?
Langenbecks Arch Surg. 2005 Apr;390(2):94-103
Abstract
Surgery for pancreatic cancer offers a low success rate, but it provides the only likeli-
hood of cure. Modern series show that, in experienced hands, the standard Whipple
procedure is associated with a five-year survival of 10 to 20% with a perioperative
mortality rate of less than 5%. Most patients, however, will develop recurrent disease
within two years after curative treatment. This occurs usually either at the site of
resection or in the liver. This suggests the presence of micrometastases at the time
of operation. Negative lymphnodes are the strongest predictor for long-term sur-
vival. Other predictors for a favourable outcome are tumour size, radical surgery and
a histopathologically well-differentiated tumour. Adjuvant therapy has so far only
shown modest results, with 5-FU chemotherapy to date the only proven agent able to
increase survival. Nowadays the choice of therapy should be based on histopatho-
logical assessment of the tumour. Knowledge of the molecular basis of pancreatic
cancer has led to various discoveries concerning its character and type. Well known
examples of genetic mutations in adenocarcinoma of the pancreas are k-ras, p53,
p16, DPC4. Use of molecular diagnostics and markers in the assessment of tumour
biology, may in future reveal important subtypes of this type of tumour and may
possibly, predict the response to adjuvant therapy. Defining the subtypes of pancre-
atic cancer will hopefully lead to target specific, less toxic and finally more effective
therapies.
Long term survival is observed in only a very small group of patients contradict-
ing the published actuarial survival rates of 10-45%. Assessment of clinical benefit
from surgery and adjuvant therapy should therefore not only be based on actuarial
survival but also on progression-free survival, actual survival, median survival and
quality of life (QOL) indicators. Survival in surgical series is usually calculated by
actuarial methods. Without information on the total number of patients, the num-
ber of actual survivors and a clear definition of the subset of patients, actuarial sur-
vival curves can prove to be misleading. Proper assessment of QOL after surgery and
adjuvant therapy is of the utmost importance, as improvements in survival rates
have so far proved disappointing.
Introduction
Adenocarcinoma of the pancreas remains a formidable therapeutic challenge. For
the majority of patients this is a systemic disease. Surgical resection offers a low
success rate, but provides the only chance of cure. Allessandro Codivilla and later
Walter Kausch first described the technique of pancreaticoduodenectomy in 1898
respectively 1912. Allen Old Father Whipple later popularised the procedure that
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today bears his name.1,2 Since Whipple’s time significant advances have been made
in the surgical management of pancreatic cancer. In early series published in
the late 1960s postoperative morbidity rates exceeding 60% and mortality rates
approaching 25% were reported. Most recent series from institutions that specialise
in treating pancreatic cancer report mortality rates less than 5%, with morbidity
remaining high at 30 to 60%. The majority of perioperative complications are not
life threatening, though they are responsible for increased length of hospital stay
and cost, readmission for care, and delays in adjuvant therapy. Limited progress has
been made at improving the survival of patients with this disease despite the ad-
vances made in surgical technique and perioperative care. The 5-year survival rate is
the lowest of all known types of cancer. Low rates of resectable tumours and early
recurrence are the main problems facing a surgeon treating pancreatic cancer. The
resectability rate for a total of 16,942 patients in the USA was only 13,3% and 5-year
survival 4%.3
The incidence of adenocarcinoma of the pancreas has been increasing world-
wide in recent years and it is currently the fourth leading cause of cancer related
mortality in North America.4 In the Netherlands and in Germany the incidence
ranges between 9 and 19 patients per 100,000 inhabitants, making it the fourth
leading cause of cancer related death. At the time of diagnosis, more than 85% of
tumours have extended beyond the organ’s margins, and invasion of the perineural
spaces within and beyond the pancreas is present.5,6,7,8,9
Definitive curative resection is possible in no more than approximately 10% of
all cases. The likelihood of a curative resection depends on both location and stage
of the tumour. Localisation of the tumour near the papilla is correlated to early
detection due to the presence of obstructive jaundice.
The main challenge is to improve survival rates over the coming years. Since the
beginning of the 20th century not much improvement of survival has been achieved
despite extensive trials into adjuvant and neoadjuvant therapy regimes. Improvement
of survival has mostly been reached by better surgical skills and improvements in
peri- and postoperative care. As has been stated earlier, mortality of less than 5%
should be achievable in high volume centres.
An urgent need exists for better insight into both genetics and natural behaviour
of pancreatic cancer. Molecular biology studies and molecular diagnostics might
lead to more sensitive and specific treatment programs and will hopefully improve
survival for patients who are diagnosed with pancreatic cancer.
Hope exists that in the new millennium, a multidisciplinary and integrated
approach to pancreatic adenocarcinoma will unravel the mystery of this malignancy,
making it more amenable to early screening and therapy.
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Surgical treatment
The ultimate goal of surgical management of pancreatic neoplasm is total curation.
Preferably surgical treatment should remove all visible tumour with low mortality
and morbidity and short hospitalisation. Surgery ideally includes a radical (R0) resec-
tion and reestablishment of gastrointestinal continuity. Although surgical manage-
ment of pancreatic cancer has so far enjoyed low success rates, it still provides the
only hope of curation. Since the introduction of pancreaticoduodenectomy by Walter
Kausch in 1912, significant advances have been made. Postoperative morbidity and
mortality rates vary in various publications over the decades. Modern series show
that in experienced hands, the standard Whipple procedure is associated with a
five-year survival of 10 to 30% in completely resected patients with a perioperative
mortality rate of less than 5%.10,11,12,13,14,15,16,17,18,19 This relatively low perioperative mortal-
ity rate represents a decline from over 15% in the 1970s, thus making the Whipple
operation a much more attractive option. The most important factor in these falling
mortality rates appears to be concentration of cases in so called high volume institu-
tions. From the Medicare database, a fourfold increase in mortality is found when
pancreaticoduodenectomy procedures are performed in hospitals with less than one
case per year compared to operations performed in hospitals handling more than 16
cases per year. A similar improvement in long term outcome was noted.20,21
The prognosis for pancreatic cancer remains poor even with surgically negative
margins in appropriately selected patients. The most important prognostic factor
in radical resections has been shown to be nodal status. Five-year survival after
pancreaticoduodenectomy is only about 10 percent for node-positive disease, while
it can be 25 up to 30% percent for node negative disease. Other predictors of a
favourable outcome include a tumour size less than 3cm, negative margins (R0
resections), well differentiated tumours, and intraoperative blood loss of less than
750 ml.13,22,14,18
Contraindications for curative resections are the presence of distant metastases,
peritoneal seeding, tumour infiltration into mesenteric and portal vessels, and ex-
tension of tumour tissue into the small bowel mesentery.
Modifications of the standard Whipple procedure have been developed in an
attempt to improve outcome or minimise the morbidity associated with the opera-
tion. Extensive experience has been gained, especially by japanese centres with ultra
radical surgery. This type of resection includes excision of the portal vein, total or
regional pancreatectomy, and extensive retroperitoneal lymphadenectomy. However,
for this type of resection, several reports failed to demonstrate improved survival. A
further problem associated with total pancreatectomy is the development of brittle
diabetes.23 Some groups in Japan routinely complement the Whipple operation with
an extensive lymph node dissection (extended lymphadenectomy). The reason for
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this being that since periampullary malignancies frequently metastasise to lymph
nodes that are beyond the confines of the standard pancreaticoduodenectomy.7 A
single prospective trial comparing conventional pancreaticoduodenectomy versus a
more extended lymphadenectomy was conducted in 81 patients with a potentially
curable adenocarcinoma of the pancreatic head.24 While overall survival was found
to be identical for both treatment groups, subgroup analysis indicated better survival
in patients with positive nodes undergoing extensive lymphadenectomy.
Yeo et al. demonstrated in their study25 that radical pancreaticoduodectomy, i.e.
addition of a distal gastrectomy and extended retroperitoneal lymphadenectomy to a
standard pancreaticoduodenectomy, can be performed with similar morbidity and
mortality as compared to the standard pancreaticoduodenectomy. This however could
not be shown to benefit survival rates.
Pylorus-preserving pancreaticoduodenectomy (PPPD), a relatively less aggressive
operation that preserves the pylorus was studied in the 1980s. Shorter operation
time, less blood loss and shorter hospital stay were found to be advantages as com-
pared to the standard pancreaticoduodenectomy.26 The PPPD is increasingly being
performed in the United States.27 Three randomised trials have directly compared a
pylorus preserving operation to standard pancreaticoduodenectomy.28,29 The study
from Seiler et al.29 showed no differences in either tumour recurrence or survival after
short follow up. From the small and under-powered study of Lin et al.28 no difference
was noted in type of recurrence or long term survival between the two groups.
Unpublished data from our own multi-centres randomised study,30 which
compared PPPD versus standard Whipple procedure in 170 consecutive patients,
showed a similar incidence of delayed gastric emptying. No significant differences
in bloodloss, duration of operation, hospital stay and postoperative weight loss
could be found either. Long term survival and disease free survival was also compa-
rable. Thus both procedures must be considered equally effective in the surgical
management of pancreatic cancer. The best predictors of survival after surgery are
stage of disease, tumour grade, and resection margins. Nonetheless, even in those
with potentially resectable disease, five-year survival following pancreaticoduodenec-
tomy is only about 25 to 30 percent for node-negative and 10 percent for node-
positive tumours.13,31,32
Standardised surgical technique for suturing pancreaticojejunostomies has led
to a decrease in pancreatic fistulas, thus minimising local septic complications. The
avoidance of the pancreaticojejunostomy does not lead to less complications.33
More than 95% of the patients undergoing surgical resection are in an advanced
stage of cancer. In one third of the patients undergoing a R0 resection, liver meta-
stasis is the most frequent site of recurrent disease. Most patients who undergo a
curative resection eventually develop recurrence, this usually occurs at the site of
primary resection or in the liver. However, little is known about the precise pattern
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of recurrence of pancreatic carcinoma. From recently published series,34,35,36,37,38 it is
known that the majority of patients who underwent a macroscopically radical resec-
tion develops a tumour recurrence within two years of operation. The most com-
mon sites of recurrence were the locoregional areas, the liver and peritoneal cavity.
The recurrence occurs even more frequently in those with a microscopically irradical
resection (R1).
More recent data suggests that outcomes may be improving over time. This is
possibly related to the combined effect of an increase in the proportion of patients
undergoing surgery at teaching hospitals, lower procedure-related mortality rates, a
better selection of surgical candidates, and/or greater use of adjuvant chemotherapy
and radiotherapy.
Nevertheless, these patients still have a relatively poor prognosis, and systemic
chemotherapy, radiation or a combination of chemotherapy and radiation have all
been used either prior to resection (neoadjuvant therapy) or following surgical resection
(adjuvant therapy) in an effort to improve the cure rate achieved with surgery alone.
The eventual outcome of surgical treatment appears to be limited by the dissemi-
nation pattern of pancreatic cancer. All international classification systems of pan-
creatic cancer (UICC, International Union Against Cancer; AJCC, American Joint
Cancer Committee; JPS, Japanese Pancreatic Society) rely on tumour size, lymph
nodes status, stage of infiltration and present of distant metastasis. Achieving a R0
resection is the prime goal of surgery; macroscopically free resection margins are
associated with an increased chance of survival. Birk et al.5 found that patients with-
out lymphnodes metastasis and a tumour size smaller than 2 cm without distant
metastasis, have a significant survival benefit after an R0 resection. (Table 1)39
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Table 1 Survival after radical resection (R0) of adenocarcinoma of the pancreas
Author R0 (n) 1 yr (%) 2 yr (%) 3 yr (%) 5 yr (%) 7 yr (%)
Median
(months)
Richter et al.39 2003
n=194
122 - - - 25,4 12,3 -
Yeo et al.89 2002
n= 140
81 (pancr)
34 (ampul)
77
85
10
56
- - - 21
NYR
Sohn et al.17 2000
n=526
423 69 - - 23 - 19
Klinkenbijl et al.44 1999
n=108
108
control arm
- 41 - 22 - 19
Yeo et al.43 1997
n=443
443 73 - 37 - - 21
Trede et al.18 1989
n=118
44 - - 25 - - -
NYR = not yet reached; Pancr = pancreatic; Ampul = (peri)ampullary
Preoperative staging remains unable to reliably predict the presence of lymphnodes
involvement and the precise extent of this. Kayahara et al36 has shown that even in
cancer stage I and II there is extensive cancer cell infiltration in the surrounding
tissue of the resected pancreas specimen. (Table 2)40 Molecular biological methods
like reverse transcriptase polymerase chain reaction and immunostaining have
given us deeper understanding of micrometastases. A better understanding of the
underlying cancer cell dissemination pattern may explain the observed frequency of
recurrence rates of patients undergoing a curative surgical resection.
This paper will seek to provide a review of adjuvant and neoadjuvant therapies
for pancreatic exocrine cancer. Separately discussed issues are the surgical manage-
ment of localised disease, treatment of locally advanced disease, and chemotherapy
for advanced disease.
Adjuvant therapy
Survival after curative resection is limited for most patients due to the development
of local or metastatic tumour recurrence. Several adjuvant regimens, designed to
reduce these recurrences, have been evaluated in prospectively randomised trials.
In 1985 the Gastro Intestinal Tumour Study Group (GITSG)41 studied the efficacy
of combined external beam radiation (EBRT) and 5-fluorouracil (5FU). After surgery
patients were randomised to receive either 5FU-EBRT or no further treatment in the
control group. Survival in the treatment arm of the study was significantly higher
than in the control arm (20 vs. 11 months, p=0,03). The trial was terminated prior to
reaching the original accrual goal and only 43 patients entered the trial over a period
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Table 2 Survival rates according to the JPS and UICC stage classification
Kobari 1998; 40
N=1689 JPS Stadium 3 year (%) 5 year (%)
I 66,2 48,1
II 37,2 27,7
III 25,4 22,3
IV 12,7 8,8
N=1521 UICC I 44,3 32,5
II 22,5 11,5
III 16,3 12
IV 9,6 6,6
JPS = Japanese Pancreatic Society; UICC = International Union Against Cancer
n óf N?
of 8 years. Both the Norwegian Pancreatic Cancer Trial (NPCT)42 and a report by
Johns Hopkins43 supported the GITSG results. The only two large multi-centres ran-
domised trials, the EORTC44 and ESPAC-1,32 however, also failed to show the survival
benefit suggested by the smaller GITSG study.
In the EORTC study we were also not able to show significant survival benefit for
5FU-EBRT (24.5 vs. 19 months, p=0.208). After exclusion of periampullary tumours,
median survival for pancreatic head cancer demonstrate a trend towards better sur-
vival after treatment (12.6 vs. 17.1, p=0.099). The ESPAC-1 study showed a moderate,
but nonetheless significant survival benefit for chemotherapy alone (19.7 vs. 14
months p=0.0005) and no benefit for the combination of 5FU and EBRT (15.5 vs. 16.1
months, p=0.24). This provided confirmation for our finding that 5FU-EBRT does not
significantly improve survival.
Treatment failure is found either as local or distant recurrence. In the EORTC
study recurrence patterns for the treatment and control group were very similar.
Half of all primary recurrences were local; the other fifty percent of patients ex-
hibited distant recurrences in addition to the local recurrence. Fifty percent of all
progressions developed liver metastases secondary. Beger and Link et al.45,46 and
Lygidakis et al.47 have published results of prospective trials assessing the effect of
intra-arterial chemotherapy on local recurrence and liver metastases. Intra-arterial
chemotherapy has theoretical advantages, since it may increase the drug concen-
tration both in the primary tumour and in the liver. It is believed that overall drug
effectiveness is determined by the amount of lymphatic drainage and the absolute
drug concentration. Lygidakis et al.47 showed in his study an improved survival for
combined regional, SMA infusion, and chemo-immunotherapy (Gemcitabine, Carbo-
platin, Mitomycin, 5FU, Leucovorin, Interleukin-2). (mean survival: 31.07, SD=17.315
vs. 18.83 months, SD=11.745)
Link et al.46 achieved a median survival of 21 months, 10 months more than in
his retrospective control group (p=0.0003). At the present time a prospective ran-
domised trial (ESPAC-2) is being conducted, to further investigate this promising
treatment modality.
Neo-adjuvant treatment has not been studied for primarily resectable but largely
for non-resectable, locally advanced pancreatic cancer. Neo-adjuvant therapy has
several theoretical advantages. For resectable patients it reduces the time interval
between diagnosis and systemic treatment. The reason for this being that patients
cannot be treated directly after surgery due to wound healing and postoperative
complications. Approximately 20% of resected patients never undergo adjuvant
therapy because of postoperative problems.44 Down staging might be able to turn
unresectable tumours into resectable ones and make resection feasible in primarily
unresectable cases. In patients with rapidly progressive disease a major surgical pro-
cedure might be avoided. Preoperative treatment may help to sterilise the tumour
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field, theoretically reducing the risk of tumour seeding during surgery. Devasculari-
sation of the surgical field, thus minimising tissue-oxygenation is avoided and this
might improve efficacy of chemo- and radiotherapy. Several retrospective studies on
this subject have been conducted, reporting a benefit in resectability and survival for
those patients qualifying for resection.48,49,50,51,52 This indicates that neoadjuvant ther-
apy might be beneficial in selected primarily unresectable patients. This finding has
not yet been confirmed in large phase III trials.
Current adjuvant therapy is relatively safe, although treatment related deaths
have been reported in several studies. Current chemotherapeutic treatment cannot
prevent, but might delay disease progression. The only adjuvant therapy that can be
recommended on the bases of high level evidence, is 5FU chemotherapy.44,32
The adjuvant-therapy studies mentioned earlier are all, except for Lygidakis et
al.,47 5FU based. Several palliative studies comparing Gemcitabine (GEM) versus 5FU
show better results for GEM53, achieving similar survival and comparable tolerability
but higher response rates and progression-free survival. Combinations of GEM (or
5FU)54 with cisplatin(CIS) seem to be even more effective.55,56 Use of GEM-CIS combi-
nations in a (neo-) adjuvant setting deserves further investigation.57
Current choice of therapy is based on histopathological assessment of the tumour.
The molecular basis of pancreatic adenocarcinoma has been studied over recent
years and has uncovered various tumour subtypes. Several genetic mutations have
been found in adenocarcinoma of the pancreas (K-ras, p53, p16, DPC4) and several
hereditary patterns have been uncovered constituting approximately 5-10% of all
cases58,59 (PRSS1, FAMM60, STK11/LKB1, BRCA-2, HNPCC, Li-Fraumeni{p53}).61 Use of
molecular diagnostics and markers in the assessment of tumour biology, might be
able to differentiate subtypes of this tumour in future. There is evidence that spe-
cific K-ras mutations (75-90% are K-ras positive) influence survival.61,60 Response to
chemoradiation might be influenced by p53 expression. Patients with p53 positive
tumours exhibit shorter survival after chemoradiation than those with p53 negative
tumours.62 Defining the subtypes of pancreatic cancer in terms of tumour biology
and response to treatment will make the choice of therapy more specific.63,62
Knowledge of the molecular basis of (pancreatic) cancer has also presented new
targets for therapy. Current developments in specific anti tumour agents are promis-
ing.
Imatinib mesylate (Gleevec®, Novartis), a specific Bcr-Abl tyrosine kinase inhibi-
tor (TKI), has yielded great results in CML and as a c-kit tyrosine kinase inhibitor in
gastrointestinal stromal tumours (GIST). Although not thought to be effective in
pancreatic cancer,64 it shows great potential for target-specific therapy. An example
of the consequences of these exciting developments for treatment of gastrointestinal
tumours are the specific agents targeting the EGF-receptor,65 (tyrosine kinase inhi-
bitors: erlotinib (Tarceva®, Genentech/OSI/Roch) gefitinib (Iressa®, AstraZeneca),
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monoclonal antibodies (cetuximab(Erbitux® ImClone). These agents are currently
under investigation in late-phase trials, hopefully leading to future use in pancreatic
cancer treatments.
Recent discoveries have also been made concerning cyclo-oxygenases (COX). These
are key enzymes that mediate the production of prostaglandines from arachidonic
acid. Two isoforms of these important enzymes, COX-1 and COX-2 have been de-
scribed. Data from animal and human studies suggest an important role for COX-2
in gastrointestinal carcinogenesis.66 Up-regulation of Cyclooxygenase-2 (COX-2) has
been observed in pancreatic adenocarcinoma.67 This process is initiated by a num-
ber of growth factors and tumour promoters and has been implicated in cancer pro-
gression.68 Furthermore COX-2 also appears to have a role in the development of
resistance to conventional cancer therapy. Increased resistance to apoptosis appear
to be an especially important factor in this regard.69,70 Enhanced growth-inhibition of
pancreatic carcinoma cells by COX-2 inhibitors in combination with chemotherapy
has also been described.71 Selective COX-2 inhibitors, such as celecoxib (Celebrex®,
Pfizer), have recently been approved for the treatment of patients with rheumatoid
arthritis and osteoarthritis and these drugs can be used with minimal side effects.
Currently we are conducting a phase II trial to assess the role of these agents in pan-
creatic cancer.
In the field of immunotherapy other examples of tumour specific approaches
can be found. Current clinical trials72 are investigating the induction of anti tumour
response by the bodies own immune system by the use of cytokines and vaccines.
Mechanistic approaches using targeted therapies, such as the examples mentioned
earlier, may help to find a more effective and less toxic therapy for pancreatic can-
cer.73 Unfortunately such a revolution has so far not been witnessed in the treatment
of pancreatic cancer.
Survival statistics and definition of endpoints in pancreatic cancer surgery
One must be cautious to draw direct conclusions based on the survival figures
presented in most studies when reviewing the results of surgery and/or adjuvant
therapy. It is important to be aware of the fact that selected patients for surgery and
adjuvant therapy only represent a fraction of all pancreatic cancer cases. They can
therefore not be considered to be representative for the survival of the total patients
group after first diagnosis for pancreatic cancer. Further long-term survival is ob-
served in only a very small group of pancreatic cancer patients. This finding contra-
dicts the published actuarial 5-year survival rates of 20-45% among resected patients.
Gudjonsson did find, after correction for repetition, no more than 300-350 survivors
after 65 years of resections.74 He stated that the statistical method used is responsi-
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ble for misleading survival results. In surgical science, survival is most commonly
calculated using the Kaplan-Meier statistical method, instead of the actual method.
The difference being that the actual method uses only proven survivors without
lost data and therefore is unlikely to exaggerate results. There is however another
approach to actuarial methods. This is to take the number of patients alive at the
start of a particular period, minus the known deaths over that period. This figure is
then divided by the number of patients alive and this figure is then multiplied for
each period or after each death. As long as there is no loss to follow-up, no differ-
ence between the actual and actuarial method will be found. In daily practise how-
ever, clinical trials will always have more or less losses to follow-up. Loss of data is
completely ignored by the Kaplan-Meier method, the most frequently used method
to calculate survival in surgical studies. Loss of data, in other words censored cases,
might influence survival dramatically using the actuarial Kaplan-Meir method; this
has also been shown clearly by Gudjunsson, (Table 3). Therefore publication of only
actuarial survival figures should be considered scientifically unacceptable without
information on the total number of patients in the study group, the number of
observed (actual) survivors, and a clear definition of the precise subset of patients
followed after resection.
Besides actual survival as an endpoint evaluation, the observed median survival
and progression free survival have been introduced in surgical series as appropriate
primary endpoints from which to measure treatment benefits. Indicators of response
in terms of clinical benefit have been introduced in recent trials as an additional
endpoint to evaluate the effect of chemotherapeutic agents. A combination of im-
provements in pain perception, performance status, and weight gain is used to
objectify clinical benefit. Clinical benefit response, however, can underestimate the
effects of chemotherapy because it does not include the assessment of other symp-
toms. Further more it can overestimate the results of chemotherapy, the reason for
this being that it does not properly assess the side effects.75,76 Therefore QOL studies
have been introduced in the latest adjuvant clinical trials.
Quality of Life (QOL)
PPPD is gaining acceptance as an appropriate procedure for various malignant and
benign diseases of the pancreas and periampullary region.77,78,79,24,80,81,82,25 As experi-
ence with pancreaticoduodenectomy grows, there is an increasing number of survi-
vors who have recovered from the procedure and who live with the resulting altered
upper gastrointestinal anatomy. These survivors have only been marginally studied
in terms of their post procedure quality of live (QOL) and as determined by para-
meters such as pain, stool habits, activity levels, among other parameters.83,84,85,86,87,88
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Additional prospective studies incorporating both preoperative and serial postopera-
tive QOL assessment are needed to further investigate the QOL after resection.
The rapidly progressive nature of pancreatic cancer causes deterioration of QOL
over time, which leads to reduce of psychological, physical and social functioning.
Thus “increased survival” might in reality mean more survival months of ever de-
creasing quality of live. This makes QOL a very important tool to measure the clinical
benefit of the adjuvant and neoadjuvant treatment protocols.
In advanced pancreatic cancer QOL was found significantly to be higher in patients
receiving chemotherapy compared to those receiving best supportive care. QOL after
resection of pancreatic cancer is mainly determined by the presence or absence of
recurrent disease.
QOL assessment in pancreatic disease is currently still in the early stages of data
retrieval and evaluation. Additional studies incorporating both preoperative and serial
postoperative QOL assessment are needed. Study results are also needed to evaluate
the QOL for the various nonsurgical management strategies. In pancreatic cancer
treatment trials, especially in series with multimodality treatment, clinical response
as well as QOL measurements are of utmost importance to evaluate the effect of the
treatment given. The primary end points of trials should be actual survival, median
survival and progression-free survival.
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Pylorus preserving
pancreaticoduodenectomy
versus standard Whipple procedure
A prospective, randomised, multi-center analysis of 170 patients with
pancreatic and periampullary tumors
Annals of Surgery 2004 Nov; 240(5):738-45
Abstract
In a prospective randomised multi-center study the pylorus preserving pancreatic-
oduodenectomy was compared to the classic Whipple operation in respect to oper-
ation time, blood loss, hospital stay, delayed gastric emptying and survival. No sig-
nificant difference was noted in duration of operation, blood loss, hospital stay,
mortality, morbidity and delayed gastric emptying. Long-term follow up showed no
significant difference in survival between both groups.
Both surgical procedures are equally effective for the treatment or pancreatic and
periampullary carcinoma.
Objective
A prospective randomised multi-center study was performed to assess whether the
results of PPPD equalize those of the standard Whipple (SW) operation, especially
with respect to duration of surgery, blood loss, hospital stay, delayed gastric empty-
ing (DGE) and survival.
Summary Background Data
Pylorus-preserving pancreaticoduodenectomy (PPPD) has been associated with a
higher incidence of delayed gastric emptying, resulting in a prolonged period of
post-operative nasogastric suctioning. Another criticism of the pylorus-preserving
pancreaticoduodenectomy for patients with a malignancy is the radicalness of the
resection. On the other hand PPPD might be associated with a shorter operation
time and less blood loss.
Methods
A prospective randomised multi-center study was performed in a non-selected series
of 170 consecutive patients. All patients with suspicion of pancreatic or periampul-
lary tumor were included and randomised for a SW or a PPPD resection. Data con-
cerning patients’ demographics, intraoperative and histological findings as well as
postoperative mortality, morbidity and follow-up up to 115 months after discharge
were analyzed.
Results
There were no significant differences noted in age, sex distribution, tumor localiza-
tion and staging. There were no differences in median blood loss and duration of
operation between the two techniques. DGE was observed equally in the two groups.
There was only a marginal difference in postoperative weight loss in favor of the
standard Whipple procedure. Overall operative mortality was 5.3%. Tumor positive
resection margins were found for 12 patients of the SW group and 19 patients of the
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PPPD group (P < .23). Long-term follow-up showed no significant statistical differ-
ences in survival between the two groups (P < .90).
Conclusions
The SW and PPPD operations were associated with comparable operation time, blood
loss, hospital stay, mortality, morbidity and incidence of DGE. The overall long-term
and disease free survival were comparable in both groups. Both surgical procedures
are equally effective for the treatment of pancreatic and periampullary carcinoma.
Introduction
Pancreatic cancer is one of the most fatal malignant diseases today and ranks fifth in
cancer mortality worldwide. Survival after surgery is still disappointing with 5-year
survival rates ranging from 10% to29%.1-6
The introduction of partial pancreaticoduodenectomy is credited to Godivilla, an
Italian surgeon and Kausch7, a German surgeon from Berlin. Later on this tech-
nique was refined by Whipple et al.8
Several modifications have been reported, including the pylorus-preserving pan-
creaticoduodenectomy (PPPD) described by Watson in 1944.9
This technique was re-introduced by Traverso and Longmire 10 in the late 1970s
for chronic pancreatitis. Preservation of the pylorus in pancreaticoduodenectomy
has been shown in retrospective studies to lead to a long-term improvement in gas-
trointestinal function, as indicated by more postoperative weight gain, fewer peptic
ulcers and less dumping. Furthermore, the pylorus preserving procedure simplifies
the operation, thus leading to shorter operations and less intra-operative blood loss.11
Initial studies reported a high incidence of complications, including delayed gastric
emptying, ulcerative lesions of the anastomosis12,13 and great concern about resection
margins.5,14 Nevertheless, similar survival rates have been described for both tech-
niques.2,15-18
Only two relatively small studies have been performed to study PPPD prospec-
tively. In a prospective randomised study of 31 patients by Lin et al.17 no differences
in operation time, blood loss, and blood transfusion were observed. Delayed gastric
emptying was observed more frequently after PPPD than after the Whipple proce-
dure, with marginal statistical significance. (P = .08) Seiler et al.19 found shorter
operation time, less blood loss and fewer blood transfusions in the PPPD-group of
their series of 77 patients. No difference in operative mortality was found but the SW
group exhibited a higher morbidity rate.
In a large randomised trial in which the extended retroperitoneal lymphade-
nectomy for periampullary adenocarcinoma was compared with a standard resection
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to preserve the pylorus,20,21 similar mortality and some increased morbidity in the
extended resection group were reported.
We conducted a prospective randomised multi-center study to evaluate whether
PPPD has an advantage over the standard Whipple procedure.
Methods
Study design
The study protocol was approved by the Ethics Committee of each center. Informed
consent was obtained according to the local rules prevailing at each participating
institution.
The following hospitals in the Netherlands participated: Erasmus Medical Cen-
ter Rotterdam; University Hospital Maastricht; Leiden University Medical Center;
Ignatius Hospital, Breda; Reinier de Graaf Gasthuis, Delft; De Weezenlanden Hos-
pital, Zwolle and Medical Center Leeuwarden.
The design of this prospective multi-center trial consisted of a pre-treatment
evaluation and a randomised treatment with either a standard Whipple (SW) or a
pylorus-preserving pancreaticoduodenectomy (PPPD). The postoperative morbidity
and mortality data were evaluated every 3 months up to 115 months of follow-up.
Preoperative Evaluation
Preoperative work-up was standardized in all centers. A CT scan of the upper abdo-
men and a chest X-ray were requested. In most cases an ERCP also was performed.
PTC (percutaneous transhepatic cholangiography), angiography, CT-angiography and
MRI were optional.
Inclusion Criteria
We included 170 consecutive patients between January 1992 and December 2000
with suspected pancreatic or periampullary cancer that was assumed to be resec-
table according to preoperative diagnostic imaging (CT and/or MRI). Patients with a
previous gastric resection were excluded.
Exclusion Criteria
Patients with distant metastasis or local unresectable tumors as indicated by pre-
operative work-up and intra-operative findings, were excluded. Patients with direct
invasion of the pylorus or stomach as well as patients with positive peri-pyloric
lymph nodes were excluded; all of the remaining patients were included in the
analysis for efficacy. However, for analysis of survival, patients with lesions other
than pancreatic or periampullary adenocarcinoma were excluded.
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Blinding and randomization
An equal number of blind envelopes with protocols for the SW and the PPPD resec-
tion was prepared. The envelopes were used sequentially as patients were enrolled
in the study. Therefore there was strict randomization in both arms. Randomization
was carried out in the operation room: a sealed envelope was opened only after it
was ascertained that both operation techniques were feasible in the patient con-
cerned. Eighty-seven patients were randomised for PPPD (50 male: 37 female) with a
median age of 64 years. 83 patients were randomised for a Whipple resection (58
male: 25 female) with a median age of 62 years. Two patients in the PPPD group
were converted to the SW resection during operation as the surgeon expected duode-
nal involvement; these two patients remained for analysis in the PPPD group.
Surgery
All patients were placed on a regimen of prophylactic antibiotics consisting of
2-gram cefazolin (Cefacidal®, Bristol-Meyers Squibb, Woerden, Holland) and 500
mg metronidazol (Flagyl®), Aventis Pharma, Hoevelaken, Holland). In addition,
octreotide (Sandostatin®, Novartis Pharma, Arnhem, Holland) was administered to
all patients preoperatively and continued postoperatively for 7 days at a dosage of
100µg given subcutaneously three times a day.22
Surgical Procedure
The standard, pylorus-preserving resection involved division of the duodenum 2 cm
distal to the pylorus with resection of all of the duodenum distal to the transection
site, removal of the gallbladder and common bile duct (proximal to the level of the
cystic duct junction), resection of the head, neck, and uncinate process of the pan-
creas (underneath the superior mesenteric vein, lateral from the mesenteric-portal
vein axis, flush with the superior mesenteric artery) and removal of the periampul-
lary tumor. For the standard resection, a distal gastrectomy varying from 20 to 40%
was performed. Frozen section was performed routinely at the transection site of the
pancreatic remnant in all patients. In case of macroscopically suspected other mar-
gins a frozen section of this margins was also performed. An end-to-side invagi-
nated pancreaticojejunostomy was performed. Further downstream an end-to-side
hepaticojejunostomy and side-to-side gastroenterostomy or an end-to-side pylorus-
jejunostomy was made.
Postoperative Management
All patients were managed according to a standard postoperative pathway. All patients
received histamine H2-receptor antagonists as prophylaxis against stress ulceration
and octreotide treatment was continued for seven days. At the end of the operation a
drain was left in the area of the pancreaticojejunostomy and the hepaticojejunos-
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tomy. The drain was removed if the amylase concentration was less than 300 U/L
(less than twice the serum concentration) and production was less than 50ml per
day or after postoperative day 10. Pancreatic fistula was defined as drainage of more
than 50ml amylase-rich fluid per day through the surgically placed drains on or after
postoperative day 10, or pancreatic anastomotic disruption demonstrated radio-
graphically.
A biliary fistula was diagnosed if there was persistent secretion of bilirubin-rich
drainage fluid of more 50ml per day or after the tenth post-operative day.
Postoperative bleeding was defined as the need for more than 2 units of red
blood cells more than 24 hours after surgery or relaparotomy for bleeding.
The nasogastric tube was removed when the production has decreased to less
than 200 ml per 24 hours.
Delayed gastric emptying was defined as gastric stasis requiring nasogastric in-
tubation for ten days or more or the inability to tolerate a regular diet on the 14th
postoperative day.23
Nineteen (10 SW and 9 PPPD) patients received postoperative chemoradiotherapy
according to the EORTC study in which the Erasmus Medical Center Rotterdam
paticipated.24
Pathological review
All pathology specimens were reviewed to determine the primary pathological diag-
nosis and the extent of the disease. Tumor stage was determined according to the
UICC classification sytem and the TNM system.25 Resection margins of the specimen
were stained and were considered positive if the neoplasm was present at the pan-
creatic neck, uncinate processus, common bile duct, duodenum/gastric resection
area, mesenteric artery and portal vein and the circumferential margin which is
defined as the dorsal resection margin (peripancreatic fat and fascia of Trietz) or
beyond the anterior pancreatic parenchyma anteriorly (peripancreatic fat, mesenteric
base of the transverse colon or posterior peritoneum of the lesser sac). A periampul-
lary tumor was defined as a tumor of the ampulla of Vater or periampullary duode-
num and distal common bile duct.
Follow-up
Patient follow-up, obtained via office records from the outpatient clinic, was com-
pleted up to May 2002. Patient demographics, intraoperative factors, pathological
findings and postoperative course were evaluated. Parameters such as blood loss,
duration of operation, delayed gastric emptying, intra operative and postoperative
complications, hospital stay, hospital mortality and weight loss were recorded at
discharge. Follow-up evaluations were conducted every three months following dis-
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charge. When signs of recurrent disease occurred during the interval, a CT scan or
MRI was performed.
Statistical analysis
Data were expressed as median and range. The primary endpoints in this study
were blood loss, operation time and hospital stay. The secondary endpoints were
delayed gastric emptying and survival. A power-analysis for these endpoints, based
on data from a former study, had shown that at least 65 patients with pancreatic and
periampullary adenocarcinomas had to be included in each group.15 With this num-
ber of patients it should be possible to demonstrate (a=0.05; b=0.05) that blood loss
and operation time will be less with pylorus preserving pancreaticoduodenectomy as
compared to the standard Whipple’s resection. This number of patients is also suffi-
cient to achieve a reduction of hospital stay. Survival was calculated from the date of
surgery using the Kaplan-Meier method and compared with the log-rank test. Data
were compared using the Mann-Whitney test. Percentages between groups were
compared using Fisher’s exact test and the Chi-square test. The level of significance
was set at P < .05.
Results
Demographics and preoperative characteristics of this study are listed in Table 1.
Follow-up results
Based on the final histological diagnosis, 29 patients with benign lesions (14 in the
SW group and 15 in the PPPD group) and 7 with endocrine tumors (3 in the SW group
and 4 in the PPPD group) were excluded from the survival analysis. For long-term
follow-up a total of 134 patients with histological proven pancreatic and periampul-
lary adenocarcinoma were included and analyzed. Median follow-up was 18.5 months
(range 1-115 months). The median intraoperative blood loss was 2.0 L, (0.3-9.5 L) in
the SW resection group and 2.0 L (0.4-21.0 L) in the PPPD group with a P-value of
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Table 1 Patient characteristics
Patient characteristics SW* (n=83) PPPD* (n=87) P-Value
Age (y)* 62 (27-78) 64 (43-78) .269
Gender (male/female)* 50/37 58/25 .112
Weight pre-op (kg)* 70.6 (46-102) 70.0 (43-110) .717
* SW, standard Whipple; PPPD, pylorus-preserving pancreaticoduodenectomy;
Data given are number of patients or median (range)
.70. The median operative time was 300 minutes (range 160-480 min.) in the SW
group and 300 min (range 130-600 min.) in the PPPD group (P=.10).
Number of units packed red blood cells given during operation was equal in both
groups, with a median of 2 in each group (P=.70).
During the postoperative course there were no differences in specific procedure-
related or general complications. 16 patients in the SW group underwent a rela-
parotomy versus 13 patients in the PPPD group (P=.40)(Table 2).
Days of nasogastric intubation were similar in both groups, with a median of
5 days (range 1-48) in the SW group and 6 days (range 1-57) in the PPPD group
(P = .80). There were also no significant differences in days until regular diet was
tolerated.
The incidence of delayed gastric emptying was comparable in both groups, 18
patients in the SW group and 19 patients in the PPPD group (P = .80). We did find a
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Table 2 Postoperative complications, relaparotomy, and mortality
Complications SW* (n=83) PDDD* (n=87) P-Value
Pancreatic fistula 12 (14%) 11 (13%)
GE leakage 2 (1%) 0
Bile leakage 0 2 (2%) .528
Post-operative bleeding 6 (7%) 6 (7%) .933
Intra-abdominal abscess 8 (10%) 9 (10%) .878
Other complications 23 (28%) 19 (22%) .375
Relaparotomy 16 (19%) 13 (15%) .479
Mortality# 6 (7%) 3 (3%) .270
* SW, standard Whipple; PPPD, pylorus-preserving pancreaticoduodenectomy; # Operative mortality within 30 days.
Table 3 Postoperative days of nasogastric intubation, Days until normal diet, Incidence of Delayed
Gastric Emptying, Postoperative hospital stay in days, and lapse in bodyweight
Outcome SW* PPPD* P-Value
Days of nasogastric intubation 5 (1-48) [83] 6 (1-57) [87] .835
Days until regular diet tolerated orally 10 (0-54) [83] 10 (0-58) [87] .574
Delayed gastric emptying* 18 (23%) [80] 19 (22%) [85] .800
Hospital stay, days 20 (11-138) [67] 18 (4-175) [74] .488
Body weight on discharge (kg) 67 (44-92) [67] 65 (41-98) [74] .789
Pre-illness body weight (kg) 75 (53-92) [75] 79 (50-120) [76] .571
Pre-operative body weight (kg) 71 (46-102) [77] 70 (46-102) [81] .764
* Delayed gastric emptying is defined as nasogastric suction for ten days or more, or diet on or before the 14th post-
operative day. Data given are median (range) or number of patients. Data given in brackets indicate number of
patients concerned, i.e. excluding patients not analyzed
significant correlation between DGE and intra-abdominal complication. (Postopera-
tive bleeding, abscess and intra-abdominal leakage) (P< .05)
The median hospital stay was in both groups equal (19 days) (P = .50). Postoper-
ative weight loss was observed in both groups with a median of 8 kg in the SW re-
section group and 13,5 kg in the PPPD group. (P = .70) (Table 3) These differences
equalize during follow-up. (Figure 1)
Pancreatic adenocarcinoma was found in 43 patients in the SW group and in
47 patients in the PPPD group (Table 4). Twenty-three patients in the SW group and
21 patients in the PPPD group were diagnosed with a periampullary carcinoma.
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Table 4 Pathology
Characteristics SW* (n=83) PDDD* (n=87)
Malignant
Pancreatic adenocarcinoma 43 (52%) 47 (54%)
periampullary adenocarcinoma 23 (27%) 21 (24%)
Other malignancy 3 (4%) 4 (5%)
Total 69 (83%) 72 (83%)
Benign
Chronic pancreatitis 10 (12%) 9 (10%)
Benign villous adenoma with dysplasia 4 (5%) 6 (7%)
Total 14 (17%) 15 (17%)
Lymph nodes SW (n=69)# PDDD (n=72)#
Hepatoduodenal ligament 5 (7%) 4 (6%)
Peripancreatic 26 (38%) 25 (35%)
Mesenteric artery/vein 7 (10%) 6 (8%)
Perigastric/Pyloric 0 2 (2%)
Tumor negative lymph nodes 31 (45%) 35 (49%)
Margins positive resection SW* (n=69) PPPD* (n=72) P-Value
Duodenum/gastric 0 1 (1%)
Pancreatic remnant 1 (1%) 1 (1%)
V.porta/V.mesenterica 2 (3%) 2 (3%)
Mesenteric artery 3 (4%) 4 (6%)
Circumferential 5 (7%) 10 (14%)
Inferior Cava vein 1 (1%) 1 (1%)
Total 12/69 ( 17%) 19/72 (26%) .230
* SW, standard Whipple; PPPD; pylorus-preserving pancreaticoduodenectomy. Data given are number of patients.
Peripancreatic: anterior and posterior pancreatoduodenal nodes. Circumferential margin: posterior resection
margin and the margin beyond the pancreatic parenchyma anteriorly.
Benign; géén
kopjes met
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steekproef?
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Figure 1 Body-weight versus time of follow-up
Figure 2 Overall survival rates for patients with adenocarcinoma
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Figure 4 Pancreatic adenocarcinomas
Figure 3 Periampullary adenocarcinomas (DBD, ampullary and duodenal carcinomas)
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Tumor positive lymph nodes were found in 38 patients in the Whipple group versus
37 patients in the PPPD group (P = .70). Loco-regional tumor positive lymph nodes
were equally spread in both groups (P = .60).
Overall operative mortality rate was 5.3 %, 6 patients in the SW group and 3
patients in the PPPD group died within 30 days.
The overall median disease free survival was 14 months in the SW-group and 15
months in the PPPD group (P = .80). The overall disease free survival was similar in
both groups (P = .90). There was no difference in median overall survival rates
between the two groups (P = .90) (Figure 2).
Periampullary cancer was diagnosed in 44 patients. Of whom 21 patients under-
went a PPPD and 23 patients a SW resection. The median disease free survival was 49
months in the SW group and 23 months in the PPPD group (P = .60). Median sur-
vival in the SW group was 17 months versus 29 months in the PPPD-group which is
not statistically significant (P = .50)
Ninety patients had pancreatic cancer of which 47 patients underwent a PPPD
and 43 patients a SW. The median disease free survival was 7 months in the SW
group and 6 months in the PPPD group (P = .90) The median survival was 11
months in the SW group and 12 months in the PPPD group (P = .70).
Combining both carcinoma groups there was no difference in median overall
long-term survival rates between the two randomised groups as shown in figure 3.
(P = .90)
Tumor positive resection margins were noted in 12 (17%) patients in the SW group
and 19 (26%) patients in the PPPD group (P = .23). Most of these positive margins
were located at and around the pancreatic resection area, which was defined as
circumferential (Table 4) and not on the pancreatic remnant.
Discussion
We hypothesized that pylorus-preserving pancreaticoduodenectomy is associated with
a reduced operation time, less blood loss, shorter hospital stay and a more physio-
logical food passage. Two smaller randomised studies reported a shorter operation
time and less blood loss, fewer transfusions and a lower morbidity for the PPPD.
However the power of both studies might be considered low.17,18
In this study the duration of the operation was equal for the two procedures. The
median blood loss also did not differ between the two groups (2.0 L) (Table 1).
Compared to reports from some large centers,20,26 blood loss in the present series
was two times higher, however, in comparison to other multi-center studies18,27 there
are only small differences.
62 chapter 3
When the results of this study are analyzed, one must take into consideration the
fact that we performed a multi-center analysis of both large volume and small vol-
ume centers which is a realistic situation in most countries.
The overall operative mortality in this study was 5.3 %. Multi-center studies are
often associated with a higher mortality rate, ranging from 5 % in Italy27 to 10% in
France28 and 17.2 % in the United States.29
PPPD has been associated with delayed gastric emptying, an increase in morbidity
and prolonged hospital stay. Warshaw and Torchiana first reported this phenomenon
after their initial study of 8 patients in 1978.30 According to the literature, the in-
cidence of delayed gastric emptying is estimated to range between 25-70%12,15,23,30-36
which is sufficient reason for some to abstain from the PPPD procedure. The inci-
dence of delayed gastric emptying in this study was equal in the two groups, 18 in the
Whipple group versus 19 in the PPPD group.
Several factors are thought to play a role in the pathophysiology of delayed gas-
tric emptying. In the present series we found a correlation between delayed gastric
emptying and intra-abdominal complications(P < .05). This relationship was re-
ported previously.23,37,38 Gastric dysrhythmias, disruption of gastroduodenal neural
connections, ischemia of the pylorus muscle and ligation of the right gastric artery
all have been related to delayed gastric emptying.32,39-42Resection of the duodenum,
the primary production site of most gastrointestinal hormones, might also play a
role in the pathogenesis of this complication. Yeo et al.36 reported in a randomised
trial that administration of erythromycin, a motulin agonist, decreased the inci-
dence of DGE by 37%. Since this difference, was not statistically significant, we did
not include erythromycin as standard therapy.
In the present study hospital stay, 20 days for the SW group and 18 days for the
PPPD group, was not significantly different (P = .50). These results are comparable
to other randomised studies.18,27
An argument in favor of pylorus preservation may be that patients subsequently
have a better nutritional status compared to patients after a gastrectomy.23,33 Post-
operative weight loss was observed in both groups with a median of 8 kg for the
Whipple resection group versus 13.5 kg for the PPPD group. This is not statistical sig-
nificant (P = .70). An argument against the use of PPPD for the resection of pancre-
atic tumors is the potential risk of positive duodenal resection margins,5,14 resulting
in lower survival rates. In this study one patient in the PPPD group had a positive
resection margin at the duodenal site. There were no significant differences in
tumor positive resection margins; subsequently we did not detect any significant
differences in survival.
According to other randomised studies which compared the PPPD versus SW18
and SW versus the extended pancreaticoduodenectomy,27 our survival outcomes are
highly comparable. It is important to note that we included the in-hospital mortality
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in our survival rate calculation in contrast to some other studies.21 Furthermore it
should be noted that adjuvant therapy was not routinely provided in contrast to
other trials.21,43,44 We did not recommend adjuvant chemotherapy and radiotherapy
for our patients since the outcome of the published trials comparing the effects of
adjuvant chemoradiotherapy to surgery alone.24,45 did not show a statistically signifi-
cant difference in survival in favor of the adjuvant therapy.
In conclusion, the incidence of delayed gastric emptying in this study of 170
consecutive patients was similar after PPPD and Whipple resection. Postoperative
nasogastric drainage period was comparable in both groups. As far as the duration
of operation, blood loss, hospital stay and postoperative weight loss are concerned,
there were also no significant differences. The PPPD appears to be just as radical
compared to the standard Whipple procedure. Long-term survival and disease free
survival did not exhibit significant differences. Thus, both procedures are equally
effective for treatment of pancreatic cancer.
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Chapter 4
Long-term survival after r-0 resection for
pancreatic and periampullary cancer
A pivotal role for the EGF-R
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Abstract
Background/ aims
Pancreatic cancer has a dismal prognosis. Ampullary cancer (defined as: cancer of
the ampulla of Vater or the distal common bile duct), has a better prognosis and is
thought to be a biologically different tumor. Aim of this study was to find factors
that could predict survival after radical (R-0) resection for pancreatic and ampullary
cancer.
Methods
We analyzed clinical and pathological data from 93 patients who underwent a true
R-0 resection for pancreatic or ampullary cancer. Furthermore we performed a Tis-
sue Micro-Array protein expression analysis for several growth factor receptors and
oncogenes: HER-2, EGF-R, ER, PR, C-myc, P53, P16, RB-1 and Chromogranin A as a
neuroendocrine differentiation marker.
Results
Median survival (14 vs 42 months) and time to recurrence (16 vs 42 months) were
significantly longer for ampullary than for pancreatic cancers. Pre-operative pain,
perineural invasion, lymph node metastasis and tumor differentiation grade are
indicators of poor survival. No differences in protein expression were found between
groups except for EGF-R expression, which was expressed more in pancreatic cancers
(p=0.026).
Conclusion
Outcomes for ampullary- are better than for pancreatic cancers. This different bio-
logical behaviour can possibly be explained by differences in EGF-R expression.
Introduction
Of all gastrointestinal malignancies, pancreatic cancer has the poorest prognosis,
with a 5-year survival of less than 5%.1,2 Men are more frequently affected by this
disease than women (relative risk 1.5).2 Ampullary cancers, however, carry a better
prognosis.3 This evident difference may be due to earlier clinical presentation or
different biological behaviour. Curative resection offers the only chance of cure, but
is possible in only 10% of patients.4 Adjuvant chemo- or chemo-radiotherapy after
curative resection are of limited value.5 Even after a macroscopically radical resec-
tion (R-0), distant micrometastases probably already exist6 and tumor cells are
often observed at one or more edges of the resected specimen (R-1).7,8 Reported rele-
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vant prognostic variables for survival after resection are: tumor size, lymph node
metastasis, histological differentiation and resection (R) status.9-12 Most studies
include radical (R-0) as well as non-radical (R-1/R-2) resections. To eliminate the
apparent effect of R-1 status on (local) recurrence and survival it would be interest-
ing to evaluate true R-0 resections only.
The aim of this study was to determine clinical, histological and molecular
factors that could predict recurrence and survival after R-0. Special focus is on the
differences between ampullary (defined as: cancer of the ampulla of Vater or distal
common bile duct) and pancreatic cancers. Additionally a Tissue Micro Array (TMA)
analysis of resected tumors (R-0) was added in order to search for relevant molecu-
lar factors.13,14 For immunohistochemical staining we selected common antibodies
raised against proteins that are frequently expressed in (pancreatic and ampullary)
cancers such as: Retinoblastoma (RB-1)15,16, p1617, C-myc18, p5317. Potential targets for
therapy: HER-219, Epithelial Growth Factor Receptor (EGF-R).20 Potential markers for
a male/female difference: Oestrogen- (ER) and Progesterone Receptor (PR).21 Chromo-
granin-A was used as a neuroendocrine differentiation marker.
Methods
From a consecutive series of 176 resections for pancreatic and ampullary adenocar-
cinoma, specimens were revised. For the purpose of this study we defined ampullary
cancer as: cancer of the ampulla of Vater and the distal common bile duct. Duodenal
tumors were not included. Pancreatic cancers adjacent or close to the ampulla were
classified as pancreatic cancer. R-0 was defined as absence of macroscopic and micro-
scopic residual tumor at 1 mm from the margin of the resection specimen. Even if
there were lymph node metastases restricted to the resected area, the resection was
considered R-0. 70 patients had an R-1 and 6 patients an R-2 resection. In 7 cases
the pathologist was not able to define whether a true R-0 resection was performed.
Therefore 93 patients were evaluated in this study.
One pathologist reviewed all specimens of R-0 resected tumors. Histological dif-
ferentiation, tumor size (T), location and extent as well as vaso-invasive growth
(small blood vessels), perineural invasive growth and lymph node metastasis (N)
were assessed. Staging was performed according to the UICC-classification, 2002.22
Pre-operative data, including age, gender, weight loss, pain (back-pain and pain
in the epigastric region), jaundice and diabetes mellitus, were obtained from clinical
records.
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Pre-operative staging and Surgical Techniques
All patients underwent conventional ultrasonography and/ or computed tomographic
scanning. Most patients (76%) underwent endoscopic retrograde cholangiopancrea-
tography (ERCP) and subsequent preoperative biliary drainage using endoprotheses.
After excluding extra regional and distant metastases, an estimation of the resecta-
bility was made by judging the involvement of the common hepatic artery, superior
mesenteric and portal vein (SMV/PV). The dissection of the pancreas was to the left of
the SMV/PV. Histological examination of the frozen section of the remaining pancre-
atic surface was performed. In case of a standard Whipple resection (SW), 1/3 of the
stomach was also resected. Only tumors without macroscopically infiltration of the
post pyloric duodenum and in absence of positive lymph nodes along the pylorus
were treated by a pylorus-preserving pancreaticoduodenectomy (PPPD). Lymph nodes
were dissected on the right hand side of the SMV/SMA up to the celiac trunk and in
the hepatoduodenal ligament along the common hepatic artery. Per-operative data
included the type of operation performed (PPPD or SW), BLOOD loss (ml) and trans-
fusions (units). Post-operative data included complications, hospital stay and
adjuvant therapy (5-FU and radiotherapy).
Tissue Micro Array (TMA)
We identified 75 patients for which paraffin blocks were available. In all other cases
paraffin blocks were either lost or insufficient. The TMA was constructed as de-
scribed by Kononen et al..13 For each carcinoma, we prepared three tissue cores of 0.6
mm in diameter from the paraffin tissue block to ensure adequate representation of
the neoplastic cells. The tissue cores from each carcinoma were then mounted in
linear arrays in a paraffin TMA block. Tissue cores from various organs (pancreas,
duodenum, and gallbladder) were used as controls, for orientation purposes and
to estimate background labelling for each of the immunohistochemical markers.
Immunohistochemistry labelling was performed according to standard protocols. In
brief, 4-µm sections for each TMA were transferred to starfrost™ slides (Starfrost,
Berlin, Germany) and immunostaining was performed using the Ultravision Large
Volume Detection System Anti-Polyvalent, HRP (Labvision, Fremont, CA) after de-
paraffinization microwave (700W) pre-treatment was performed for 15 minutes using
citrate buffer (100mM citric monohydrate pH6.0). Antibodies (clone) (Manufacturer)
used for immunostaining were: ER-a (1D5), PR (PgR636), P16 (E6H4), p53 (DO-7),
RB-1 (RB-1), EGF-R (H11), HER2 (C-erB-2) (DAKO A/S, Denmark), Chromogranin A
(LK2H10) (Biogenex Inc., USA) and C-myc (9E10) (Santa Cruz Inc., USA).
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TMA Scoring Strategy
One pathologist and one experienced analyst examined the TMA slides for each
immunohistochemical marker with a multi-observer microscope. Both observers
were blinded for the type of cancer and its location on the slide. Only moderate or
strong labelling was scored as positive. Weak or “blush” labelling was ignored. A
2-tiered scheme (positive or negative) was used scoring the TMA. A percentage exceed-
ing 1% of positive cells was regarded as protein over-expression. A score of negative
or positive for each carcinoma was determined after examining the 3 tissue cores.
Focal and diffuse positive scores were combined for the sake of statistical analysis.
Statistics
Survival analysis consisted of overall survival and time to recurrence. Curves were
calculated by the Kaplan-Meier method, followed by log-rank tests. Factors, which
showed to be significant in the univariate analysis, were entered into a multivariate
Cox proportional hazards model to evaluate their independent prognostic value by
backward elimination. To determine whether factors differed between patients with
ampullary versus pancreatic carcinoma, appropriate interaction terms were used.
P values (two-sided) of less than 0.05 were considered significant. All calculations
were performed using SPSS 13.0 statistical software (SPSS Inc., USA).
Results
Survival
Follow-up was more than 10 years (median 12 years). Median survival and time to
recurrence were significantly longer for ampullary than for pancreatic cancers (14
and 42, p=0.001, 16 and 34 months, p=0.024, respectively, table 1). Survival curves
are shown in figure 1. There were no differences between groups in site of recur-
rence (p=0.497).
Pre-operative factors
No differences in pre-operative factors were observed between both groups. Survival
was better for women than for men in the pancreatic cancer – but not in the am-
pullary group. Preoperative abdominal – and back pain influenced survival and
time to recurrence significantly for both groups. Jaundice was a predictor of survival
and time to recurrence in ampullary cancers. Weight loss and diabetes mellitus did
not influence survival (Table 1 and 2).
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Table 1 Group Comparison
Factor Positive (%) Head (N=56) Ampullary (N=37) Total (N=93) P (Fisher Exact)
Pr
e-
op
er
at
iv
e
Fa
ct
or
s
Male 37(66) 19(51) 37(39) 0.191
Age (years) 63 63 63 0.993
Pain 31(55) 20(56) 51(55) 1
Jaundice 49(88) 30(83) 79(86) 0.76
Pruritus 13(23) 15(44) 28(31) 0.059
Weight loss 45(80) 28(78) 73(79) 0.796
>5kg 23(51) 18(64) 41(56) 0.335
Obstruction 5(9) 5(14) 10(11) 0.505
Diabetes 10(18) 8(22) 18(20) 0.603
Endoprothesis 44(79) 27(71) 71(78) 1
Pe
ri
-o
pe
ra
tiv
e
Fa
ct
or
s
PPPD 28(50) 18(49) 46(50) 1
PV resection 1(2) 0 1(1) 1
AMS-Resection 0 1(3) 1(1) 0.398
Blood loss (ml) 2700 1950 2400 0.028#
Blood loss 1liter 5(9) 6(18) 11(13) 0.324
Transfusion (U) 2.4 1.5 1.2 0.038#
Transfused patients 22(41) 7(21) 29(33) 0.064
Complications 24(44) 20(54) 44(48) 0.396
Leakage pancreaticojejunostomy 5(5)
Pancreatic Fistula (6(6)
Leakage biliary anastomosis 1(1)
Abdominal Abcess 11(12)
Minor Complications 17(18)
Mortality 2(2)
Hospitalisation (m) 28 21  0.048#
Radiation / 5-Fu 19(34) 9(24) 28(30) 0.363
Pa
th
ol
og
ic
al
Fa
ct
or
s
T1 7(12) 8(22) n.t.
T2 15(27) 16(43) n.t.
T3 34(61) 13(35) n.t.
Diameter CM 23(41) 28(76) 51(55) 0.001
N 29(52) 26(70) 55(59.1) 0.088
M 0 0 0
G1 6(11) 7(19) 0.509$
G2 43(79) 25(68)
G3 7(12) 5(13)
R-0 56(100) 37(100)
Perineural Invasion 31(55) 7(19) 38(41) 0.001
Vasoinvasive 11(20) 5(14) 16(17) 0.579
Su
rv
iv
al
Recurrences 41(73) 26(70) 67(72) 0.816
Local 7(18) 6(26) 0.497$
Distant 18(46) 8(35)
Both 12(31) 9(39)
Deaths 51(91) 28(76) 79(85) 0.073
Median Survival (m) 14 42 0.001*
Median Time to Recurrence (m) 16 34 0.024*
Ti
ss
ue
M
ic
ro
A
rr
ay
Factor (%) Head (N=47) Ampullary (N=28) Total (N=75) P (Fisher Exact)
ER-a 0(0) 1(3.7) 1(1) 0.365
PR 5(11) 1(3.7) 6(80) 0.406
P16 10(21) 9(33) 19(25) 0.28
P53 9(20) 5(19) 14(19) 1
RB-1 28(62) 20(77) 48(64) 0.293
C-Myc 19(41) 16(59) 35(47) 0.154
Chromogranin A 10(22) 6(22) 16(21) 1
EGF-R 11(24) 1(3.7) 12(16) 0.026
HER-2 4(9) 3(11) 7(9) 1
PPPD: pylorus preserving pancreaticoduodenectomy, N: positive lymphnodes, G: differentiation grade, m: months,
AMS: superior mesenteric artery, PV: portal vein, *log-rank test, # T-test, $Chi-square for 3x2 table, n.t.: not tested.
Peri-operative findings
The surgical technique used (PPPD vs. SW) DID not correlate with survival (p=1.000).
Per-operative blood loss and peri-operative blood transfusions (units) were higher in
the pancreatic cancer group (p=0.028 and 0.038). Hospitalization was longer for
pancreatic cancers (p=0.048). However these factors did not influence survival (Table
1 and 2).
Mortality and Morbidity
Two patients (2%) died postoperatively because of aspiration pneumonia and sepsis.
These patients remained in our analysis because of the intention to treat principle.
Postoperative complications occurred in forty-four (48%) cases. In 5 patients (5%)
leakage of the pancreaticojejunostomy was seen, defined as presence of amylase
(3x serum concentration) in drainage or abdominal fluid. Six patients developed a
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Figure 1 Kaplan-Meier survival curves for ampullary and pancreatic cancers (p=0.001, log-rank test)
200.0150.0100.050.00.0
Time (months)
1.0
0.8
0.6
0.4
0.2
0.0
C
u
m
u
l a
t i
v
e
S
u
r v
i v
a
l
Periampullary-
censored
Head-censored
Periampullary
Head
No at risk Months: 12 24 36 48 60 72 84 120
Head N=56 31 22 15 11 10 10 5 3
Ampullary N=37 32 27 19 16 14 13 13 10
pancreaticocutaneous fistula. Leakage of the biliary anastomosis occurred in one
patient. Eleven patients (12%) had an intra-abdominal abscess. Minor complications
were found in 17 patients (18%). Complications did not influence survival or time to
recurrence (Table 1 and 2).
Adjuvant therapy
Adjuvant therapy (5-FU chemotherapy and radiotherapy) was given to 28 patients
distributed evenly between both groups (p=0.363) (Table 1). Survival data is omitted
here because of bias. These patients participated in a trial in which we compared the
effect of chemo-radiation with surgery alone.3
Pathological Factors
Pancreatic head tumors were larger (p=0.001) than ampullary. Perineural invasion
was also observed significantly more in this group (p=0.001).
The strongest negative histological factor for survival and time to recurrence was
lymph node involvement in the resected specimen. Tumor diameter as well as extent
of the tumor (T) did not influence survival. Histological grading was correlated with
survival and time to recurrence for pancreatic head cancers. Invasive growth into
intrapancreatic perineural tissue significantly influenced survival (p=0.001) and time
to recurrence (p=0.000) in ampullary cancers. Tumor invasion of small surround-
ing blood vessels was not correlated with survival (Table 1 and 2).
Tissue Micro Array
The overall failure rate secondary to lack of interpretable neoplastic tissue was 3%.
In all other cases in which cores were without malignant glands, interpretation of
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Table 2 Univariate analysis
Univariate Analysis Relation to Survival Time to Recurrence
Factor Positive (%)
Direction
of Effect
Head
(N=56)
Ampullary
(N=37)
Pooled*
(N=93)
Head
(N=56)
Ampullary
(N=37)
Pooled*
(N=93)
Male - 0.028 0.688 0.046 0.072 0.614 0.086
Pain - 0.018 0.001 0.000 0.006 0.000 0.000
Jaundice + 0.364 0.029 0.044 0.773 0.017 0.097
N - 0.064 0.013 0.004 0.016 0.006 0.000
G - 0.034 0.624 0.012 0.046 0.384 0.012
Perineural Invasion - 0.273 0.001 0.025 0.053 0.000 0.001
C-Myc + 0.034 0.968 0.078 0.015 0.858 0.038
EGF-R - 0.084 N.T. 0.080 0.037 N.T. 0.042
N: positive lymphnodes, G: differentiation grade, pain: pre-operative back and abdominal pain. * test for trend,
N.T.: not tested.
the labeling pattern was possible with the remaining tissue cores from that same
carcinoma. Although histologically very similar, adenocarcinomas of the ampullary
region are thought to be biologically different compared to pancreatic ductal ade-
nocarcinomas. However for most tested proteins the labeling was not significantly
different between both groups. Interestingly, EGF-R is expressed more frequently in
pancreatic than in ampullary cancers (p=0.026). For pancreatic cancers, EGF-R over-
expression is an indicator for shorter time to recurrence (p=0.037) (Figure 2). A
trend was observed towards poor survival (median survival: 14 vs 25 months, p=0.084).
Furthermore, no long-term survivors were observed in the EGF-R positive group.
C-myc over-expression is correlated with improved survival (p=0.034) and longer
time to recurrence (p=0.015). It is clear that these last two factors are of significance
for pancreatic head cancers but not for ampullary cancers (table 1 and 2).
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Figure 2 Kaplan-Meier curves for EGF-R expression in pancreatic head cancers, time to recurrence
(p=0.037, log-rank test)
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Multivariate Analysis
All factors that were significant in the univariate analysis were entered in a cox-
regression model. Independent prognostic factors for survival for the pancreatic
head group were: pre-operative back and abdominal pain (B(exp):0.548 / p=0.05)
and differentiation grade (2.004/0.016). No independent prognostic factors were
found for ampullary cancers.
For time to recurrence independent prognostic factors for the pancreatic head
group were: pre-operative back and abdominal pain (0.446/0.015), positive lymph
nodes (0.491/0.033), EGF-R over expression (0.448/0.034). Independent prognostic
factors for ampullary cancers are pre-operative back and abdominal pain (0.224/0.007)
and perineural invasion (0.199/0.031).
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Figure 3 Kaplan-Meier survival curves for C-myc expression in pancreatic head cancers (p=0.034,
log-rank test)
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tekst naar Figure 3.
Discussion
Median survival and time to recurrence after radical resection were significantly lon-
ger for ampullary than for pancreatic cancers. This evident difference may be due to
earlier clinical presentation or different biological behavior. We found no differences
in pre-operative factors between both groups.
Pre-operative back and abdominal pain was found in 51(55%) patients. It was also an
independent negative prognostic factor for time to recurrence for both groups and
for survival in univariate analysis. We further found that intra-pancreatic perineural
invasion was a negative prognostic factor for survival (not for pancreatic cancers,
p=0.273) and time to recurrence in the univariate analysis (both groups). Pre-opera-
tive pain as a negative prognostic factor has been reported earlier by Ridder et al.23
and Okusaka et al.24 Forty-one % of patients with preoperative pain had intra-pan-
creatic perineural growth and 55% of perineural growth had preoperative pain. These
findings suggest that pain is not always caused by intra-pancreatic perineural growth
and vice versa. Indeed pain is usually interpreted as resulting from tumor infiltra-
tion into extra-pancreatic (retro-pancreatic) splanchnic nerves and thus may indicate
advanced tumor growth beyond the borders of the pancreas.
In the present study 72% of all patients had recurrence of their cancer and almost
half of all recurrences were local (table 1). This is similar to previously reported
rates in two large trials on adjuvant therapy by Klinkenbijl3 and Neoptolemos et al.25
Although both studies included only 18-22% R-1 resections, the reported rate of
recurrence was approximately 70 % and 37-52% of these recurrences were local.
Possibly our definition of R-0 may have included some “irradical” resections.
Verbeke et al. suggested that R-1 can be underestimated when pathological exami-
nation is not completely standardized.26 They compared pathological examinations
in two consecutive periods with and without a highly standardized protocol. The
number of R-0 resections for pancreatic cancer in the standardized period was
lower than in the non-standardized period (p=0.009). Interestingly, long-term sur-
vival for pancreatic cancer was not predicted by R status in either cohort. A similar
observation was made by Neoptolemos et al. in a sub-analysis of their trial on
adjuvant therapy. They found that R status was not an independent prognostic fac-
tor for survival. Only after omission of nodal status and differentiation grade, R
status became significant.12,25
It is intuitive that R-1 is a predictor of poor survival, and indeed long-term survivors
are sparse after R-1. Therefore R-0 is often considered to be the most important
factor predicting favorable outcome after resection. Consequently, extended resec-
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tions, including extensive clearing of retroperitoneal soft- and lymphatic tissue,
have been advocated. Several randomized controlled trials27-29 were performed
but failed to show a survival benefit for extended surgery. In a recent study by
Hishinuma et al. 27 patients who had undergone extended resection were studied
by autopsy. Most resections were R-0 (25/27), 3 patients died postoperatively, the
majority died of metastatic disease and only 4 patients died due to local recurrence.
Evidence of local recurrence was found in 18 of 24 (75%).30 This study clearly shows
that even after extended surgery local recurrences are still frequent. Possibly R-0
and R-1 are both accompanied by (occult) metastatic disease. Indeed, in an overview
of advanced molecular detection techniques6, it was shown that tumor cells can be
found pre- and peri-operatively in peritoneal lavage fluids, the liver, blood, “tumor
negative” lymphnodes and bone marrow of patients without “conventional” evidence
of metastatic disease. As a result, R-0 offers an opportunity for long-term survival for
a limited number of patients. However, in the majority of cases resection cannot
provide curation and recurrence remains imminent. This further emphasizes the
importance of additional prognostic parameters to predict outcomes after “R-0”
(“R”) resection and to select patients in need of (aggressive) systemic adjuvant therapy.
The Tissue Micro Array technique proved to be a simple, efficient and relatively
inexpensive method to explore protein expression in large groups of patients. Our
failure rate of 3% is acceptable and did not cause statistical problems. Expression
of p53 and p16 proteins is well known in pancreatic cancer.17 Nevertheless their
prognostic value remains unclear. We found similar expression of p16 (21-33%)
(table 1) compared to previously reported studies (13-59%).17 Expression of p53 in
our study (19-20%) was lower than previously reported (35-69%).17 This may be due
to our techniques or a selection bias in our group (R-0). RB-1 protein expression has
been reported previously in tissue and cell-lines, the exact prevalence however was
unclear.31,32 We found RB-1 to be positive in 62-77% of cases. C-myc, a proto-oncogene,
expression has been previously reported.18 We found improved survival for patients
with over-expression of this protein. This is counterintuitive since, as a known proto-
oncogene, it is thought to promote oncogenesis and tumor growth. Alternatively
C-myc expression is thought to be an early step18 in the rapid oncogenesis of pancre-
atic cancer33 and may be an indicator of relatively early point in tumor progression.
Hypothetically this implicates an early stage disease and thus a less aggressive nature.
Nevertheless, the exact role of C-myc remains unclear. We found 22% of cancers to
be positive for Chromogranin A, a neuroendocrine differentiation marker. This is
similar compared to a previous report of neuroendocrine differentiation by Tezel et
al..34 However, they did not find any Chromogranin A positive tumors in their speci-
mens, in contrast to 18-36% expression of other neuroendocrine markers (NCAM,
NSE, Synaptophysin, CD57). This may be due to differences in antigen retrieval,
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immunohistochemical techniques and/or antibody clones used. HER-2 was positive
in only 9-11% of cases and did not show correlation with survival. This is compara-
ble with previously published results 8-58%.17
EGF-R, a well-known growth factor receptor, was positive in ampullary (4%) but
significantly more often in pancreatic cancers (24%, p=0.026). This is in accor-
dance to expression rates previously reported (28-68%).17 The difference in EGF-R
expression between pancreatic and ampullary cancers was previously suggested by
Friess et al..35 Although their study did not provide matched clinical and survival
data, they suggested a role for the EGF-R in the less favorable outcome for pancreatic
cancers. In our study, EGF-R over-expression is a negative prognostic factor for time
to recurrence (p=0.037) and possibly survival (p=0.084) in pancreatic cancer. This
effect on survival has been described previously in several studies, while others
found no effect.17,36 For head and neck cancer EGF-R expression was shown to be cor-
related to survival and relapse.37 In breast- and colorectal cancer, however, no corre-
lation was evident.38,39
So in conclusion, the difference in biological behavior between pancreatic and
ampullary cancers could be confirmed in this study. The poor prognosis of patients
with pancreatic cancer can possibly be related to the increased EGF-R expression of
these tumors compared to ampullary cancers. Our data support the rationale to use
drugs that have recently been designed to target the EGF-R selectively (Tarceva,
Iressa, Erbitux)40 in adjuvant targeted therapy regimens.
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Chapter 5
Long-term survival and metastatic pattern of
pancreatic and periampullary cancer after
adjuvant chemoradiation or observation
Ann Surg. 2007 Nov;246(5):734-40
Summary
Background
The role of adjuvant chemoradiation in pancreatic cancer remains unclear. This re-
port presents the long-term follow-up results of EORTC trial 40891, which assessed
the role of chemoradiation in resectable pancreatic and periampullary cancer.
Methods
218 patients were randomized after resection of the primary tumor. Eligible patients
had T1-2 N0-N1a M0 pancreatic cancer or T1-3 N0-N1a M0 periampullary cancers,
all histological proven.
Patients in the treatment group (n=110) underwent post-operative chemo-
radiation (40 Gy plus 5-FU). Patients in the control group (n=108) had no further
adjuvant treatment.
Findings
After a median follow-up of 11.7 years, 173 deaths (79%) have been reported. The
overall survival did not differ between the two treatment groups (Chemoradiation
treatment versus Controls: death rate ratio 0.91, 95% CI: 0.68-1.23, p-value 0.54).
The 10-year overall survival was 18% in the whole population of patients ( 8% in the
pancreatic head cancer group and 29% in the periampullary cancer group ).
Interpretation
These results confirm the previous short-term analysis, indicating no benefit of
adjuvant chemoradiation over observation in patients with resected pancreatic can-
cer or periampullary cancer. Patients with pancreatic cancer may survive over 10
years. Recurrence occurred up to seven years, one even after 7 years.
Introduction
Pancreatic cancer has a poor prognosis with an overall survival rate ranging from
0.4 to 4 percent, and is one of the top five causes of death from cancer in the west-
ern world1,2. Surgical resection improves the outcome, but only about 10 percent of
patients are eligible for the procedure. Most treatment failures are due to local recur-
rence, hepatic metastases or both, and occur within one to two years after surgery.3,4
Adjuvant therapy has been studied in a few trials but its routine use is not uni-
versal because earlier trials reported contradictory results.5-11,13
The Gastrointestinal Tumor study group (GITSG) randomly assigned 43 patients
to surgery alone or chemoradiation followed by maintenance chemotherapy.5,7 The
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median survival was significantly longer in the adjuvant treatment group compared
to the surgery group (20 months versus 11 months), with respectively 18 percent and
8 percent survival at five years.5,7,28,29 Further larger randomized studies however did
not confirm a benefit of adjuvant treatment.12-14 Moreover, it is unclear whether the
survival advantage in the GITSG trial was due to the combination of chemoradiation
and maintenance chemotherapy or to only one of these treatments.9 The first large
multicenter trial in pancreatic cancer was a randomized phase III conducted by
the EORTC Gastro-intestinal group, initiated in 1987 (EORTC 40891). Based on 218
patients, this trial did not show a benefit for adjuvant chemoradiation although they
suggested a trend in favor of chemoradiation (p=0.09) in the patients with ductal
pancreatic adenocarcinoma . 13
In 1994, the European Study Group for Pancreatic Cancer (ESPAC) undertook a
multicenter factorial phase III trial to investigate the possible benefits of adjuvant
chemoradiation and maintenance chemotherapy in patients with pancreatic cancer.
In this trial, a deleterious effect of adjuvant chemoradiation on survival was shown
whereas chemotherapy significantly improved survival in patients with resected
pancreatic cancer.15-17
The goal of this trial was to evaluate the effect of adjuvant treatment with post-
operative radiotherapy and 5-FU after potentially curative resection in patients with
cancer of the pancreatic head and periampullary region. We here report the long-
term results (with 11.7 years follow-up) of the EORTC 40891 trial. Together with the
results of the ESPAC-1 trial, these results might allow for more definitive conclusions
about the value of adjuvant chemoradiation. It is the first time actual survival rates
of more than ten years are presented for resectable pancreatic cancer.
Methods
The trial design has been reported extensively before. 13 Therefore we shall summa-
rize only the main aspects. It was designed as a multicenter trial with a central
pathology review. Eligible patients were patients with T1-2 N0-1a M0 pancreatic
head cancer or T1-3 N0-1a M0 periampullary cancer. TNM staging (according to the
UICC’s 1987 guidelines) was modified for N stage. N1a-stage positive lymph nodes
were located within the resection specimen, and N1b-stage positive lymph nodes
were located outside the resection area for instance, retroperitoneally along the aorta.
Cancer of the periampullary region was defined as tumor in the distal common bile
duct, papilla of Vater or duodenum. Patients with stage T3 pancreatic head cancer
and stage T4 periampullary cancer were excluded because of ingrowth into sur-
rounding organs, with a limited prognosis.
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After tumor resection, whenever the pathology report was available and the patient
had recovered from surgery, (but within 8 weeks of surgery), patients were random-
ized between chemoradiation and observation by minimization, with stratification
for institution and tumor localization (pancreatic head vs. periampullary).18 A Whipple
procedure or pylorus-preserving pancreatoduodenectomy was accepted as standard
resection. An extended lymph node resection was not performed.
The chemoradiation regimen differed from that used in the GITSG study. 5-FU
was given concomitantly with radiotherapy, and as a continuous infusion instead of a
bolus injection. Radiotherapy was started 2 to 8 weeks after surgery and given using
megavoltage equipment (min 6MV) using a 3 or 4 field technique. Radiotherapy was
delivered over a period of 6 weeks, with a 2-week break. A total of 40 Gy was deliv-
ered in two courses of 20 Gy (2 Gy/d, 5d/wk at weeks 1-2 and 5-6). During each
course, chemotherapy was started before radiotherapy and consisted of 5-FU (25
mg/kg/day), with a maximal daily dose of 1500 mg. Depending on toxicity, the sec-
ond course consisted of zero (if grade 3-4 toxicity), three (if grade 1-2 toxicity), or
five days of 5-FU (if no toxicity). Toxicity was scored according to the World Health
Organization (WHO) guidelines.
The primary end-point was survival, secondary end-point was recurrence of dis-
ease.
The trial was designed to detect an absolute increase of 20% in 2-year overall
survival (from 30% to 50%, 110 events needed) with 80% power and a two-sided
0.05 significance level. The sample size was 218.
All efficacy analyses were performed according to intention-to-treat (i.e. as ran-
domized) and with a 5% significance level. Toxicity reports are on all patients who
started their treatment. Event-free rates were estimated by Kaplan-Meier method
and compared by log-rank test. The Cox proportional hazards regression was used
for prognostic factor modeling and to adjust the treatment comparison for most
important prognostic factors. A backward variable selection was applied, with a
0.05 significance level. Factors evaluated were gender, age (<60 years (median) vs
³60 years), T-category (tumor £2 cm vs >2 cm), microscopic invasiveness of the
resection margin (yes vs no), lymph node involvement (yes vs no), degree of differ-
entiation of the tumor (1 vs 2 vs 3-4), vasoinvasive growth (yes vs no) and WHO per-
formance status (0 vs 1-2). Ordinal categories were defined for histopathological
grading. Adjacent levels of discrete variables with small numbers were pooled
together. Internal model validation was performed by the bootstrap resampling
technique (1000 replicates).
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Results
Between September 1987 and April 1995, 218 patients were randomized to the
EORTC trial 40891, 108 patients in the observation arm (Obs) and 110 patients in
the treatment arm (Trt). Patients were recruited from 29 centers in Europe, but 4
centers entered 70% of all patients. At the time of this analysis, the median fol-
low-up was 11.7 years and the patients still alive had been followed for a median of
9.8 years (min=3.5 months, max=14.3 years).
Eleven patients were ineligible (5 on Obs and 6 on Trt): N1b: 5 patients, T3
tumors: 5 patients and 1 patient had concurrent disease. The patient’s baseline char-
acteristics were reported earlier and were comparable between the two study groups
(Table 1).
Treatment Data
Ten of the 104 eligible patients in the Trt group refused to start treatment, and
another 11 patients developed contraindications to adjuvant treatment after random-
ization (the most noticeable were long-lasting septic shock developed as a result of
leakage of the pancreaticojejunostomy in one patient; rapid progression in four
patients; one patient had only one functional kidney, located within the radiation
field). In two more patients, revision of pathology reports showed that a T3 tumor
was included. As a result, in the treatment arm a total of 81 eligible patients could be
evaluated for treatment toxicity.
Chemoradiation
As reported previously, 75 of the 81 eligible treated patients received 40 Gy radiation
therapy13. The median dose of 5-FU 197 mg/kg (range: 99 to 275 mg/kg) correspond-
ing to a median dose intensity of 89% (range: 50% to 122%).
Toxicity
As reported earlier, thirty-five patients (44%) received only 3 days of 5-FU infusion
during the second course of radiotherapy because of grade 1 or 2 acute toxicity. No
leucopenia or thrombopenia worse than WHO grade 2 was observed, and the daily
dose of 5-FU was never reduced. Minor non-hematological toxicity was observed in a
few patients, with a maximal WHO grade 3 toxicity, especially nausea/vomiting (7
[8%] patients), diarrhea (1 [1%] patient) and constipation (1 [1%] patient). The only
instance of major toxicity was observed in one patient who developed duodenal ulcer
after the first treatment course. It was treated with anti-acids and beta-blockers but
did not heal after 6 weeks, therefore the second course was not given.
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Table 1 Baseline Characteristics (all patients). TNM data according to 1987 UICC criteria
Observation (n=108) Treatment (n=110)
Median age (years) [range] 61 [39-79] 58 [23-78]
Median time from surgery to randomization
(days) [range]
17 [1-57] 17 [6-57]
Sex; number (%) Male 58 (54) 68 (62)
Female 50 (46) 42 (38)
WHO performance status 0 55 (51) 63 (57)
1 44 (41) 44 (40)
2 9 (8) 3 (3)
Weight loss relative to
normal weight (%) (range)
8 (-28 – 37) 7 (- 15-30)
Jaundice Yes 64 (59) 71 (64)
No 42 (39) 39 (36)
Unknown 2 (2) 0 (0)
Resection Margins Negative 80 (74) 87 (79)
Negative after
re-resection
2 (2) 1 (1)
Positive 24 (22) 22 (20)
Unknown / Missing 2 (2) 0 (0)
Vasoinvasion Yes 36 (33) 35 (32)
No 70 (65) 73 (66)
Histopathological grading Well differentiated 42 (39) 35 (32)
Moderately differentiated 45 (42) 44 (40)
Poorly differentiated 20 (19) 30 (27)
Unknown 0 (0) 1 (1)
Pathology data Pancreatic duct 57 (53) 63 (57)
Papillary 39 (36) 33 (30)
Duodenal 1 (1) 1 (1)
Bile Duct 10 (9) 13 (12)
Unknown 2 (2) 0 (0)
T category T1 6 (11) 16 (25)
(pancreatic head) T2 48 (84) 39 (62)
T3 2 (3) 6 (10)
Unknown / Missing 1 (2) 2 (3)
T category T1 5 (10) 5 (11)
(periampullary region) T2 23 (46) 16 (34)
T3 19 (38) 25 (53)
T4 1 (2) 1 (2)
Unknown / Missing 2 (4) 0 (0)
N category N0 26 (46) 28 (44)
(pancreatic head) N1a 21 (37) 23 (37)
N1b 2 (4) 0 (0)
Unknown / Missing 8 (14) 12 (19)
N category N0 24 (48) 25 (53)
(periampullay region) N1a 21 (42) 18 (38)
N1b 2 (4) 1 (2)
Unknown / Missing 3 (6) 3 (6)
Overall Survival
After 11.7 years of follow-up, 173 patients have died. The cause of death was malig-
nant disease in 143 (83%) patients (75 [86%] Obs, 68 [79%] Trt), in-hospital death in
4 (2%) patients (0 Obs, 4 [5%] Trt), nonmalignant/nontoxic death in 13 (8%) patients
(4 [5%] Obs, 9 [11 %] Trt), and unknown in 13 patients (8 [9%] Obs, 5 [6%] Trt).
There was no evidence that survival was influenced by treatment (HR=0.91 [95% CI:
0.68-1.23], p=0.540, Figure 1), with a median survival of 1.6 years [95% CI: 1.2-2.3
years] and 1.8 years [95% CI: 1.5-2.4 years] in the Obs and Trt group, respectively. The
5-year survival rates were 22% [95% CI, 14-31%] in the Obs group and 25% [95% CI,
16-34%] in the Trt group, and the 10-year survival rates were 18% [95% CI, 11-26%]
in the Obs group and 17% [95% CI, 9- 25%] in the Trt group.
No difference was seen when analyzing the two tumor locations separately
(HR=0.76 [95% CI: 0.52-1.12] for pancreatic head cancer and HR=1.03 [95% CI: 0.63-1.68]
for periampullary cancer), but these analyses lack statistical power (Figures 2 and 3).
In both treatment arms, the median survival for the pancreatic head cancers was
only about 1 year (1.0 year [95% CI: 0.8-1.4 years] in Obs and 1.3 year [95% CI: 1.1-1.8
years] in Trt).
Progression-free survival
Of the 218 patients, 76 (70%) in the Obs group and 75 (68%) in the Trt group had
a documented progression of disease. The site of first progression and the site of
distant progression are shown in Table 2.
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Figure 1 Survival
Overall Logrank test: p=0.539
No advantage of adjuvant treatment in progression-free survival was shown, neither
on all patients (HR=0.94, 95% CI: 0.70-1.26, p=0.663), nor in the 2 tumor locations
separately (HR 0.81, 95% CI: 0.55-1.17, p=0.259 pancreatic head and HR 1.0 95%
CI: 0.63-1.65, p=0.930 periampullary) For all patients in the Obs group, the median
progression-free survival was 1.2 years [95% CI: 0.9-1.7 years] and it was 1.5 years
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Figure 2 Survival, Pancreatic head cancer
Overall Logrank test: p=0.165
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Figure 3 Survival, Periampullary cancer
Overall Logrank test: p=0.921
[95% CI: 1.0-1.8 years] in the Trt group. The 5-year progression-free survival rates
were 20% [95% CI, 12-27%] and 21% [95% CI, 13-29%], respectively, and the 10-year
rates were 17% [95% CI, 9-23%] and 16% [95% CI, 9- 24%].
The results regarding overall survival and progression-free survival were similar
when the analyses were repeated in the per protocol subgroup of eligible cases who
followed the assigned treatment policy. There were 75 patients in the treatment
group and 102 in the observation group. Median overall survival was 1.9 years [95%
CI: 1.4-2.5 years] in the treatment group and 1.6 years [95% :0.8-1.5 years] in the obs
group.
The median progression- free survival was 1.6 years [95% CI: 1.2-1.9 years] in the
treatment group and 1.33 years [95% CI: 1.0- 1.8 years] in the obs group.
Influence of Prognostic Factors
Prognostic factors for overall survival were evaluated separately for patients with
cancer in the pancreatic head and for patients with a periampullary tumor. Due to
small numbers in the T1 and R1 categories, T category and invasiveness of the resec-
tion margin could not be studied in the periampullary cancer patient group. For the
pancreatic head tumor, a larger tumor (p=0.004), a worse histopathological grade
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Table 2 Progression Status (all patients)
Observation (N=108) Number (%) Treatment (N=110) Number (%)
No documented progression 32 (30) 35 (32)
Documented progression 76 (70) 75 (68)
Site of first progression
Local 16 (21) 15 (20)
Distant 35 (46) 36 (48)
Both 23 (30) 22 (29)
Second malignancy 1 (1) 1 (1)
Unknown/Missing 1 (1) 1 (1)
Site of distant progression
Liver 37 (49) 38 (51)
Lung 8 (11) 5 (7)
Other 28 (37) 23 (31)
Pancreatic head N=57 N=63
Progression 45 (79) 47 (75)
No progression 12 (21) 16 (25)
Periampullary N=50 N=47
Progression 30 (60) 28 (60)
No progression 20 (40) 19 (40)
(p=0.042), the presence of vasoinvasive growth (p=0.041) and a deteriorated WHO
performance status (p=0.021) were associated with a shorter survival by univariate
analysis. A marginal non-statistically significant impact of positive lymph nodes was
also observed (p=0.090). The final multivariate model retained only T-category, grade
and WHO performance status as independent prognostic factors. The bootstrap
internal validation showed good model stability and internal validity as the three
variables were the most frequently retained (in 79.2%, 45.0% and 58.5% of the
models, respectively, against <31.0 % for all other variables).
When adjusting for the three independent prognostic factors, the conclusions
remained unchanged as regards the absence of treatment effect (Table 3).
Univariate analysis in the periampullary group showed that positive lymph nodes
(p=0.030), vasoinvasive growth (p=0.006) and a worse degree of differentiation of
the tumor (p<0.001) were associated with a shorter survival. At the end of the multi-
variate selection process, 3 variables were retained as independent prognostic fac-
tors: vasoinvasive growth, presence of positive lymph nodes and age >60 years. The
validation showed that these variables were selected in 72.2%, 56.2% and 53.5% of
the models, respectively (against =35.0% for all other variables). The multivariate
model with these three variables was also the most frequently selected model (19.5%).
When adjusting for age, N category and vasoinvasive growth, the conclusions
regarding the treatment effect in the periampullary cancer patients remained un-
changed (Table 3).
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Table 3 Cox proportional hazards models for overall survival separately for pancreatic head- and peri-
ampullary cancers, adjusting for the baseline covariates with the strongest prognostic value
Variable
Death rate Hazard ratio
(95% confidence interval) p-value
Pancreatic head cancer
Treatment (radiochemotherapy vs no
adjuvant therapy)
0.74 (0.49-1.10) 0.137
T-category (T2-4 vs T1) 2.38 (1.38-4.10) 0.002
Histopathological grade 1.41# (1.10-1.79) 0.006
Performance status (WHO 1-2 vs 0) 1.62 (1.08-2.43) 0.019
Periampullary cancer
Treatment (radiochemotherapy vs no
adjuvant therapy
1.09 (0.65-1.84) 0.750
Age (³60 vs <60 yrs) 1.87 (1.10-3.19) 0.021
Nodes (Positive vs neg.) 1.86 (1.09-3.18) 0.023
Vasoinvasive growth (Present vs Absent) 2.70 (1.53-4.76) <0.001
# trend: grade 2 (moderate) vs grade 1 (well) and grade 3 (poor) vs grade 2
Discussion
To our knowledge this is the first randomized trial of pancreatic cancer with a follow
up exceeding 10 years. This trial shows no difference between adjuvant chemo-
radiotherapy and observation, neither for survival nor for progression-free survival.
This study also shows that long-term survival after curative resection is possible in
12% of all patients (26/218 patients are still alive by year 10). In addition, only 1
cases of 31 recurred after 7 years . This means that future trials in pancreatic cancer
should manage to provide a follow-up of 7 years or longer.
Overall prognosis of pancreatic cancer is still dismal. The incidence of locoregio-
nal recurrence is high (up to 80%), and occurs in most cases together with distant
metastases. Patients with periampullary carcinoma have a more favorable outcome,
with a 5-year survival rate of 40% to 70%.19-26 To improve survival, several therapeutic
modalities have been tested (intraoperative radiotherapy, chemotherapy, and combi-
nations of both) in patients with unresectable and resectable disease, with varying
success.12,27-37 The GITSG trial, with 43 patients, was the first study to show a benefit of
adjuvant treatment in pancreatic cancer.7, 5,28,29 Because of the long accrual time and
the small number of patients entered in the GITSG study, we decided to assess the
possible value of radiotherapy and 5-FU as an adjuvant to surgery in a larger group
of patients. The current trial was initiated in 1987 and accrued 218 patients with
resected pancreatic head and periampullary cancer. The adjuvant treatment was the
same as in the GITSG trial except that the 5-FU treatment was only during the first
week of each radiation course. Radiotherapy and 5-FU treatment did not induce
major toxicity (the worst observed toxicity was WHO grade 3); all patients but the one
with severe toxicity completed the treatment. However, despite the success of this
treatment in the only other randomized study7, the present trial demonstrated no
advantage for adjuvant chemoradiation, neither for progression-free, nor for overall
survival . The first analysis of this trial, at a median follow-up of 7.3 years and based
on 144 events, suggested a trend towards advantage of adjuvant chemoradiation in
patients with pancreatic head cancer (median overall survival was 12.6 months in the
Obs group and 17.1 months in the Trt group (HR=0.7, 95% CI: 0.5-1.1, p=0.099)).
The present long-term follow-up analysis, with a median follow-up of 11.7 years and
173 events, confirmed the absence of a difference in survival, overall and in the
different disease groups.
This trial has been criticized15,17 for being powered for a too optimistic difference
(20% benefit at 2 years, HR=0.58). At present, with 173 events, the study has 80%
power to detect a somewhat smaller benefit (15.7%) in 2-year survival (HR=0.65).
The study still lacks power to detect smaller differences and differences within
subgroups, in particular for the analyses by tumor type that are based on a smaller
number of events. We think that this trial together with the ESPAC-1 results provide a
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strong evidence for concluding that adjuvant treatment using chemoradiation is not
effective. Chemotherapy alone may be effective according to the ESPAC study, the
five-year survival rate was 21 percent for patients who did receive chemotherapy and
8 percent among patients who did not receive chemotherapy. The effect of chemo-
therapy was encouraging although 18 percent of the patients had positive resection
margins.
Radiotherapy with chemotherapy has been applied as neoadjuvant treatment with
some success, but the value of this treatment is not yet proven.30,38-44
For the time being, surgery alone is considered inadequate and adjuvant chemo-
therapy should be considered. The question remains as to what kind of adjuvant
chemotherapy should be proposed. New chemotherapeutic agents such as docetaxel,
gemcitabine, and topotecan have been studied, with response rates of 10% to 25%.45
Link et al described a technique of intra-arterial infusion chemotherapy using the
celiac axis after resection; they found promising results with respect to median
survival, but only in 18 patients after curative resection.46-48
As discussed above the trial missed power to detect small differences between sub-
groups. Beforehand it would have been better to include only pancreatic cancer and
not periampullary cancer which nowadays is known to have a better prognosis and a
different tumor behaviour. Further this trial would have benefit from prestudy entry
CT-scanning, more precise: not only a CT-scan before surgery but also a CT-scan
before starting radiotherapy.
We have learned lessons from this trial design. For future trials on pancreatic
cancer there is a need for quality control of pathology assessment. Every specimen
needs to be examined and described following a complete and strict protocol.
In this trial’s protocol the pathologist needed to describe the location of the
tumor, the size of the tumor, the extent of tumor in resection margins and the
frozen sections. Further the number and location of lymphnodes involved with tumor,
vasoinvasive growth of tumor, histopathological grading and finally the TNM classifi-
cation had to be given. There was no standardized protocol for the pathologist how
to determine and describe the presence or absence of tumor at the surgical margins.
As a consequence, some patients with R-2 tumors might have been included in this
trial. In our opinion a standardized pathology protocol how to assess specimens
tumor margins is likely to minimize the risk of including R-2 resections. Both this
and the fact that we included R-1 tumors (according to our inclusion criteria) impli-
cate that the median survival is rather low, approximately one year.
In conclusion our results show no beneficial effect for combined radiotherapy
with 5-FU chemotherapy as standard adjuvant treatment after curative resection for
either pancreatic or periampullary cancer.
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Chapter 6
Adjuvant 5-FU based chemoradiotherapy for
patients undergoing R1/R2 resections for
pancreatic cancer
Dig Surg. 2005;22(5):321-8
Abstract
Background
Pancreatic cancer is the fifth leading cause of cancer related death worldwide.
Among patients treated with surgery alone, liver metastasis occurs in up to 50%,
peritoneal recurrence in 25%, and local recurrence occurs in 50-80% of all patients
who underwent resection. Even after a macroscopically curative resection, tumour
cells might be observed by microscopy at one or more edges of the resected speci-
men in 20% to 51% (R-1) which might account for the high local recurrence.
Aim of the study
In this study an analysis was performed in 54 patients who underwent an irradical
resection (R-1 and R-2) for pancreatic cancer. Thirty-three patients were treated with
chemoradiotherapy. To evaluate the effect of therapy on survival and recurrence, this
group was retrospectively compared to a group of 21 patients that did not receive
chemoradiotherapy.
Methods
Radiotherapy consisted of 50 GY external upper abdomen radiation in two courses
of 3 weeks, concomitant with intravenous 5-FU 25-mg/kg/24 hours continuously on
the first 4 days of each treatment course. Follow-up was performed mainly by
CT-scanning and occasionally by US and was completed for all but one patient.
Results
The treatment protocol was completed in all patients without complications. Local
recurrence was found in 6 (18%) patients in the group of patients who received
adjuvant therapy versus 16 (48%) patients in the group that did not receive adjuvant
therapy (p=0.001). The median survival time for the treated group was 12.8 months
versus 13.7 months in the group that did not receive chemoradiotherapy (p=0.9).
Three (9%) patients are still alive 140, 88 and 70 months after receiving surgery and
adjuvant treatment.
Conclusion
Adjuvant chemoradiotherapy clearly gives asignificant better local control. How-
ever, treatment with 5-FU and radiotherapy does not improve survival due to distant
metastases. In only a few patients this therapy probably prolongs survival. More
effective treatment methods have to be designed to prevent metastatic disease and
improve survival.
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Introduction
In 2002, adenocarcinoma of the exocrine pancreas will account for approximately
28,900 deaths in the U.S.-the fifth leading cause of cancer related death for both
men and women this year (following lung, colon, breast, and prostate cancer.1 Exocrine
pancreatic cancer characteristically spreads by infiltration of lymphatics, perineural
tissues and bloodvessels resulting in lymphatic, peritoneal and distant spread. Sub
clinical metastases are present in most patients at the time of diagnosis, even when
imaging studies are normal. Therefore, disease recurrence following potentially cura-
tive pancreaticoduodenctomy remains common, and long-term survival is realized
in only 10%-20% of patients who undergo potentially curative surgery.2 Even after a
macroscopically curative resection, tumour cells might be observed by microscopy
at one or more edges of the resected specimen in 20% to 51% (R-1).2-7 Among patients
treated with surgery alone, local recurrence occurs in up to 50%-80% peritoneal
recurrence in 25%, and liver metastases in 50%.2 Therefore, a treatment approach
combining local and systemic adjuvant treatment in pancreas and periampullary
cancer seems interesting. One small prospective study and some retrospective data
suggested that the combination of pancreaticoduodenectomy with postoperative ad-
juvant 5-fluorouracil (5-FU) and external-beam radiation therapy (EBRT) improved
survival in curative resected patients compared to surgery alone.8,9 From European
trials evidence now exists that adjuvant radiotherapy and 5-FU is not effective for
curative resected patients with adenocarcinoma of the pancreas. The recently pub-
lished large randomised trials by The European Organization for Research and Treat-
ment of Cancer (EORTC) and European Study Group of Pancreatic Cancer (ESPAC)-1
showed no survival benefit for patients treated with chemoradiotherapy.3,4,6,8 ESPAC-1
only showed survival benefit for patients who were treated with chemotherapy;
patients who underwent curative resections and treated with chemoradiotherapy did
not prove to live longer than patients who were treated with surgery alone. The
EORTC-study showed a 5.5 months increase in median survival but this difference
was not statistically significant. In these studies local recurrence rate was not posi-
tively affected by chemoradiotherapy in patients who underwent curative resections.
In both studies not only patients with R-0 resections were included but also patients
with R-1 resections.
Where no doubt remains about the lack of beneficial effects adjuvant chemo-
radiotherapy has for curative resected patients, radiation therapy with or without
chemotherapy has been showed to prolong survival in loco regional advanced dis-
ease, especially the combination of external radiotherapy combined with 5-fluor-
ouracil (5-FU).11-18 However, interpreting these results it has to be mentioned that
no prospective randomised multicenter trials have been performed to confirm the
suggestion that chemoradiotherapy might be beneficial for these patients. The
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results obtained in patients with irresectable disease leads us to the concept that
radiotherapy with the radiosensitizer 5-FU may have an effect on tumour growth of
pancreatic cancer and might give a better local control and prognosis in patients
with irradical resected or locally advanced pancreatic cancer.
Until now data of survival rates, patterns of recurrence and local tumour control
of patients who received chemoradiotherapy after macroscopically and microscopi-
cally irradical resections are rare. Most studies report on mixed radical and irradical
resected groups. Willet et al. did not find survival benefit for patients with tumor
present at the resection margin, the UKPACA and later on the ESPAC-1 however,
showed that patients with R-1 resections appeared to benefit from adjuvant chemo-
therapy but not from chemoradiotherapy in means of survival.4,6,19,20
In this study we performed an evaluation of the effects of treatment on local and
distant recurrence in patients who showed to have undergone macroscopically (R-2)
as well as microscopically (R-1) irradical resections.
Materials and methods
We reviewed all hospital charts from 1990 to 2000 of patients who underwent pan-
creatic resections for suspected malignancies of the pancreatic head. None of the
patients had evidence of metastatic disease by physical exam, chest radiograph, com-
puted tomography (CT) scan of the abdomen, or by explorative laparotomy before
resection. Either a standard Whipple procedure or a pylorus preserving pancreatic-
oduodenctomy (PPPD) was performed. Diagnosis of pancreatic adenocarcinoma was
established by definitive histological examination of the resection specimen and,
included type (origin) of carcinoma, tumour size, grade of differentiation and, lymph
node involvement. Special attention was paid to the resection margin(s). During
operation standard frozen sections were performed of the hepatic and pancreatic
resection area. Post-operatively perineural invasion and vaso-invasive ingrowth was
also scored.
All of the histopathology specimen were revised by a single pathologist. Only
patients with macro-and microscopically tumour positive resection margins (R-2/R-1)
for invasive pancreatic ductal adenocarcinoma were included in this analysis and
patients with ampullary, duodenal, and distal bile duct tumors or patients with
pancreatic islet cell or cystadenomas were excluded for were included. The resec-
tion margins were defined into the ventral or dorsal part of the pancreatic head,
uncinate process (base of the mesenteric artery, resection margin around the portal
or mesenteric vein) and pancreas transsection line, bile duct transection line and
duodenum/stomach.
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Radiotherapy
Adjuvant treatment schedule
After post-operative recovery a new helical CT-scan was performed two weeks before
the start of radiotherapy (RT) in order to again exclude metastatic disease and to plan
the RT-field. On an intention to treat basis the decision was made for no additional
therapy, or for radiotherapy with concomitant 5- fluorouracil (5-FU).
Postoperative radiotherapy and 5-FU was started when the clinical condition of the
patient allowed for it but within 2 months after the operation. Radiotherapy and 5-FU
treatment were performed in the Dr Daniël den Hoed Cancer Centre, Rotterdam.
Radiotherapy was given according to our protocol consisting of 50 Gy EBRT com-
bined with intravenous 5-FU in two courses, with a split-course of 2-3 weeks. 5-FU was
given as a continuous infusion with a dose of 25 mg/kg/24 hours, with a maximum
of 1500 mg, the first 4 days of both radiation courses.
The first course consisted of 13 times 2 Gy, followed after the split, by 12 times 2
Gy, 5 days per week. Radiation technique involved multiple-field treatment plan-
ning using computed tomography (CT). Megavolt energy of 25 MV was preferred,
although occasionally 4, 6 or 8 MV was used. Three-field plans using wedges were
more common.
The target volume comprised the tumour and first lymph nodes stations as seen
on the planning CT, adding 10 mm for the planning target volume.
The main concern was protection of the kidneys (a renography was always per-
formed) and spinal cord. Technical details of the radiotherapy protocol have been
previously published.21 This protocol was developed on basis of the results of GITSG.8,22
The choice of radiation dose of 50 Gy was a compromise between the 40 and 60 Gy
doses used in the GITSG study. By using the dose of 50 Gy in fractions of 2 Gy, the
actual treatment time was limited to 5 weeks. A treatment split of 2-3 weeks was
considered valuable to allow acute reactions to therapy to subside. Toxicity was
scored according to the common toxicity criteria scale (CTC) of the World Health
Organisation (WHO).
In-hospital records and follow-up
Patients were seen every three months at the outpatient clinic the first two years
after operation, thereafter every six months. During follow-up additional investiga-
tions were performed when there was any clinical suspicion of tumour recurrence.
Locoregional and/or distant recurrence was diagnosed by using ultrasonography or
trifasic CT-scan and Ca19-9 was used as tumour marker. If possible histological
confirmation was obtained.
All patients except one underwent routine US or trifasic CT (US was used rou-
tinely during 1989 to 1995 later on trifasic CT-scan was used routinely). The first two
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years, follow-up using US or CT was performed every 3 months and thereafter every
six months, or more frequently as indicated.
Statistics
Survival was calculated from the date of surgery on an actuarial basis using the
Kaplan-Meier method. Statistical analysis was performed using the Chi-square test and
the Fisher’s exact test. A p-value below 0.05 was considered statistically significant.
Results
During a 10-year period a total of 54 (21%) patients out of 250 had positive resection
margins. Thirty-three patients were treated post-operatively whereas 21 patients did
not receive any adjuvant treatment. In this period 33 patients with R1 resections
were included in the EORTC-trial, 14 were randomised for the control arm and 19 for
chemoradiotherapy.3 All other patients (n=21) was offered chemoradiotherapy how-
ever, this therapy had to start within 8 weeks after surgery. Four patients refused
therapy and another 3 patients had prolonged recovery (more than 8 weeks) after
surgery. These patients were included in the control group. Patient’s characteristics
and operative procedures are described in table 1.
Pathology
Staging for all pancreatic adenocarcinoma is shown in table 2. In the treated group
most positive margin(s) were found at the posterior part of the resection specimen,
namely at the portal vein, superior mesenteric artery, the processus uncinatus or
peripancreatic tissues. One patient had a positive resection margin at the common
bile duct and three patients had a positive resection margin (perineural invasion) at
the transsection site of the pancreas.
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Table 1 Patient’s characteristics and operative procedures
Patients No additional therapy Radiotherapy and 5-FU
Total 21 33
Gender
Male 12 18
Female 9 15
Age (years) 59 [43-65] 60 [39-76]
PPPD 14 21
Whipple 7 12
In the control group 20 patients had positive resections margins at the posterior part
of the resected specimen (superior mesenteric vein and artery and the portal vein) and
one at the transsection site of the pancreas and was due to perineural invasion.
There were no statistical differences between both groups regarding patient’s
characteristics, post-operative morbidity and tumour stage.
Radiotherapy & 5-FU, morbidity
Radiation was started within two months after operation. All patients successfully
fulfilled the treatment schedule. Eight patients had no morbidity, 13 patients experi-
enced complaints, mostly of gastrointestinal origin. Grade III toxicity meant that
medication was needed to alleviate symptoms. Grade III nausea occurred in 6
patients, four of them had concomitant diarrhea grade III. No patient needed to
stop radiation and 5-FU therapy due to morbidity. No hospitalisation was necessary.
Follow-up
In the treatment group 59 postoperative CT-scans and 54 US were performed. In the
control group 47 CT-scans and 17 US were performed. There was no statistically sig-
nificant difference between both groups according to number of follow-up scans.
Survival analysis is complete for all but one patient, this patient emigrated.
Local recurrence and/or distant metastases in both groups are shown in table 3.
Local recurrence was found in 6 patients in the group of patients that received
adjuvant therapy versus 16 patients in the group that did not receive adjuvant ther-
apy (p=0.001). Metastatic disease was seen in 25 patients in the treatment group
and in 18 patients in the control group (p=0.8). In the treatment group develop-
ment of both local and distant disease was found in 3 patients versus 13 in the
group of patients that received surgery alone (p=0001). Median time to recurrence
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Table 2 Staging
TNM classification No additional therapy (n=21) Radiotherapy and 5-FU (n=33)
Stage II 5 5
Stage III 7 16
Stage IV 9 12
R-1 10 17
R-2 11 16
Positive margins/areas
pancreas 1 3
bile duct 2 1
duodenum 1 0
uncinate process* 17 29
* the level uncinate process: adjacent to the SMV, portal vein, or SMA)
(both metastatic and local recurrence) was 7.8 months in the no-treatment group
versus 12.7 months in the treatment group (p=0.43). Overall time to recurrence is
shown in figure 2.
Pathology proven recurrence was obtained in 14 patients of the treatment group
and in 11 patients of the control group (p=0.9)
Median survival in the no additional treatment group was 13.7 months versus 12.8
months in the radiotherapy & 5-FU group (p=0.9). Three patients in the radiotherapy
106 chapter 6
1 alinea van
maken?
Table 3 Recurrent disease and distant metastases in the no additional therapy and the radiotherapy
& 5-FU group
Recurrent disease No additional therapy (n=21) Radiotherapy & 5-FU (n=33) P-value
Local recurrence 16 6
No local recurrence 4 27 0.001
Distant metastases 18 25
No metastases 2 8 0.8
Both 13 3 0.001
No local recurrence or metastases 4 1 0.3
Lost to FU 1 0 0.7
Median time to recurrence was 7.8 months in the No additional treatment group versus 12.7 months in the
12.7 months in the...
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Figure 1 Survival (Kaplan-Meier) for patients with irradical resected adenocarcinoma and adjuvant
therapy (5-FU/RT) versus patients with irradical resected adenocarcinoma and no-additional
therapy (p=0.9)
Number of patients at risk
No Ch/Rt 21 16 6 3 1 1 1
Ch/rt 33 20 10 7 6 4 4
Je verwijst éérst
naar figure 2, op
de volgende pag.
naar fig.1
& 5-FU group are still alive 140, 88 and 70 months after initiation of treatment. In the
no-treatment group one patient is still alive after 132 months. Survival curves are
shown in figure 1.
Discussion
After potentially curative resection for cancer of the pancreatic head, the 1-year sur-
vival estimate is 50% to 60%, 2-year survival is 15% to 35%, and 5-year survival is 5%
to 20%.23,24 Even after macroscopically radical resection recurrence rates might run
up to 97%.23,24 The sites of failure most frequently found are local, in the resected
region and in the liver. Even when peroperative frozen sections are negative for
tumour, definitive paraffine coupes can show perineural and/or vasoinvasive inva-
sion (in the circumferential area) missed in the frozen section.
Because of the high recurrence percentages development of adjuvant treatment
strategies seems to be logical and they have been studied extensively. Prospective
data however, are rare and are available from both the Gastrointestinal Stage Study
Group (GITSG), ESPAC-1 and from Klinkenbijl et al..3,8
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Figure 2 Time to recurrence in months (Kaplan-Meier) for patients with irradical resected adenocarci-
noma and adjuvant therapy (5-FU/RT) versus patients with irradical resected adenocarcinoma
and no-additional therapy (p=0.2)
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In the GITSG randomised study of adjuvant chemoradiotherapy (5-FU 500 mg/m2
for 6 days and 4 Gy EBRT) following pancreaticoduodectomy, 24% of the patients in
the adjuvant arm could not begin chemoradiotherapy until more than 10 weeks after
surgery because of prolonged recovery time.8 Similar findings were more recently
reported by Klinkenbijl et al. (EORTC) with a drop-out percentage of 20%. In the
EORTC-study, 218 patients who had undergone pancreaticoduodenctomy for pancre-
atic carcinoma of either the pancreas or the periampullary region were randomised
to receive either chemoradiotherapy (40 Gy EBRT in a split course and 5-FU given as
continuous infusion at a dose of 25 mg/kg per day during radiotherapy) or no fur-
ther treatment. Of the 207 eligible patients, 114 (55%) had pancreatic cancer; the
median survival was 17.1 months for those who received chemoradiotherapy and
12.6 months for those who received surgery alone (p=0.099).3 The recently reported
interim and final results of the European Study Group of Pancreatic Cancer (ESPAC)-1
study suggest that chemotherapy rather than chemoradiotherapy, is the essential
component of adjuvant therapy.4,6 The ESPAC-1 trial was a four arm study with a 2*2
factorial design that compared the effects of adjuvant chemoradiotherapy (5-FU and
40 Gy in a split course) adjuvant chemotherapy (5-FU and folonic acid) chemo-
radiotherapy followed by chemotherapy and observation alone following panreatic-
oduodenctomy for pancreatic and periampullary adenocarcinomas. After a median
follow-up period of 10 months, 227 (42%) were alive. The overall results showed no
benefit for chemoradiotherapy (median survival time 15.5 months in 175 patients
with chemoradiotherapy vs 16.1 months in 178 patients without (p=0.24) There was,
however, evidence of a survival benefit for chemotherapy (median survival time 19.7
months in 238 patients with chemotherapy vs. 14.0 months in 235 patients without
(p=0.0005).
In conclusion, the ESPAC-1 study showed no survival benefit for adjuvant chemo-
radiotherapy, but revealed a potential benefit for adjuvant therapy, justifying further
randomised controlled trials of adjuvant chemotherapy for pancreatic cancer.
Comparing our results in patients who underwent R-1 and R-2 resections with the
results of these studies which included both R-0 and R-1 resected patients, we may
conclude that chemoradiotherapy indeed does not prolong survival in patients who
underwent irradical resections for pancreatic cancer. Median survival in the no addi-
tional treatment group was 13.7 months (9–33 months) versus 12.8 months (4-93
months) in the radiotherapy & 5-FU group (p=0.9). Remarkable fact was that three
patients in the radiotherapy & 5-FU group are still alive 140, 88, and 70 months after
initiation of treatment. Two of them had stage II (UICC) moderate/well differentiated
tumours whereas the other patient had moderate differentiated stage III tumour.
These patients are alive without progression of disease suggesting their tumours
behave biologically different compared to the other patients. This phenomenon has
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been previously reported by Neoptolemos, Geer and Brennan.5,25 They suggested
that R-1 status is being linked to the underlying biological phenotype. The three
survivors in the treatment group suggest that there is difference in aggressiveness
between R-1/R-2 resected tumours also which might be explained by a better response
on chemoradiotherapy resulting in long term survival.
The study of Klinkenbijl et al. did not find differences in local recurrence be-
tween both groups.3 ESPAC-1 showed a significant lower recurrence free survival
rate in patients treated with chemoradiotherapy and a significant higher recurrence
free survival rate in patients treated with chemotherapy alone.6 Suggesting chemo-
radiotherapy has a deleterious effect on survival. No information is given about
difference in local and distant recurrence of the R-1 and R-2 resections in the
chemoradiotherapy group.6
Looking closely to our results, it is important to note that chemoradiotherapy pro-
vides a better local control compared to patients that received a resection alone. In
the end distant (mainly liver) metastasis remains the underlying death cause in the
group that was treated with 50 Gy radiation and concomitant 5-FU radiotherapy.
Evaluating the results of the EORTC and ESPAC-1 it seems that chemoradiotherapy
does not provide survival benefit. Evaluating our results it appears that most patients
treated with chemoradiotherapy died because of metastatic disease rather than local
relapses. Therefore treatment strategies other than locally given chemoradiotherapy
must be designed to prevent or retard metastatic disease.
The rationale for such treatment has been provided by Link et al. and Ozaki et al..26-28
In a study of extended radical resections of pancreatic cancer combined with regional
adjuvant chemotherapy which was performed using hepatic artery and/or portal
vein infusion and intraoperative radiotherapy, reported a survival improvement as
compared with standard radical surgery with a 5-year survival rate of 32%. Since the
main concerns after R-1 or R-2 resections is to get local control at the pancreatic site
and, to prevent distant metastases particularly in the liver, regional chemotherapy
and irradiation might be an effective strategy. This is an intriguing adjuvant treat-
ment concept26 and a randomised trial to test this hypothesis is currently underway.
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Chapter 7
Locally advanced pancreatic cancer treated
with radiation and 5-fluorouracil
A first step to neoadjuvant treatment?
Dig Surg. 2005;22(3):191-7
Abstract
Aim of the study
A retrospective analysis was performed, in two institutions, of patients with his-
tologically proven locally advanced pancreatic cancer without distant metastases.
The aim of this analysis is to assess whether chemoradiotherapy provides survival
benefit for patients with locally advanced pancreatic cancer.
Methods
Forty-five patients from Erasmus Medical Centre (Erasmus MC), Rotterdam, received
5-FU and radiotherapy and, 38 patients from the Academic Medical Centre Amster-
dam (AMC) was offered best supportive care. Radiotherapy consisted of 50 GY exter-
nal upper abdomen radiation in two courses, concomitant with intravenous 5-FU 25
mg/kg/24 hours continuously on the first 4 days of each treatment course.
Results
The treatment protocol was completed in 38 out of 45 patients (84%) without com-
plications. Radiological response was evaluated in 38 patients. Ten patients (26%)
showed a partial response, stable disease in 6 (16%) patients and progressive dis-
ease in 22 (58%) patients. A second look operation was performed in 8 out of 10
patients (72%) showing radiological response, in three patients the tumour could be
resected. Median overall survival time for the Erasmus MC group (n=45) was 9.8
months compared to 7.6 months when best supportive care was performed (AMC
group, p=0.04).
Conclusion
Although overall survival remains poor, treatment with 5-FU and radiotherapy might
benefit some patients with locally advanced pancreatic cancer.
Introduction
Pancreatic cancer has a dismal prognosis, with an overall 5-year survival rate of only
0-4%.1 At the time of presentation, approximately 40% of the patients with pancreatic
cancer already have metastatic disease; only 10% to 20% of patients are candidates
for resection and 40 % to 50% have locally advanced disease that is not amenable to
a microscopically radical surgical treatment.2 Since 1982 Erasmus MC has offered
treatment to patients with locally advanced non-resectable adenocarcinoma without
presence of distant metastases and with a Karnofsky performance score of 80 or
more.3 Treatment consisted of local radiotherapy combined with 5- fluorouracil (5-FU).
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The value of this combined treatment was suggested by the results of a comparative
trial conducted by the Gastro Intestinal Tumour Study Group (GITSG), showing
better survival after a combination of 5-FU and radiotherapy, as compared to radia-
tion alone.4,5 In contrast to the high response rates reported for combined modality
therapy in oesophageal and rectal cancer, chemoradiotherapy for pancreatic cancer
rarely achieves a complete radiographically or histopathologically response.6 In
recent years several studies showed possible beneficial effect on survival when chemo-
radiotherapy was given for locally advanced pancreatic cancer. Reported median sur-
vival ranged between 9 and 13 months. However non of these studies are adequately
randomised clinical trials.3,7-15 In most studies overall survival of the treated patients
was retrospectively evaluated and compared with historical controls, who did not
receive any form of treatment. Before initiating a prospective randomised trial we
first wanted to analyse our data and consider the overall survival in relation to a
group of patients who received best supportive care.
The aim of this analysis is to evaluate the radiologic and clinical response in all
patients who started chemoradiation and to assess whether our chemoradiotherapy
protocol provides survival benefit in patients with locally advanced pancreatic cancer.
Materials and Methods
All patients with suspected locally advanced disease without metastases on CT scan,
underwent an explorative laparotomy at two University hospitals in the Netherlands
(EMC and AMC) were studied. At the EMC all patients were offered chemoradiation,
whereas at the AMC not all patients received treatment (see description below).
Both centres locally advanced disease was defined as tumour in growth in the
mesenteric root (superior mesenteric vein and/or portal vein, hepatic or superior
mesenteric artery confirmed by biopsy at vessel location), transverse mesocolon or
mesentery of the small bowel (at the ligament of Treitz), and positive regional lymph
nodes at other stations than those to be removed en bloc with the pancreatoduo-
denectomy. The resectable nodes are described by the Japanese Pancreas Society
Classification.16
Histopathological biopsies of the primary tumour were obtained during operation
in all cases to confirm the diagnosis. In addition biopsies of suspected lymph nodes
outside the resection area were taken. For this study, only patients with tumours
smaller than 6 cm and a Karnofsky performance status of > 80 points were in-
cluded. Positive lymph nodes (proven by biopsy) had to be located within the radiation
field otherwise patients were excluded.
Between May 1982 and January 1998, 45 of 190 patients with incurable disease
had locally advanced pancreatic cancer without metastases. They were offered com-
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bined radiotherapy and 5-FU after discharge from hospital at the EMC. In order to
compare the results of chemoradiotherapy in the EMC, patients who underwent a
bypass between 1992 and 1998 in the AMC for locally advanced disease and only
observed after discharge from hospital were selected. Of the 82 patients with locally
advanced disease during this time period, 16 patients were excluded since they
had histologically proven positive lymphnodes outside the radiation field. Forty-four
patients (Study Group) underwent either high dose radiotherapy (n=20), chemo-
radiation (n=4) or chemotherapy alone (n=4) in trial settings. The remaining 38
patients (Excluded Group) served either as controls or did not participate in any
study. To eliminate any selection bias, the study group (SG) was compared with the
excluded group (EG). Postoperative complications were comparable (SG 34% vs. EG
23%, p=0.367) as was the case for postoperative hospital stay (SG 10 days vs. EG 11
days, p=0.204) and tumour size (SG 3.6 cm. vs. EG 3.5 cm., p=0.461) The Karnofsky
performance status was > 80 points for both the SG and EG group. The complete
group of patients from the AMC is also described in detail elsewhere 9,15,17.
Radiotherapy
Radiotherapy was given according to Erasmus MC Daniel den Hoed Clinic protocol
consisting of 50 Gy EBRT in two courses, with a split-course of 2-3 weeks, combined
with intravenous 5-FU. Radiotherapy started at a mean of 48 days postoperatively.
Till the end of the 1980s 5-FU was given in a dose of 375 mg/m2 as a bolus injection
4-6 hours before radiation on the first 4 days of each treatment course. From 1990,
and currently, 5-FU is given as a continuous infusion with a dose of 25 mg/kg/24
hours, with a maximum of 1500 mg, the first 4 days of both radiation courses. This
protocol was developed on basis of the results of GITSG.16-17 The choice of radiation
dose of 50 Gy was a compromise between the 40 and 60 Gy doses used in the GITSG
study. By using the dose of 50 Gy in fractions of 2 Gy, the actual treatment time was
limited to 5 weeks. A treatment split of 2-3 weeks was considered valuable to allow
acute reactions to therapy to subside.
We are aware that today this treatment technique is suboptimal, but at the time it
was considered acceptable according to the GISTSG data. The first course consisted
of 13 times 2 Gy, followed after the split, by 12 times 2 Gy, 5 days per week. Radiation
technique involved multiple-field treatment planning using computed tomography
(CT). Megavolt energy of 25 MV was preferred, although occasionally 4, 6 or 8 MV
was used. Three-field plans using wedges were more common.
The target volume comprised the tumour and first lymph nodes stations as seen
on the planning CT, adding 10 mm for the planning target volume.
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The main concern was protection of the kidneys (a renography was always
performed) and spinal cord. Technical details of the radiotherapy protocol have
been previously published.18 According to our protocol, one third of the kidneys
should not receive a dose higher than 20 Gy, taking also into account the reno-
graphy. The maximal radiation dose accepted for the spinal cord was 50 Gy. Toxicity
was scored according to the common toxicity criteria scale (CTC) of the World
Health Organisation (WHO).
After completion of chemoradiotherapy, patients were given a two months break
before re-staging, to allow for recovery of blood counts, side effect of radiation, and
overall functional activity. Tumour size on restaging CT was compared to initial CT
tumour size in the treatment group only by measuring.
Response Assessment
CT-scan was planned two months after chemoradiotherapy regimen was completed.
Partial response was defined as a greater than 50% decrease in tumour size for
at least 4 weeks without disease progression at another site. Bidimensionally mea-
surable tumours must have had a 50% decrease in tumour size, as measured by
multiplication of the greatest diameter by the perpendicular diameter, whereas
unidimensional tumours must have had a 30% decrease at linear tumour measure-
ment. Stable disease was defined as no significant change in measurable or evaluable
disease for at least 4 weeks, no appearance of new areas of malignant disease, and
no decrease in malignant disease by greater than 50% or increase by greater than
25%. Progression was defined as a greater than 25% increase in area of any malig-
nant lesion greater than 2 cm2, or appearance of any new lesion at another site.
Specimens of resections after chemoradiotherapy were evaluated for size, tumour
margins, and degree of differentiation and lymph node status.
Statistics
Survival was calculated from the date of operation until October 2002, on an actu-
arial basis using the Kaplan-Meier method. Comparison of survival was done only
for patients with pancreatic adenocarcinoma, using the log-rank test. To test for dif-
ferences between the treatment group and the control group the Chi-Square Test or
Mann-Whitney test was used. P-values (two sided) less then 0.05 were considered
significant.
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Results
Patient’s characteristics are listed in Table 1. There were no significant differences
regarding age, sex and tumour characteristics between both groups. Use of gas-
tro/biliary by-pass and preoperative stents differs between both groups (see discus-
sion).
As far as could be defined, no ampullary tumours were included in this study. A
majority of patients had locally advanced disease due to direct tumour invasion
either in large vessels or transverse mesocolon found during explorative laparotomy.
Toxicity
Thirty-eight out of 45 patients (85%) completed the planned regimen of chemoradio-
therapy. Three patients (7%) discontinued from treatment; In one patient treatment
was discontinued due to nonreversible haematological (grade III) toxicity and two
patients refused further treatment because of severe (grade III) nausea and vomit-
ing. Neither grade four toxicity nor treatment- related deaths were observed. Details
of toxicity grade for all patients who started chemoradiotherapy are summarised in
Table 2.
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Table 1 Patients characteristics and pathology (data given are number of patients or mean (range)
EMC AMC p-value
No. of patients 45 38
Age in years [means (SD)] 62 (41-80) 65 (45-78) n.s
Sex (M/F) 29/16 17/21 p= 0.81
Laparotomy
Tumour growth in transverse mesocolon 7 9 n.s.
Regional lymph nodes* 17 12 n.s.
Tumour growth in large vessels
(mesenteric artery/vein and vena porta)
24 20 n.s.
Pathology type
Adenocarcinoma 45 38 n.s.
Tumour location
Head 44 38
Corpus 1 n.s.
Bypass surgery
Biliary bypass 28 38 0.001
Gastrojejunal bypass 21 38 0.001
Pre-operative stent 19 27 0.001
*Positive lymph nodes outside the resected specimen but within the radiation field
Radiological Tumour Response
Four patients stopped treatment due to development of malignant ascites, proven by
cytology during chemoradiotherapy. For 38 patients who received the full treatment,
evaluation of local tumour response was planned two months after chemoradio-
therapy regimen was completed. Ten patients (10/38; 26%) had shown a partial
response on CT-scan, 6 (6 /38; 16%)had stable local disease and 22(22/38; 58%)
showed tumour progression either local or at distant sites. Loco regional progres-
sion was found in 11 patients (24%), liver metastases were found in 11 patients
(24%). Three out of 22 patients with progressive disease, developed concomitant
metastases elsewhere, one patient developed lung metastases, one patient bone meta-
stases and one patient developed peritoneal metastases.
Eight of 10 patients, who had shown tumour regression and were free of meta-
static disease on CT-scan, underwent a second-look operation, between 4 and 6 months
after chemoradiotherapy. Two patients refused surgical re-exploration because of
general conditions. In three patients a resection could be performed. Definitive
histological diagnosis demonstrated that all tumours were adenocarcinomas, two
resections were radical (R-0) and one was an irradical (R-1) resection. Overall in only
2 patients (5%) of the total group who started chemoradiotherapy curative resection
could be performed. The remaining patients failed to demonstrate adequate tumour
regression to be considered resectable at the second-look laparotomy.
Survival
Overall median survival for the EMC group (n=45, including 3 resected patients)
that received radiotherapy and 5-FU was 9.8 months [CI 7.6-12.0] and 7.6 months
[CI 6,2-9.0] for the AMC control group (n=38) (p= 0.046). The survival curve is
shown in Figure 1. Survival for the three patients who underwent a resection for
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Table 2 Toxicity
WHO Grade 1 Grade 2 Grade 3
Haematological toxicity
Leucocytopenia 1 0 1
Thrombocytopenia 0 0 1
Anaemia 0 0 1
Non-haematological toxicity
Nausea/emesis 3 2 10
Diarrhoea 3 3 8
Fever 0 3 1
Pain 1 2 2
(Data given are number of patients)
adenocarcinoma was 11, 15, and 157 months. If these three patients are not included
in the survival analysis median survival is 9.2 [6.35-12.05] in the EMC group (n=42)
vs. 7.6 months in the AMC group (p=0.1).
Discussion
In the Netherlands surgery for pancreatic cancer is partly centralized in two major
centres, the AMC and the Erasmus MC. This study was designed to evaluate the
radiologic and clinical response of chemoradiotherapy, which routinely was offered
to patients with locally advanced pancreatic cancer at the Erasmus MC. The overall
survival of these patients was compared with a group of similar patients who received
best supportive care at the AMC. Of the 45 patients who started our chemoradiation
protocol, 38 patients (84%) received full treatment.
Toxicity associated with chemoradiotherapy was relatively low. Three patients
had grade III toxicity and four patients developed malignant ascites during therapy.
Grade 3-4 haematological toxicity was observed in 6.5 % of the patients. Nausea
was the most common non-haematological toxicity with this treatment; 25% of the
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Figure 1 Overall survival. The solid curve represents the treated group from the EMC (n=45) and the
dotted curve represents the control group from the AMC (n=38)
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patients experienced this adverse effect and 2 patients refused to continue the treat-
ment. This is similar to toxicity reported by other studies using 5-FU radiotherapy
regimens.4,5,7,8,10-12,14,22 26,27,30-35
There was a significant difference in bypass surgery and use of biliairy stents. In
the AMC every patient with locally advanced disease underwent a double bypass in
trial setting.38,39 In the EMC only patients with signs of obstruction peri- and post-
operatively underwent a bypass. That explains the difference between both groups.
Difference in preoperative stent using can also be explained by a different policy in
both institutions. In the EMC a stent is used only when patients do have clinical and
lab signs of obstructive jaundice. In the AMC every patient gets a preoperative stent.
Two months after completion of the chemoradiation already 22 patients (58%)
showed progression of disease. In this study 26% of patients showed a response and
16% had stable disease after two months which is again comparable to international
results.3,7-9,11,12,19-23,27-29 However, only two patients (5%) of the total group underwent a
R-0 resection. Distant metastasis, especially in the liver (11 patients in this study) is
the most important cause of death in pancreatic cancer32-34, and was found in 11
patients in this study two months after finishing chemoradiotherapy. Eight patients
who had shown tumour regression underwent a second look laparotomy followed
by resection in three patients. All three patients had histopathologically proven
adenocarcinoma after resection. In two cases a radical (R0) resection and one had
an irradical (R1) resection was performed. Median survival for these three patients
was 83 months (11,15, >157(still alive)). Remarkably, two patients were not found to
have positive resections margins or positive lymphnodes, which suggests that pre-
operative chemoradiotherapy, may yield pathologic down staging for patients with
locally advanced pancreatic cancer.
Pilepich and Miller et al. have also described this concept of down staging. They
performed a second-look laparotomy in 11 of 17 patients after preoperative irradia-
tion. The tumour could be resected in six of them, and two patients were still alive
after 5 years. However, in this small series the resectability at first laparotomy was in
doubt for at least 5 patients.34
Recently Kastl et al.25 described a combination of radiotherapy, chemotherapy
and mitomycin which was given to 27 patients with locally advanced pancreatic can-
cer. A second look relaparotomy was performed in sixteen patients. In ten patients
the tumour could be resected. Although this study shows an improved resectablility
median survival remained poor (9 months).25
Although these groups are very similar (Table 1), care must be taken to draw con-
clusions because selection bias might have occurred. The control group may be
partly selected in terms of patients who did not prefer radiotherapy for instance due
to general conditions. High dose radiotherapy (70-72 Grays) without subsequent
chemotherapy was offered in a phase II study at the AMC, to evaluate the effect of
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radiotherapy on pain control.9,15 So the control group in our study consisted of
patients in a poor condition and therefore it is even more surprising that the benefit
of chemoradiotherapy in means of survival is so poor. The radiotherapy group in the
AMC-study had a median survival time of 11 months (10 months from the start of
radiotherapy) which is comparable with the results in the EMC group.9
This study shows a small survival benefit for patients with unresectable locally
advanced adenocarcinoma of the pancreas treated with radiotherapy and 5-FU (9.8
months versus 7.6 in the control group p=0.046). This is comparable to results pub-
lished in international literature in which survival ranges from 9-14 months.3,7-12,14,19-31
Ishii et al.10 reported in a recent trial the results of 20 patients who were treated
with 5-FU (200mg/m2/d) infusion + radiotherapy (50.4 Gy over 25 fractions) for
locally advanced pancreatic cancer similar to those reported in this study. Ten per-
cent of Ishii’s patients achieved partial radiographic response and tumour remained
stable in 80%. The median overall survival was 10.3 months.10
A more recent randomised trial of 31 patients by Shinchi et al.12 found a signifi-
cantly better survival for the patients treated with external-beam radiotherapy and
continuous 5-FU (13.4 versus 6.4 months). However, as in our study their survival
curves separate immediately after surgery. The difference at this point is 7 months,
suggesting a worse prognosis for the control group at the time of admission.12
In a study by De Lange et al.36 gemcitabine-radiotherapy was found to yield a
similar median survival (10 months). In some studies Cisplatin is found to have
some value when added to the 5-FU or Gemcitabine regimens.20,36 The rationale for
this addition is that 5-FU and Gemcitabine are primarily used as a radiosensitizers
and therefore have a local effect; Cisplatin might help to target the disease more ef-
fectively at distant locations of (micro-) metastasis.
Of the studies discussed above only one (Shinchi et al.) was designed as a ran-
domised clinical trial, however the results should be interpreted with caution because
only 31 patients were enrolled and an adequate power analysis was lacking. All other
studies are cohort studies.
According to the present study we cannot conclude that there is a clear benefit
using 5-FU and radiotherapy for patients with locally advanced pancreatic cancer.
The significant difference in survival appearing in figure 1 is most likely due to the
worse prognosis of patients who did not receive radiotherapy. The beneficial effect
of chemoradiotherapy should be expected after a few months so that the two curves
would only begin to separate some time after the completion of treatment. In fact
the curves separate immediately after surgery, making the conclusion viable that a
worse prognosis is most obvious the reason for this significant difference. Despite
some positive reports in the literature there is no level one evidence that subscribes
the positive effect of chemoradiotherapy in patients with locally advanced pancreatic
carcinoma. To draw final conclusions, randomised clinical trials are necessary. The
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lack of efficacy of the above mentioned modalities gives rise to the question whether
further modifications of this multimodality approach could lead to better clinical
results. Data from the MD Anderson showed promising results for patients with
resectable pancreatic cancer treated with either rapid-fractionation chemoradiother-
apy and intra-operative chemoradiotherapy.37 They reported a overall median survival
of 19 months which compares favourably with recently reported series of patients
treated by pancreaticoduodenectomy alone, and to those treated with combined post-
operative adjuvant 5-FU-based chemoradiotherapy (median survival 11-20 months).
However in patients with locally advanced pancreatic carcinoma no such positive
results with 5-FU and radiotherapy alone have been reported yet.
Lymph Node Group Classification by the JPS
Group Carcinoma pancreatic head Carcinoma of the pancreatic body-tail
1 13,17 8,11,18
2 6,8,12,14 7,9,14,15
3 1,2,3,4,5,7,9,10,11,15,16,18 5,6,12,13,17,17,16,16
Numbers and names of lymph nodes: 1, right cardial;2, left cardial;3, along the
lesser curvature of the stomach; 4, along the greater curvature of the stomach;5,
suprapyloric;6, infrapyloric; 7, along the left gastric artery; 8, along the common
hepatic artery; 9 around the celiac artery; 10, splenic hilum; 11, along the splenic
artery; 12, in the hepatoduodenal ligament; 13, on the posterior surface of the pancre-
atic head; 14, along the superior mesenteric artery; 15, along the middle colic artery;
16, around the abdominal aorta; 17, on the anterior surface of the pancreatic head;
18, along the inferior margin of the pancreatic body-tail
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Chapter 8
Summary and conclusions
Surgery for pancreatic cancer offers a low success rate, but it provides the only likeli-
hood of cure (chapter 2). Modern series show that, in experienced hands, the stan-
dard Whipple procedure is associated with a five-year survival of 10 to 20% with a
perioperative mortality rate of less than 5%. The most feared complication is leakage
of the pancreaticojejunostomy which is the main cause for postoperative mortality.31
Many patients will develop recurrent disease within two years after curative treat-
ment. This occurs usually either at the site of resection or in the liver. This suggests
the presence of micrometastases at the time of operation. Negative lymphnodes are
the strongest predictor for long-term survival. Other predictors for a favourable out-
come are tumour size, radical surgery and a histopathologically well-differentiated
tumour. Adjuvant therapy so far has only shown modest results, with 5-FU and
folonic acid chemotherapy to date the only proven agent able to increase survival.
Long term survival is observed in only a very small group of patients contradicting
the published actuarial survival rates of 10-45%.
Assessment of clinical benefit from surgery and adjuvant therapy should there-
fore not only be based on actuarial survival but also on progression-free survival,
actual survival, median survival and quality of life (QOL) indicators. Survival in sur-
gical series is usually calculated by actuarial methods. Without information on the
total number of patients, the number of actual survivors and a clear definition of
the subset of patients, actuarial survival curves can prove to be misleading.
Use of molecular diagnostics and markers in the assessment of tumour biology,
may in future reveal important subtypes of this type of tumour and may possibly,
predict the response to adjuvant therapy. Defining the subtypes of pancreatic cancer
will hopefully lead to target specific, less toxic and finally more effective therapies.
In the international literature pylorus-preserving pancreaticoduodenectomy (PPPD)
has been associated with a higher incidence of delayed gastric emptying, resulting
in a prolonged period of post-operative nasogastric suctioning.1-4 Another controversy
of the pylorus-preserving pancreaticoduodenectomy for patients with malignancy is
the radicality of the resection.5 In a retrospective study from our center we found
that the PPPD is associated with a shorter operation time, less blood loss, shorter
hospital stay and the same amount of positive resection margins as for the standard
Whipple procedure.1
A prospective randomized multi-center study was performed to assess whether
the results of PPPD equalize those of the standard Whipple operation, especially with
respect to duration of surgery, blood loss, hospital stay, delayed gastric emptying and
survival (chapter 3).
We found that the incidence of delayed gastric emptying in this study of 170
consecutive patients was similar after PPPD and Whipple resection. Postoperative
nasogastric drainage period was comparable in both groups. As far as the duration
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of operation, blood loss, hospital stay and postoperative weight loss are concerned,
there were also no significant differences. The PPPD operation seems to be as radical
as a standard Whipple procedure for periampullary and pancreatic head cancer.
Long-term survival and disease free survival did not exhibit significant differences.
Thus in conclusion both procedures are equally effective for treatment of pancre-
atic cancer. With respect to radical resection, morbidy, mortality and survival our
results are confirmed by the latest literature.6,7 However, the latest review by Diener
et al. showed that intra operative blood loss and duration were significantly reduced
in the PPPD group.6
Pancreatic cancer has a dismal prognosis. Periampullary adenocarcinoma, how-
ever, has a better prognosis and is thought to be a biologically different tumor. Yet
even after radical (R-0) resection of pancreatic cancer survival remains poor and
most patients may still die of disseminated disease. Adjuvant therapy may only be
of marginal benefit. Aim of this study was to find clinical, pathological and molecu-
lar factors that could predict long-term survival after R-0 resection for pancreatic
and periampullary cancer (chapter 4).
After multivariate analysis the following factors were isolated.
Gender, pre-operative pain, tumor differentiation, nodal status were all inde-
pendent prognostic factors for pancreatic and periampullary cancer. In literature
these features have all been described before.16-24 Over expression of EGF-R in pancre-
atic cancers appeared to have a negative effect on survival. The EGF family and its
receptors are known to be involved in tumor progression and mediate growth of
pancreatic cancer. Since this has been proved, EGFR has been a target for new treat-
ment strategies. It is the aim of these treatments to interrupt the EGFR signal intro-
duction and so inhibit tumor growth. Some very interesting approaches have been
launched lately. The most promising is usage of EGFR antibodies e.g. C225, erlotinib
and Herceptin. Treatment with these antibodies combined with gemcitabine and
radiotherapy have been tested in nude mise with high rates of apoptosis and growth
inhibition.8 A Phase III trail by Moore et al showed promising results. 27 In a this
multicenter randomized trial a total of 569 patients with advanced non-resectable
pancreatic cancer were randomly assigned to receive standard gemcitabine plus
erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo in a double-blind,
international phase III trial. Overall survival based on an intent-to-treat analysis was
significantly prolonged on the erlotinib/gemcitabine; median 6.24 months v 5.91
months). Progression-free survival was significantly longer with erlotinib plus gem-
citabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; P = .004).
In the near future further development of EGFR targeted therapies might reveal
even better results. Our data support the rationale to use these drugs in adjuvant
targeted therapy modalities.
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Alinea?
The role of adjuvant chemoradiation for resectable pancreatic cancer has long been
under discussion. So far only adjuvant chemotherapy has shown significant survival
benefit.9,25
We reported the long-term follow-up results of our multicenter study, which
assessed the role of chemoradiation in resectable pancreatic cancer (chapter 5).
In the initial short-term results a trend toward increased survival was found in
the pancreatic head cancer group treated with chemoradiation. However this was
not a significant finding.15 The long-term results show again that overall survival did
not differ between the two treatment groups. The 10-year overall survival was 18% in
the whole population of patients (8% in the pancreatic head cancer group and 29%
in the periampullary cancer group). Patients with pancreatic cancer may survive
over 10 years. Only 1 of 31 cases recurred after year 7. Thus it seems that follow-up
should at least extent a term of 7 years.
So far this is the only study on pancreatic cancer with a long-term follow up
exceeding 10 years. Where most studies report actuarial survival we report more
than 10 years actual survival. The results indicate no benefit of adjuvant chemo-
radiation over observation in patients with resected pancreatic cancer or periampullary
cancer. This conclusion is confirmed by the results of the ESPAC-1 trial in which
chemoradiation even showed a deleterious effect on survival.9
The reason for relative ineffective treatment of chemoradiation or chemotherapy
might be found in the heterogeneity of solid tumors with high and low mitotic
areas. It is believed that tumor hypoxia, which is common in pancreatic cancer,
plays an important role in local and systemic tumour progression, leading to a
more aggressive phenotype.28,29,30 Recent data by Graeber et al demonstrated in-
creased levels and growth of p53(tumor suppressor gene) mutated cells under low
oxygen conditions. Clinical tumor treatment with chemotherapy and/or radiother-
apy is based on disruption of the cell cycle particularly in cells with high mitotic
activity, in other words tumor cells. High proliferating cells however consume a lot
more oxygen than dormant cells. Sufficient oxygenation is of pivotal importance to
achieve an adequate response on chemo/radiotherapy. The reason for the poor
response of pancreatic cancer on chemoradiation might be the low oxygenation of
the inner tumor cells.
Further our results show that curative surgery offers long-term survival of 8% for
patients with pancreatic head cancer. Metastases still occur up to seven years. This
makes long-term follow-up necessary in trials which evaluate the effect of adjuvant
treatment.
Current challenges for the treatment of resectable pancreatic cancer is to im-
prove survival by multimodality approaches to treatment in the hope to create more
efficient agents. Chemoradiation has no role anymore in the treatment of resectable
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pancreatic cancer. Until know only chemotherapy treatment confers a modest but
significant survival advantage.9,25,26,27
Among patients treated with surgery alone, liver metastasis occur in up to 50%,
peritoneal recurrence in 25%, and local recurrence occurs in 50-80%. Even after a
macroscopically curative resection, tumour cells might be observed by microscopy
at one or more edges of the resected specimen in 20% to 51% (R-1), which might
account for the high local recurrence. Therefore a rationale for chemoradioation in
this group seems reasonable.13
An analysis was performed in patients who underwent an irradical resection (R-1
and R-2) for pancreatic cancer (chapter 6). Thirty-three patients were treated with
therapeutic chemoradiotherapy. To evaluate the effect of therapy on survival and
recurrence, this group was retrospectively compared to a group of 21 patients that
did not receive chemoradiotherapy.
Adjuvant chemoradiotherapy clearly gave a significant better local control. How-
ever, treatment with 5-FU and radiotherapy did not improve survival due to distant
metastases. In only a few patients this therapy probably prolongs survival, however
no randomised clinical trials are available at this time. More effective treatment
methods have to be designed to prevent metastatic disease and improve survival.
No role for adjuvant chemoradiation has been found so far. However the effect of
chemoradiation for patients with locally advanced pancreatic cancer remains un-
clear.10-14
A retrospective analysis was performed, in two institutions, of patients with
histological proven locally advanced pancreatic cancer without distant metastases
(chapter 7). The aim of this analysis is to assess whether chemoradiotherapy pro-
vides survival benefit for patients with locally advanced pancreatic cancer.
The treatment protocol was completed in 38 out of 45 patients (84%) without
complications. Radiological response was evaluated in 38 patients. Ten patients (26%)
showed a partial response, stable disease in 6 (16%) patients and progressive dis-
ease in 22 (58%) patients. A second look operation was performed in 8 out of 10
patients (72%) showing radiological response, in three patients the tumour could be
resected. Median overall survival time for the Erasmus MC group (n=45) was 9.8
months compared to 7.6 months when best supportive care was performed (AMC
group, p=0.04).
Although overall survival remains poor, treatment with 5-FU, folonic acid and
radiotherapy might benefit some patients with locally advanced pancreatic cancer.
Its future role needs to be assessed in randomised trials. Recently Moore et al.27 pub-
lished the first phase III trial known todate that showed significant survival benefit
(1 year 23%, treatment vs 17% no treatment) for patients treated with Gemcitabine
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and targeted therapy for EGFR (erlotinib) in order to disrupt the signal pathway and
inhibit tumor growth. Hopefully even better agents can be designed in order to
improve survival more significantly.
Conclusion
Today, surgery provides the only likelihood of cure for patients having pancreatic
cancer. Centralization of surgery has helped a great deal in lowering mortality rates.
Modern series show that, in experienced hands, pancreatic surgery is associated
with a perioperative mortality rate between 0.5% and 5%, and a five-year survival of
10-20%.
In this thesis two surgical procedures for treating periampullary and pancreatic
cancer, the PPPD and the Whipple operation, show equal survival and morbidity
results. These procedures can be carried out with acceptable morbidity and mortality.
Chemoradiotherapy given as split course (total 40 Gy) with concomitant 5-FU
(25 mg/kg/day) and folonic acid, is ineffective as adjuvant treatment after resection
of pancreatic cancer. Up to date only one multicenter trial (ESPAC-1) shows that
adjuvant chemotherapy offers a significant (actuarial) survival increase, however
survival benefit remains marginal (a few months). More evidence is needed before
chemotherapy can be standardized as adjuvant treatment after resection for pancre-
atic cancer.
In patients with locally advanced cancer survival benefit might occur, although
define proof by randomized multicentre studies has yet to be given.
The molecular mechanism of pancreatic cancer should be revealed in the near
future and might help to develop and design more specific and effective adjuvant
and neoadjuvant therapies, for instance targeting therapy with an EGFR antibody. In
this thesis EGFR proofs to have negative effect on survival. Therefore EGFR targeted
therapy might reveal a new era in treatment of pancreatic cancer. Lately treatment
strategies using EGFR targeted therapies have been published and show promising
results although the measured affects on survival are moderate.
It is a harsh conclusion that in the last decades all our effort to improve survival
by adjuvant and neoadjuvant strategies has resulted in only modest survival advan-
tage without any standard approved adjuvant protocol. Even worse is the fact that
proven inefficient chemoradiation as adjuvant treatment is still widely used in some
countries.
To counter this trend we need effort from oncologist, surgeons as well as the
medical industry to give patients with this devastating disease new hope. New, more
effective agents need to be developed and tested. Because of the long accrual times
in most multicenter trails, valuable time is lost before conclusions can be drawn.
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Therefore we plea for centralization. Performing pancreas surgery in high volume
setting not only reduces the risk of mortality and morbidity but also shortens trial
durations. Patients have the right and the need to know as quick as possible if a new
agent is effective or not. By cooperating extensively in multidisciplinary and multi-
center setting it must be possible to shorten time schedules needed for clinical
trials. Together with a search for more effective regiments such as targeted therapy
against EGFR and effort to unravel the whole genome of pancreatic cancer this era
must bring the define solution in the cure pancreatic cancer.
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Samenvatting en conclusies
Een operatieve behandeling van alvleesklierkanker heeft een geringe kans op sla-
gen, maar vormt de enige mogelijkheid tot genezing (hoofdstuk 2). Hedendaagse
operatiereeksen tonen aan dat, wanneer uitgevoerd door zeer ervaren chirurgen, de
standaard Whipple procedure gepaard gaat met een overlevingspercentage van 10
tot 20% in 5 jaar tijd met een peri-operatief sterftecijfer van minder dan 5%. De
meest gevreesde complicatie is lekkage van de pancreaticojejunostomie hetgeen de
hoofdoorzaak is van postoperatieve sterfte.31 Bij een groot aantal patiënten zal de
ziekte terugkeren binnen twee jaar na de curatieve behandeling. De ziekte komt
meestal terug op de plaats van resectie of in de lever. Dit doet vermoeden dat er
micro-uitzaaiingen waren ten tijde van de operatieve behandeling. Negatieve lymfe-
klieren zijn de beste voorspellers van langdurig herstel. Andere voorspellers van een
gunstig resultaat zijn de grootte van de tumor, radicale chirurgie en een tumor die
zich histopathalogisch gunstig onderscheidt. Adjuvante therapie heeft tot nog toe
slechts magere resultaten opgeleverd, met tot op heden 5-FU en foliumzuur chemo-
therapie als enige bewezen middelen om de overlevingskans te vergroten. Lang-
durige overleving wordt slechts bij een klein aantal patiënten geconstateerd en dit
spreekt de gepubliceerde actuariële overlevingspercentages van 10-45% tegen. De
beoordeling van de klinische voordelen van een operatieve behandeling en adju-
vante therapie dient niet slechts gebaseerd te worden op actuariële overleving maar
ook op progressievrije overleving, feitelijke (actual) overleving, mediane overleving
en de kwaliteit van leven (QOL) indicatoren. Overleving in operatieve reeksen wordt
meestal berekend door middel van actuariële methoden. Zonder informatie over het
totale aantal patiënten, het aantal feitelijke overlevingen en een duidelijke omschrij-
ving van de samenstelling van de groep patiënten, kunnen actuariële overlevings-
curven misleidend blijken te zijn.
Het gebruik van moleculaire diagnostiek en markers bij de beoordeling van de
tumorbiologie, kan in de toekomst belangrijke subtypen van deze tumor openbaren
en mogelijk de reactie op adjuvante therapie voorspellen. De ontrafeling van de
subtypen alvleesklierkanker resulteert hopelijk in doelgerichte, minder toxische en
uiteindelijk effectievere therapieën.
In de internationale vakliteratuur wordt de maagpoortbehoudende pancreaticoduo-
denectomie (PPPD) in verband gebracht met een grotere incidentie van vertraagde
maaglediging, hetgeen resulteert in een verlengde periode van postoperatieve
nasogastrische afzuiging1-4. Nog een controverse van de maagpoortbehoudende
pancreaticoduodenectomie voor patiënten met kwaadaardige tumoren is de mate
van radicaliteit van de resectie5. Door middel van een retrospectief onderzoek van-
uit ons centrum kwamen wij tot de conclusie dat PPPD in verband wordt gebracht
met een kortere operatieduur, minder bloedverlies, een kortere ziekenhuisopname
en dezelfde hoeveelheid positieve resectiemarges als bij de standaard Whipple
ingreep.1
Er werd een prospectief multi-centeronderzoek uitgevoerd om vast te stellen of
de PPPD resultaten gelijk zijn aan die van de standaard Whipple operatie, in het bij-
zonder met betrekking tot de operatieduur, het bloedverlies, de duur van de zieken-
huisopname, vertraagde maaglediging en de overleving (hoofdstuk 3).
Wij concludeerden dat de incidentie van vertraagde maaglediging in dit onder-
zoek bij 170 opeenvolgende patiënten gelijk was na de PPPD en Whipple resectie.
De periode waarin postoperatieve nasogastrische afzuiging moest worden toe-
gepast was van vergelijkbare duur in beide groepen. Er waren geen opmerkelijke
verschillen wat betreft de duur van de ingreep, het bloedverlies, de duur van de zie-
kenhuisopname en het postoperatieve gewichtsverlies. De PPPD-operatie lijkt even
ingrijpend te zijn als een standaard Whipple procedure voor periampullaire en
alvleesklierkopkanker. Er werden geen belangrijke verschillen aangetroffen bij lang-
durige overleving en ziektevrije overleving.
We kunnen daarom de conclusie trekken dat beide procedures evenredig effec-
tief zijn bij de behandeling van alvleesklierkanker. Met betrekking tot drastische
resectie, ziekte, sterfte en overleving worden onze resultaten bevestigd door recente
literatuur.6,7 Een recente beoordeling door Diener e.a. toonde echter aan dat intra-
operatief bloedverlies en duur aanmerkelijk waren verminderd bij de PPPD groep.6
Alvleesklierkopkanker gaat gepaard met een slechte prognose. Bij een periampullair
adenocarcinoom wordt daarentegen een betere prognose gegeven en het lijkt zo te
zijn dat deze tumor biologisch gezien afwijkt van de alvleesklierkoptumor. In beide
gevallen echter, is zelfs na radicale (R-0) resectie van de tumor, de overlevingskans
klein en de meeste patiënten sterven alsnog als gevolg van uitzaaiingen. Adjuvante
therapie voegt hier vaak weinig positiefs toe. Het doel van dit onderzoek was om
klinische, ziekte- en moleculaire factoren te ontdekken die de duur van overleving
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zouden kunnen voorspellen na R-0 resectie van de alvleesklierkop- en periampul-
laire tumor (hoofdstuk 4).
Door middel van een multivariabele analyse werden de hiernavolgende factoren
geïsoleerd.
Geslacht, preoperatieve pijn, tumor differentiatie en nodale status waren stuk
voor stuk onafhankelijke prognostische factoren bij alvleeskler- en periampullaire
tumoren. In de literatuur zijn deze kenmerken reeds beschreven.16-24 Overexpressie
van EGF-R bij alvleeskliertumoren bleek een negatief effect te hebben op de over-
leving. Het is bekend dat de EGF-familie en haar receptoren meespelen bij de ont-
wikkeling van de tumor en de indirecte groei van alvleeskliertumoren. Na deze
bekendmaking werd EGFR het doelwit van nieuwe behandelmethoden. Het doel
van deze behandelingen is om de EGFR signaalwegen te onderbreken en op deze
wijze de groei van de tumor te remmen. Enkele interessante aanpakken zijn recen-
telijk uitgevoerd en een van de meest veelbelovende aanpakken is het gebruik van
EGFR antilichamen zoals bijv. C225, erlotinib en Herceptin. Behandelingen met
deze antilichamen in combinatie met gemcitabine en radiotherapie zijn getest op
naakte muizen met een hoge mate van apoptose en groeiremming.8 Een door
Moore e.a. uitgevoerd fase III onderzoek bracht eveneens veelbelovende resulta-
ten.27 Bij dit internationaal gerandomiseerd multicenteronderzoek, werd een totaal
aantal van 569 patiënten met inoperabel alvleesklierkanker in een vergevorderd sta-
dium willekeurig uitgekozen om te worden behandeld met standaard gemcitabine
plus erlotinib (100 of 150 mg/d oraal) of met gemcitabine plus placebo. De algehele
levensduur bij een zogenaamde ‘intent-to-treat’ analyse werd aanzienlijk verlengd
in het geval van de erlotinib/gemcitabine; (gemiddeld 6,24 maanden versus 5,91
maanden). De progressievrije overleving was van aanzienlijk langere duur bij het
gebruik van erlotinib plus gemcitabine, met een geschatte HR van 0,77 (95% CI,
0,64 tot 0,92; P = ,004).
In de nabije toekomst zal de verdere ontwikkeling van EGFR-gerichte therapieën
wellicht nog betere resultaten opleveren. Onze gegevens ondersteunen de grond-
gedachte deze medicijnen te gebruiken bij op adjuvante therapie gerichte modali-
teiten.
De rol van adjuvante chemoradiatie bij operatief verwijderbare alvleeskliertumoren
is reeds lang een onderwerp van discussie. Tot nog toe heeft alleen adjuvante chemo-
therapie een aanzienlijke verlenging van de levensduur aangetoond.9,25
We berichtten de follow-up resultaten op lange termijn van ons gerandomiseerde
multicenteronderzoek waarin de rol van chemoradiatie bij de behandeling van ope-
ratieve alvleeskliertumoren wordt beoordeeld (hoofdstuk 5).
Bij de eerste resultaten op korte termijn constateerden we een verlenging van
de levensduur bij de groep patiënten met een alvleesklierkoptumor die behandeld
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werden met chemoradiatie. Dit was echter een trend maar nog geen significant ver-
schil.15 De resultaten op lange termijn gaven wederom aan dat er geen verschillen
waren in de algehele overleving bij de twee behandelde groepen. De algehele over-
leving binnen 10 jaar was 18% bij de totale groep patiënten (8% bij de groep met
alvleesklierkopkanker en 29% bij de groep met periampullaire kanker). Patiënten
met alvleesklierkanker kunnen meer dan 10 jaar overleven. Een aantal patiënten
kreeg een recidief na 5 jaren overleving een enkeling zelfs na 7 jaar. Hieruit blijkt,
dat in geval van klinische studies, de follow-up periode een termijn van tenminste 7
jaar in beslag zou moeten nemen.
Tot op heden is dit het enige onderzoek naar alvleesklierkanker met een follow-up
op lange termijn die de 10 jaar overschrijdt. Daar waar de meeste onderzoeken
actuariële overleving aantonen kunnen wij een feitelijke overleving van meer dan
10 jaar aantonen. Helaas geven de resultaten aan dat adjuvante chemoradiatie geen
toegevoegde waarde heeft ten opzichte van observatie bij patiënten met operatieve
alvleesklierkanker of periampullaire kanker. Deze conclusie wordt bevestigd door
de resultaten van het ESPAC-1 onderzoek dat aantoonde dat chemoradiatie zelfs een
negatief effect heeft op de overleving.9
De reden voor de relatief ineffectieve behandeling met chemoradiatie zou kun-
nen worden toegeschreven aan de heterogeniteit van deze tumoren met hoge en
lage mitotische gebieden. Men is van mening dat tumor hypoxia, veelvoorkomend
bij alvleesklierkanker, een belangrijke rol speelt in de lokale en systemische tumor-
progressie, en leidt tot een agressiever fenotype.28,29,30 Recente gegevens van Graeber
e.a. toonden toegenomen hoeveelheden aan alsmede groei van p53 (gen dat de tumor
onderdrukt) gemuteerde cellen in omstandigheden met een laag zuurstofniveau. De
klinische tumorbehandeling door middel van chemotherapie en/of radiotherapie is
gebaseerd op de verstoring van de celcyclus en in het bijzonder van cellen met een
hoge mitotische activiteit, ofwel tumorcellen. Snel vermenigvuldigende cellen nemen
echter veel meer zuurstof op dan inactieve cellen. Voldoende oxygenatie is van zeer
groot belang om een degelijke reactie te krijgen op de chemo/radiotherapie. De lage
oxygenatie van de binnenste tumorcellen zou kunnen verklaren waarom alvlees-
klierkanker hier slecht op reageert.
Verder geven onze resultaten aan dat curatieve chirurgie een overlevingspercen-
tage van 8% op lange termijn biedt aan patiënten met alvleesklierkopkanker. Het is
daarmee vooralsnog de enige behandeling die curatie kan bieden, zij het dus met
kleine percentages. Uitzaaiingen komen tot na 7 jaar na de operatie en behandeling
nog voor. Hierdoor is een follow-up op lange termijn noodzakelijk bij onderzoeken
waarbij het effect van adjuvante behandeling wordt geëvalueerd.
Op dit moment blijft het een uitdaging om bij de behandeling van operatieve
alvleesklierkanker de levensduur te verbeteren, het meeste heil valt te verwachten
een multimodale behandelingen in de hoop op deze wijze efficiënter en effectiever
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pancreaskanker te kunnen gaan bestrijden. Chemoradiatie speelt niet langer een
rol in de behandeling van operatieve alvleesklierkanker. Tot op heden geeft alleen
een behandeling door middel van chemotherapie een bescheiden overlevingsvoor-
deel.9,25,26,27
Bij 50% van de patiënten die alleen operatief behandeld zijn komen later uitzaaiingen
in de lever voor, bij 25% worden er buikvliesuitzaaingen geconstateerd, en bij
50%-80% keerde de ziekte op lokaal niveau terug. Zelfs na een macroscopisch
curatieve resectie worden na microscopie bij 20% tot 51% (R-1) gevallen tumorcel-
len gevonden aan een of meerdere uiteinden van de operatief verwijderde mon-
sters, wat in feite de hoge mate van lokale terugkeer verklaart. Daarom lijkt het
motief voor chemoradiatie in deze groep een redelijke te zijn en werd zodoende aan
patiënten aangeboden.13
Wij verrichten een analyse uitgevoerd bij patiënten die een niet radicale resectie
van de alvleeskliertumor ondergingen (R-1 en R-2)(hoofdstuk 6). Drieëndertig pati-
enten werden behandeld door middel van therapeutische chemoradiotherapie. Om
het effect van de therapie op de overlevingskans en de kans op het terugkeren van
de ziekte te kunnen evalueren, werd deze groep retrospectief vergeleken met een
groep van 21 patiënten die geen chemoradiotherapie onderging.
Adjuvante chemoradiotherapie bewerkstelligde een zichtbaar betere lokale con-
trole. Maar als gevolg van uitzaaiingen elders in het lichaam resulteerde de behan-
deling met 5-FU en radiotherapie niet in een langere levensduur. Deze vorm van
therapie verlengt slechts bij een klein aantal patiënten de levensduur, maar er zijn op
dit moment geen gerandomiseerde klinische onderzoeken beschikbaar. Effectievere
behandelingsmethoden zullen moeten worden ontwikkeld om metastatische ziekte
te voorkomen en de overlevingskansen te vergroten.
Vooralsnog is tot op heden geen rol weggelegd voor adjuvante chemoradiatie. Echter,
het effect van chemoradiatie op patiënten met lokaal vergevorderde alvleesklier-
kanker blijft onduidelijk.10-14
In twee verschillende instellingen werd een retrospectieve analyse uitgevoerd bij
patiënten met alvleesklierkanker in een vergevorderd stadium zonder uitzaaiingen
elders in het lichaam (hoofdstuk 7). Het doel van deze analyse is om vast te stellen of
chemoradiotherapie de levensduur verlengt bij patiënten met lokaal vergevorderde
alvleesklierkanker.
Het behandelingsprotocol werd afgerond bij 38 van de in totaal 45 patiënten
(84%) zonder dat er complicaties optraden. Bij 39 patiënten werd de radiologische
reactie gemeten. Tien patiënten (26%) toonden een gedeeltelijke reactie, bij zes
patiënten bleef de ziekte stabiel (16%) en bij 22 patiënten schreed de ziekte onver-
stoord voort (58%). Een tweede operatie werd uitgevoerd bij 8 van de 10 patiënten
samenvatting en conclusies 139
(72%), waarbij radiologische reacties werden geconstateerd en bij drie patiënten
kon de tumor operatief worden verwijderd. De mediane algehele overlevingduur bij
de Erasmus MC groep (n=45) was 9,8 maanden vergeleken met 7,6 maanden bij de
AMC groep (p=0,04).
Hoewel de algehele overleving gering blijft, zou de behandeling met 5-FU, folium-
zuur en radiotherapie een gunstig effect kunnen hebben op sommige patiënten met
alvleesklierkanker in een vergevorderd stadium. Een toekomstige rol voor deze
behandeling dient te worden vastgesteld in gerandomiseerde onderzoeken.
Recentelijk hebben Moore e.a27 het eerste fase III onderzoek gepubliceerd bij
patiënten met waarbij een significante verlenging van de levensduur werd waarge-
nomen. (1 jaar behandeling 23%, tegenover 17% bij geen behandeling) bij patiënten
behandeld met Gemcitabine en gerichte EGFR-therapie (erlotinib) met als doel de
signaalwegen te verstoren en de groei van de tumor te remmen. Hopelijk kunnen er
nog betere middelen worden ontwikkeld om zodoende de levensduur aanzienlijk te
kunnen verlengen.
Conclusie
Op dit moment biedt chirurgie de enige mogelijkheid tot genezing aan patiënten
met alvleesklierkanker. De centralisatie van chirurgie heeft enorm bijgedragen aan
de vermindering van het aantal sterfgevallen. Moderne operatiereeksen tonen aan
dat, wanneer uitgevoerd door ervaren chirurgen, alvleesklierchirurgie gepaard gaat
met een perioperatieve sterfte van 0,5% tot 5%, en een overleving bij vijf jaar van
10-20% .
In deze thesis tonen twee operatieve procedures voor de behandeling van periam-
pullaire kanker en alvleesklierkanker, te weten de PPPD en de Whipple procedure,
gelijke resultaten als het gaat om overleving en sterfte. Het uitvoeren van deze pro-
cedures gaat gepaard met acceptabele ziekte- en sterftecijfers.
Chemoradiotherapie toegepast als gespreide kuur (totaal 40 Gy) in combinatie
met 5-FU (25 mg/kg/dag) en foliumzuur, blijkt ineffectief te zijn als adjuvante be-
handeling na het verwijderen van de alvleeskliertumor. Tot op heden heeft alleen
een multicenteronderzoek (ESPAC-1) aangetoond dat adjuvante chemotherapie een
significante (actuariële) toename van de overleving teweegbrengt, echter het over-
levingsvoordeel blijft marginaal (slechts enkele maanden). Er is meer bewijs nodig
voordat chemotherapie kan worden gestandaardiseerd als adjuvante behandeling na
de resectie van een alvleeskliertumor.
Bij patiënten met kanker een vergevorderd stadium zou een overlevingsvoordeel
kunnen optreden, hoewel duidelijk bewijs daarvoor bij gerandomiseerd uitgevoerde
multicenteronderzoeken nog ontbreekt.
140
De moleculaire samenstelling van de alvleeskliertumor dient in de nabije toe-
komst te worden blootgelegd. Dit zou kunnen bijdragen aan de ontwikkeling van
een EGFR antilichaam. In deze thesis blijkt EGFR een negatief effect te hebben op de
overleving. Daarom zou op een op EGFR gerichte therapie een nieuw tijdperk kunnen
inluiden in de behandeling van alvleesklierkanker. Onlangs zijn er behandelingsstra-
tegieën gepubliceerd waarbij op EGFR gerichte therapieën werden toegepast. Deze
tonen veelbelovende resultaten ten aanzien van respons hoewel de gemeten effecten
op de overleving gering zijn.
Helaas moeten we de conclusie trekken dat in de laatste tientallen jaren alle
inspanningen om de overlevingskans te verhogen middels toepassing van adju-
vante en neoadjuvante strategieën slechts geresulteerd hebben in een summiere
verlenging van de levensduur. Om deze trend tegen te gaan hebben we de hulp
nodig van oncologen, chirurgen en de medische industrie om patiënten met deze
moeilijk te behandelen ziekte nieuwe hoop te kunnen geven. Nieuwe, effectievere
middelen zullen moeten worden ontwikkeld en getest. Doordat de meeste multi-
centeronderzoeken gepaard gaan met zeer lange looptijden verliezen we waarde-
volle tijd voordat er conclusies kunnen worden getrokken. Daarom pleiten wij voor
centralisatie. Het uitvoeren van operaties op het gebied van alvleesklierkanker op
brede schaal vermindert niet alleen het risico op ziekte en sterfte maar verkort
eveneens de onderzoeksduur. Patiënten hebben immers het recht zo snel mogelijk
te worden geïnformeerd wanneer een nieuw middel effectief blijkt te zijn of niet.
Door op grote schaal samen te werken in een multidisciplinaire en multicenter-
omgeving zou het mogelijk moeten zijn om de duur van de klinische onderzoeken
te verkorten. In combinatie met de ontwikkeling van effectievere regimenten zoals
doelgerichte therapie tegen EGFR en de inspanningen om het gehele genoom van
alvleesklierkanker te ontrafelen, zal het tijdperk dat nu aanbreekt een gerichte oplos-
sing moeten kunnen brengen om te komen tot de genezing van alvleesklierkanker.
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